{"id": "DDI-DrugBank.d244.s0.p32", "sentence": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d137.s9.p0", "sentence": "In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "label": "0"}
{"id": "DDI-DrugBank.d46.s7.p5", "sentence": "- @DRUG$ and colestipol resins: Cholestytamine and colestipol resins have the potential of binding @DRUG$ and reducing diuretic absorption from the gastrointestinal tract", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1226", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p43", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, @DRUG$, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, @DRUG$, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d179.s38.p0", "sentence": "- @DRUG$ (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate", "label": "0"}
{"id": "DDI-MedLine.d111.s5.p71", "sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-DrugBank.d531.s90.p33", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p473", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d312.s1.p0", "sentence": "In Study 1, patients with colorectal cancer were given @DRUG$/@DRUG$/leucovorin (bolus-IFL) with or without AVASTIN.", "label": "0"}
{"id": "DDI-DrugBank.d395.s2.p1", "sentence": "@DRUG$: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d480.s17.p3", "sentence": "Cimetidine, @DRUG$, and @DRUG$ may increase plasma levels of Clozapine, potentially resulting in adverse effects.", "label": "0"}
{"id": "DDI-DrugBank.d318.s8.p29", "sentence": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d76.s17.p9", "sentence": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with @DRUG$ Tablets, the initial @DRUG$ dosage should be at least halved and titration to the lowest effective dose is recommended.", "label": "0"}
{"id": "DDI-DrugBank.d485.s41.p14", "sentence": "Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by @DRUG$, increasing plasma levels of @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p590", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p268", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p802", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s13.p9", "sentence": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: @DRUG$, @DRUG$(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "label": "0"}
{"id": "DDI-MedLine.d140.s1.p0", "sentence": "OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ", "label": "0"}
{"id": "DDI-DrugBank.d82.s6.p0", "sentence": "However, when any additional drug, including @DRUG$, is added to the treatment of patients on @DRUG$ therapy, the patients should be observed for alterations of the prothrombin time.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d94.s11.p336", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d124.s18.p2", "sentence": "Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p57", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-MedLine.d94.s12.p2", "sentence": "The uptake inhibitors cocaine and @DRUG$ (3 mumol/liter) potentiated the positive inotropic effects of @DRUG$ in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d328.s41.p0", "sentence": "However, because higher doses (up to 360 mg QD) of @DRUG$ are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for @DRUG$ is recommended at current doses.", "label": "0"}
{"id": "DDI-DrugBank.d236.s7.p2", "sentence": "@DRUG$, tricyclic: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p792", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-MedLine.d5.s0.p3", "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and @DRUG$.  ", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p468", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), @DRUG$ (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p46", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p55", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d514.s2.p8", "sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other @DRUG$, including alcohol, benzodiazepines such as @DRUG$ (Valium), and, to a rising degree, methadone.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p186", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, @DRUG$, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, @DRUG$, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p54", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p553", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d568.s39.p9", "sentence": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic @DRUG$ (@DRUG$), the two agents should not be coadministered.", "label": "0"}
{"id": "DDI-DrugBank.d455.s8.p2", "sentence": "More than 600 Parkinsons disease patients in clinical trials have used @DRUG$ in combination with entacapone and levodopa/@DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d48.s15.p45", "sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, @DRUG$, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d94.s14.p1", "sentence": "Pharmacological/Pharmacodynamic Interactions with @DRUG$ Concomitant administration of carbamazepine and @DRUG$ may increase the risk of neurotoxic side effects.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p107", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d521.s7.p13", "sentence": "- a steroid medicine such as @DRUG$ (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (@DRUG$, Pediapred, others), and others;", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p344", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, @DRUG$, troleandomycin, valproate(1), verapamil, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d238.s16.p0", "sentence": "While all the @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p3", "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d131.s5.p0", "sentence": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "label": "0"}
{"id": "DDI-DrugBank.d137.s2.p2", "sentence": "Beta-blocking Agents: The concomitant use of @DRUG$ and @DRUG$ has been well tolerated in patients with stable angina.", "label": "0"}
{"id": "DDI-DrugBank.d526.s17.p2", "sentence": "@DRUG$, phenytoin, or rifampin increased metabolic clearance of @DRUG$ because of the induction of hepatic enzymes.", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d5.s0.p1", "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with @DRUG$, trichlorfon, and phenobarbital sodium.  ", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p714", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), @DRUG$ (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d251.s0.p20", "sentence": "Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "label": "0"}
{"id": "DDI-MedLine.d106.s1.p12", "sentence": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d506.s6.p0", "sentence": "@DRUG$ does not increase serum @DRUG$ levels.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p57", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p548", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;@DRUG$;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p88", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, @DRUG$, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p126", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d212.s5.p4", "sentence": "Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p393", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d456.s6.p2", "sentence": "Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, phenytoin, @DRUG$, phenobarbital and St. Johns Wort.", "label": "0"}
{"id": "DDI-DrugBank.d249.s4.p0", "sentence": "Ingestion of @DRUG$ may increase serum concentrations of @DRUG$ and methotrexate and increase cyclosporine s nephrotoxicity.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p627", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;@DRUG$;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p0", "sentence": "@DRUG$ may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d254.s0.p11", "sentence": "Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d175.s1.p3", "sentence": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p2", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p840", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p165", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;@DRUG$;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d544.s5.p8", "sentence": "The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, @DRUG$, corticosteroids, cyclosporine, mycophenolate mofetil, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p54", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d437.s9.p2", "sentence": "@DRUG$: Coadministration of amprenavir and methadone can decrease plasma levels of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p314", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;@DRUG$;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d208.s0.p16", "sentence": "Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "label": "0"}
{"id": "DDI-DrugBank.d463.s8.p0", "sentence": "In vitro, @DRUG$ may displace less firmly bound drugs like @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d78.s1.p29", "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "label": "0"}
{"id": "DDI-MedLine.d3.s5.p2", "sentence": "Serial plasma and urine samples for measurement of @DRUG$, rifabutin, and rifampin and their @DRUG$, were measured by high-performance liquid chromatography. ", "label": "0"}
{"id": "DDI-MedLine.d27.s0.p6", "sentence": "[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of d@DRUG$ phenazepam, p@DRUG$and amizyl and reduces the action of phentolamine. ", "label": "0"}
{"id": "DDI-DrugBank.d97.s72.p2", "sentence": "Use lowest possible dose of @DRUG$ with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, @DRUG$, or rosuvastatin in combination with CRIXIVAN.", "label": "0"}
{"id": "DDI-DrugBank.d480.s8.p3", "sentence": "Although it has not been established that there is an interaction between @DRUG$ and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a @DRUG$ or any other psychotropic drug.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p267", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-MedLine.d15.s0.p23", "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h@DRUG$(0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a@DRUG$in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "label": "0"}
{"id": "DDI-DrugBank.d437.s14.p0", "sentence": "Appropriate laboratory testing should be considered prior to initiating combination therapy with @DRUG$ and @DRUG$ and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d45.s8.p0", "sentence": "Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.", "label": "0"}
{"id": "DDI-DrugBank.d531.s80.p1", "sentence": "@DRUG$: Saquinavir/@DRUG$ combination", "label": "0"}
{"id": "DDI-DrugBank.d190.s1.p0", "sentence": "However, since there is an increased risk of bleeding with @DRUG$, caution should be employed when @DRUG$ is used with other drugs that affect hemostasis.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p50", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), @DRUG$, @DRUG$, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d225.s0.p7", "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d456.s1.p56", "sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p32", "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p16", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of @DRUG$, carbamazepine, @DRUG$, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d257.s0.p61", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d78.s11.p4", "sentence": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on @DRUG$ indicates that grepafloxacin inhibits @DRUG$ metabolism, which is mediated by CYP1A2.", "label": "0"}
{"id": "DDI-DrugBank.d103.s4.p1", "sentence": "@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p47", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-MedLine.d59.s4.p0", "sentence": "@DRUG$ at 10 microM preferentially blocked the secretory effect of @DRUG$ and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p217", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;@DRUG$;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d54.s14.p4", "sentence": "Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if @DRUG$ or estrogen-containing oral @DRUG$ are given.", "label": "0"}
{"id": "DDI-DrugBank.d334.s9.p1", "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to PRINIVIL given concomitantly with @DRUG$, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1032", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d115.s10.p3", "sentence": "Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).", "label": "0"}
{"id": "DDI-DrugBank.d485.s8.p6", "sentence": "Antibiotics (@DRUG$, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d384.s2.p0", "sentence": "@DRUG$/@DRUG$: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p32", "sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p321", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, @DRUG$, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), @DRUG$, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d198.s9.p1", "sentence": "Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p314", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d307.s9.p5", "sentence": "In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral @DRUG$, resulting in a lower plasma concentration of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d245.s4.p54", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s4.p8", "sentence": "- a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil);", "label": "0"}
{"id": "DDI-DrugBank.d111.s0.p10", "sentence": "Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p46", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d360.s1.p9", "sentence": "A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.", "label": "0"}
{"id": "DDI-DrugBank.d82.s16.p3", "sentence": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p4", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d86.s1.p68", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, @DRUG$, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., @DRUG$), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d449.s2.p0", "sentence": "@DRUG$, @DRUG$, sertraline, diltiazem, macrolide antibiotics (exercise caution).", "label": "0"}
{"id": "DDI-DrugBank.d480.s15.p0", "sentence": "@DRUG$, @DRUG$, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "label": "0"}
{"id": "DDI-DrugBank.d543.s1.p4", "sentence": "@DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.", "label": "0"}
{"id": "DDI-DrugBank.d46.s16.p2", "sentence": "Diuretic agents reduce the renal clearance of @DRUG$ and add a high risk of @DRUG$ toxicity.", "label": "0"}
{"id": "DDI-DrugBank.d167.s2.p20", "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, @DRUG$, and terbutaline.", "label": "0"}
{"id": "DDI-DrugBank.d468.s10.p4", "sentence": "When therapeutic concentrations of @DRUG$, propranolol, dipyridamole, warfarin, quinidine, or @DRUG$ were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "label": "0"}
{"id": "DDI-DrugBank.d31.s2.p0", "sentence": "Profound hypotensive episodes may occur when @DRUG$ infection and @DRUG$ are used concomitantly.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s29.p107", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;@DRUG$;carbamazepine;chloral hydrate*;@DRUG$;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-MedLine.d1.s1.p0", "sentence": "Since the arrival of oral @DRUG$, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of @DRUG$ in particular. ", "label": "0"}
{"id": "DDI-DrugBank.d72.s4.p9", "sentence": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced @DRUG$ clearance based upon the known property of @DRUG$ to decrease glutathione levels in the blood and tissues.", "label": "0"}
{"id": "DDI-DrugBank.d561.s7.p4", "sentence": "Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "label": "0"}
{"id": "DDI-DrugBank.d140.s1.p5", "sentence": "Antacid: When atorvastatin and @DRUG$ suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p121", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;@DRUG$;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;@DRUG$;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d254.s0.p10", "sentence": "Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.", "label": "0"}
{"id": "DDI-DrugBank.d108.s1.p0", "sentence": "In a single study, rats given high intraperitoneal doses of an @DRUG$ plus @DRUG$ experienced severe toxicity, including convulsions and death.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d3.s11.p0", "sentence": "@DRUG$: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p308", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p12", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p213", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), etodolac (Lodine), indomethacin (@DRUG$), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d299.s6.p0", "sentence": "@DRUG$ (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "label": "0"}
{"id": "DDI-DrugBank.d522.s15.p7", "sentence": "Antacids or @DRUG$: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.", "label": "0"}
{"id": "DDI-DrugBank.d30.s9.p5", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the @DRUG$ @DRUG$", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p264", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (@DRUG$), @DRUG$ (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d12.s8.p0", "sentence": "While it is not known whether this interaction occurs with @DRUG$ other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p97", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p75", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d567.s21.p0", "sentence": "@DRUG$: In patients with hypercholesterolemia, concomitant administration of @DRUG$ and digoxin resulted in no effect on digoxin plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d434.s23.p0", "sentence": "In four subjects with epilepsy ingesting @DRUG$, the steady-state trough (Cmin) @DRUG$ plasma concentration was 63 16 micrograms/mL.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p75", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p137", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), @DRUG$ (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), @DRUG$ (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d251.s0.p23", "sentence": "Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d76.s13.p0", "sentence": "The clearance of @DRUG$ metabolized by glucuronidation (e. g., @DRUG$, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.", "label": "0"}
{"id": "DDI-DrugBank.d521.s5.p21", "sentence": "- a beta-blocker such as propranolol (Inderal), @DRUG$ (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;", "label": "0"}
{"id": "DDI-DrugBank.d480.s30.p24", "sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and @DRUG$), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "label": "0"}
{"id": "DDI-DrugBank.d357.s3.p6", "sentence": "@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p92", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d565.s38.p0", "sentence": "no change in @DRUG$ AUC and Cmax was observed during @DRUG$ coadministration.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p12", "sentence": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d216.s9.p7", "sentence": "Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.", "label": "0"}
{"id": "DDI-DrugBank.d84.s1.p13", "sentence": "Although deferasirox has a lower affinity for aluminum than for iron, @DRUG$ should not be taken with aluminum-containing @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p92", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, @DRUG$, lithium, narcotic pain medication (e.g., @DRUG$), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d229.s3.p0", "sentence": "The addition of 540 mg/kg/day of @DRUG$ (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of @DRUG$ (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d60.s12.p105", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d236.s27.p2", "sentence": "Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d9.s5.p0", "sentence": "by the nonlinear kinetic characteristics for @DRUG$ and @DRUG$ (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; ", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p910", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, @DRUG$), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (@DRUG$), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p50", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d257.s0.p31", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d546.s0.p0", "sentence": "Drug Interactions with @DRUG$: Concomitant use of @DRUG$ with beta-blockers should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d195.s8.p2", "sentence": "Co-administration of @DRUG$ and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with @DRUG$ alone.", "label": "0"}
{"id": "DDI-DrugBank.d5.s20.p8", "sentence": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving @DRUG$ concurrently with either levodopa or @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d379.s1.p17", "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d367.s1.p7", "sentence": "In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, @DRUG$, @DRUG$ or indomethacin.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p17", "sentence": "Central nervous system depressant (CNS) drugs including @DRUG$, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, @DRUG$, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d85.s8.p0", "sentence": "Inhibition of renal @DRUG$ clearance leading to increases in plasma @DRUG$ concentrations has also been reported.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p83", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, @DRUG$, nicotine, somatropin, @DRUG$, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p78", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p84", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;@DRUG$;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;@DRUG$;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p25", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d350.s12.p18", "sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p1291", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d143.s15.p0", "sentence": "Other substances: Grapefruit juice given to healthy volunteers increased @DRUG$ AUC by 50% and Cmax by 84%, resulting in increased plasma levels of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d212.s5.p14", "sentence": "Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, @DRUG$, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.", "label": "0"}
{"id": "DDI-DrugBank.d382.s24.p2", "sentence": "In another study with intravenous administration of @DRUG$, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of @DRUG$ and on Days 4, 8, and 15.", "label": "0"}
{"id": "DDI-DrugBank.d476.s3.p20", "sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain @DRUG$ (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as @DRUG$, are used concurrently.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p9", "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d236.s0.p20", "sentence": "Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d499.s17.p0", "sentence": "Because prostaglandina play an important role in hemostasis and @DRUG$ has an effect on platelet function as well, concurent therapy with @DRUG$ and warfarin requires close monitoring of patients on both drugs.", "label": "0"}
{"id": "DDI-DrugBank.d260.s3.p1", "sentence": "Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d103.s3.p8", "sentence": "Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.", "label": "0"}
{"id": "DDI-DrugBank.d413.s19.p6", "sentence": "However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with @DRUG$, doxorubicin, @DRUG$, procarbazine and/or mechlorethamine.", "label": "0"}
{"id": "DDI-DrugBank.d220.s16.p0", "sentence": "Nevertheless, the effects of @DRUG$ on travelers receiving comedication, particularly diabetics or patients using @DRUG$, should be checked before departure.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d386.s23.p16", "sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as @DRUG$ or sedative/@DRUG$, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "label": "0"}
{"id": "DDI-DrugBank.d434.s37.p19", "sentence": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg @DRUG$ for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral @DRUG$ cycles.", "label": "0"}
{"id": "DDI-DrugBank.d509.s23.p4", "sentence": "No clinically significant effect of famotidine, @DRUG$, or lithium was seen on the pharmacokinetics of @DRUG$ (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).", "label": "0"}
{"id": "DDI-DrugBank.d132.s7.p0", "sentence": "@DRUG$: In normal volunteers, the concomitant administration of @DRUG$ and furosemide had no effect on the diuretic activity of furosemide.", "label": "0"}
{"id": "DDI-DrugBank.d431.s1.p52", "sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, @DRUG$, @DRUG$, or terfenadine in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d78.s7.p1", "sentence": "Serum @DRUG$ concentrations increase when grepafloxacin is initiated in a patient maintained on @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d434.s11.p0", "sentence": "Specific Effects of @DRUG$  on Other @DRUG$ Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d478.s4.p3", "sentence": "@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.", "label": "0"}
{"id": "DDI-DrugBank.d382.s43.p7", "sentence": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.", "label": "0"}
{"id": "DDI-MedLine.d87.s7.p0", "sentence": "@DRUG$ analgesia and pupil constriction were unaffected by @DRUG$ and differed from placebo (P < .002). ", "label": "0"}
{"id": "DDI-DrugBank.d220.s9.p1", "sentence": "This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d485.s26.p0", "sentence": "@DRUG$: Combination @DRUG$ may increase the clearance of morphine.", "label": "0"}
{"id": "DDI-DrugBank.d478.s1.p4", "sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and naratriptan within 24 hours is contraindicated.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p839", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d10.s1.p0", "sentence": "Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.", "label": "0"}
{"id": "DDI-DrugBank.d94.s8.p25", "sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, @DRUG$, felbamate, rifampin, phenobarbital, Phenytoin(2), @DRUG$, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "label": "0"}
{"id": "DDI-MedLine.d58.s7.p13", "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel. ", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p71", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p502", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d241.s3.p15", "sentence": "In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p65", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d210.s21.p4", "sentence": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of rofecoxib (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p178", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, @DRUG$, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, @DRUG$, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d531.s90.p61", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, @DRUG$, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d426.s1.p5", "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "label": "0"}
{"id": "DDI-DrugBank.d543.s0.p6", "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p524", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p214", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), etodolac (Lodine), indomethacin (Indocin), @DRUG$ (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p750", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p279", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d338.s6.p0", "sentence": "Consequently, @DRUG$ should be avoided in patients receiving @DRUG$ and itraconazole, which are very potent inhibitors of CYP3A.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d506.s0.p1", "sentence": "If @DRUG$ or other hepatic enzyme inducers are taken concurrently with Norpace or @DRUG$, lower plasma levels of disopyramide may occur.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d382.s19.p18", "sentence": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of @DRUG$, decreased the AUC of @DRUG$ by 43%, and decreased the AUC of norethindrone by 8%;", "label": "0"}
{"id": "DDI-DrugBank.d43.s14.p4", "sentence": "Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of @DRUG$ (20%) and indinavir (84%) occurred following simultaneous administration of these agents with @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s3.p8", "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p1460", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p90", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d561.s11.p12", "sentence": "Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, @DRUG$, @DRUG$, and hydralazine, without evidence of clinically important adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d488.s6.p13", "sentence": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, @DRUG$, or antihistamines may partially counteract the anticoagulant action of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p767", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, @DRUG$), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), @DRUG$ (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d212.s7.p0", "sentence": "Pharmacokinetics of @DRUG$ were also not affected by @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d400.s0.p0", "sentence": "@DRUG$: As with other @DRUG$, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p118", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d335.s3.p7", "sentence": "The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, phenothiazines, @DRUG$ or other antidepressants.", "label": "0"}
{"id": "DDI-DrugBank.d165.s16.p2", "sentence": "@DRUG$, tacrolimus and digoxin concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d113.s7.p4", "sentence": "Antacids: Concomitant administration of @DRUG$s does not interfere with absorption of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d397.s13.p1", "sentence": "There have been postmarketing reports of drug interactions when @DRUG$ is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of @DRUG$ by erythromycin.", "label": "0"}
{"id": "DDI-DrugBank.d20.s3.p3", "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p473", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d140.s13.p0", "sentence": "@DRUG$ doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered @DRUG$ dose level (P = .13, .82, and .76, respectively). ", "label": "0"}
{"id": "DDI-DrugBank.d525.s5.p2", "sentence": "Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release @DRUG$) with no clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p677", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d536.s1.p58", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d503.s3.p1", "sentence": "Avoid the concomitant use of @DRUG$ and tramadol (@DRUG$).", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d558.s32.p0", "sentence": "Other Drugs: In healthy volunteers, @DRUG$, @DRUG$, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d388.s5.p8", "sentence": "No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.", "label": "0"}
{"id": "DDI-DrugBank.d536.s1.p33", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d124.s14.p7", "sentence": "Antiarrhythmics: @DRUG$, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.", "label": "0"}
{"id": "DDI-DrugBank.d390.s0.p0", "sentence": "@DRUG$ such as @DRUG$ or haloperidol;", "label": "0"}
{"id": "DDI-DrugBank.d3.s12.p4", "sentence": "The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.", "label": "0"}
{"id": "DDI-DrugBank.d88.s0.p4", "sentence": "@DRUG$: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of @DRUG$ was investigated in 12 cancer patients.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p321", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p75", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p2", "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p500", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d258.s0.p3", "sentence": "Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.", "label": "0"}
{"id": "DDI-DrugBank.d568.s26.p7", "sentence": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and @DRUG$ (20 mg) did not affect the pharmacokinetics of either @DRUG$ or escitalopram.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p43", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, @DRUG$, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and @DRUG$ showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d82.s0.p1", "sentence": "In normal volunteers receiving @DRUG$, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d111.s5.p0", "sentence": "@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-DrugBank.d321.s3.p0", "sentence": "The pharmacokinetics of @DRUG$ were unchanged following coadministration with @DRUG$ (400 mg).", "label": "0"}
{"id": "DDI-DrugBank.d289.s15.p0", "sentence": "Co-administration of @DRUG$ and @DRUG$ resulted in markedly increased plasma concentrations of bosentan in animals.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d106.s4.p2", "sentence": "Coadministration of SULAR with @DRUG$ or any known CYP3A4 inducer should be avoided and alternative @DRUG$ therapy should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d143.s28.p2", "sentence": "There have been case reports of increased steady-state levels of @DRUG$, procainamide, and phenytoin during concomitant therapy with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d443.s8.p0", "sentence": "@DRUG$: May decrease @DRUG$ anti-inflammatory action by competing for the same receptors.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d203.s2.p5", "sentence": "Compounds tested in man include warfarin, @DRUG$, @DRUG$, diazepam, aminopyrine and antipyrine.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p112", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;@DRUG$;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;@DRUG$*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d249.s3.p3", "sentence": "@DRUG$, Methotrexate, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.", "label": "0"}
{"id": "DDI-DrugBank.d211.s2.p9", "sentence": "Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.", "label": "0"}
{"id": "DDI-DrugBank.d151.s0.p3", "sentence": "Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p642", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (@DRUG$), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d414.s6.p3", "sentence": "In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p717", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), @DRUG$ (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d20.s10.p4", "sentence": "Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.", "label": "0"}
{"id": "DDI-DrugBank.d140.s17.p4", "sentence": "Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p131", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d191.s1.p0", "sentence": "@DRUG$ enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d123.s2.p2", "sentence": "Some quinolones, including @DRUG$, have been associated with transient elevations in serum creatinine in patients receiving @DRUG$ concomitantly.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d434.s31.p4", "sentence": "@DRUG$: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of @DRUG$  given as monotherapy.", "label": "0"}
{"id": "DDI-DrugBank.d263.s23.p2", "sentence": "The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/aluminum-containing @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d124.s17.p9", "sentence": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d345.s11.p14", "sentence": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with @DRUG$;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d170.s5.p16", "sentence": "Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d48.s4.p9", "sentence": "In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$) are indicated, alternative agents with less enzyme induction potential should be used.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p35", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d132.s4.p5", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p175", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;@DRUG$;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;@DRUG$;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p10", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d531.s39.p2", "sentence": "When @DRUG$ at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when @DRUG$ (800 mg every 8 hours) was given alone.", "label": "0"}
{"id": "DDI-DrugBank.d480.s30.p6", "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and @DRUG$), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d484.s0.p646", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (@DRUG$), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, @DRUG$, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d225.s0.p22", "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.", "label": "0"}
{"id": "DDI-DrugBank.d333.s6.p1", "sentence": "Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d106.s4.p0", "sentence": "Anticoagulant inhibition was observed during the administration of @DRUG$, @DRUG$ and glutethimide; ", "label": "0"}
{"id": "DDI-DrugBank.d313.s1.p6", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "label": "0"}
{"id": "DDI-DrugBank.d140.s7.p3", "sentence": "Digoxin: When multiple doses of @DRUG$ and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s16.p1", "sentence": "@DRUG$/Somatropin: Excessive concurrent use of @DRUG$ may accelerate epiphyseal closure.", "label": "0"}
{"id": "DDI-DrugBank.d257.s3.p2", "sentence": "Although no interaction between MAO inhibitors and @DRUG$ has been observed, it is not recommended for use with @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d412.s4.p0", "sentence": "@DRUG$ has been shown to increase the bioavailability of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d558.s25.p6", "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d131.s0.p5", "sentence": "The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d18.s1.p4", "sentence": "Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d257.s0.p74", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d441.s2.p4", "sentence": "Adrenergic Agents:Some individuals receiving @DRUG$ may experience a reversible enhancement of the pressor response to indirect-acting @DRUG$, vasopressor or dopaminergic agents.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d216.s15.p0", "sentence": "Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.", "label": "0"}
{"id": "DDI-DrugBank.d178.s4.p18", "sentence": "These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d464.s0.p27", "sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other @DRUG$ (including @DRUG$) has additive depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p50", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-MedLine.d83.s19.p1", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with @DRUG$ and risperidone in the treatment of negative and depressive symptoms support the choice of @DRUG$ as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "label": "0"}
{"id": "DDI-DrugBank.d77.s15.p7", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e. g., @DRUG$, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p72", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d176.s14.p0", "sentence": "In a pharmacokinetic interaction study with @DRUG$, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of @DRUG$ were not significantly changed.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1021", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p17", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d481.s0.p0", "sentence": "Milk, milk products, and @DRUG$-rich foods or drugs may impair the absorption of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s4.p170", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d420.s2.p0", "sentence": "There are no significant effects on @DRUG$ pharmacokinetics if the @DRUG$ is administered 2 hours before or 2 hours after cefdinir.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p145", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;@DRUG$;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;@DRUG$;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d531.s87.p0", "sentence": "Expected to substantially decrease plasma levels of @DRUG$;has not been studied in combination with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p311", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1292", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d104.s0.p9", "sentence": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p121", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) @DRUG$ fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (@DRUG$) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d176.s9.p23", "sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d192.s0.p15", "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d299.s11.p2", "sentence": "Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p76", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (@DRUG$, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d226.s3.p0", "sentence": "The use of @DRUG$ in patients receiving @DRUG$ may be rarely associated with ventricular fibrillation.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d114.s2.p6", "sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p47", "sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, @DRUG$ (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, @DRUG$ and progestins, and digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d263.s22.p13", "sentence": "Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.", "label": "0"}
{"id": "DDI-MedLine.d76.s7.p2", "sentence": "Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised @DRUG$ (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of @DRUG$ from 1.8 to 1.2. ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p610", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d396.s0.p20", "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and @DRUG$ tablets may exhibit an additive CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p429", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d558.s11.p0", "sentence": "@DRUG$ Alone or in Combination with @DRUG$: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.", "label": "0"}
{"id": "DDI-DrugBank.d162.s5.p5", "sentence": "Single doses of either cholestyramine or colestipol @DRUG$ bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d4.s0.p1", "sentence": "Synergism between @DRUG$ (e.g., theophylline), @DRUG$, and other sympathomimetic bronchodilators has been reported.", "label": "0"}
{"id": "DDI-DrugBank.d188.s0.p4", "sentence": "Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.", "label": "0"}
{"id": "DDI-DrugBank.d131.s8.p21", "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p67", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d220.s11.p1", "sentence": "In patients taking an @DRUG$ (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "label": "0"}
{"id": "DDI-DrugBank.d123.s3.p3", "sentence": "Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d338.s4.p13", "sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and barbiturates) would be expected to decrease @DRUG$ concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p32", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d174.s1.p0", "sentence": "Caution should be exercised when administering @DRUG$ with @DRUG$ since interactions have been seen with other NSAIDs.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d45.s5.p0", "sentence": "Concomitant Crohn s disease medications were @DRUG$, @DRUG$, corticosteroids, 6-MP/AZA and aminosalicylates.", "label": "0"}
{"id": "DDI-DrugBank.d404.s0.p14", "sentence": "Interactions for vitamin D analogues (Vitamin D2, @DRUG$, Calcitriol, and @DRUG$): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d413.s20.p7", "sentence": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.", "label": "0"}
{"id": "DDI-DrugBank.d384.s0.p7", "sentence": "Interactions for vitamin D analogues (@DRUG$, @DRUG$, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p252", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d568.s17.p18", "sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "label": "0"}
{"id": "DDI-DrugBank.d334.s15.p11", "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p911", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, @DRUG$), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d241.s3.p1", "sentence": "In clinical trials, @DRUG$ was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p31", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d175.s21.p1", "sentence": "@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-@DRUG$ interaction could be found.", "label": "0"}
{"id": "DDI-DrugBank.d568.s32.p7", "sentence": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the @DRUG$ @DRUG$ (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "label": "0"}
{"id": "DDI-DrugBank.d521.s6.p10", "sentence": "- a diuretic (water pill) such as hydrochlorothiazide (@DRUG$, Hydrodiuril), @DRUG$ (Diuril), and others;", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1358", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p2", "sentence": "Drugs that have been reported to diminish oral @DRUG$ response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;@DRUG$;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d291.s0.p6", "sentence": "When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d342.s0.p10", "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d417.s0.p4", "sentence": "Netilmicin should not be administered concomitantly with potent @DRUG$ such as furosemide and @DRUG$ as the potential for ototoxicity is enhanced by the combination.", "label": "0"}
{"id": "DDI-DrugBank.d338.s1.p0", "sentence": "The action of the @DRUG$ may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d257.s0.p20", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d94.s8.p63", "sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and @DRUG$ Thus, if a patient has been titrated to a stable dosage on @DRUG$, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d53.s13.p1", "sentence": "Until further data are developed regarding drug interactions when @DRUG$ and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated @DRUG$ concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1022", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;@DRUG$;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d115.s2.p50", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus @DRUG$) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d324.s10.p6", "sentence": "Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d171.s0.p12", "sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d488.s2.p24", "sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, @DRUG$, ibuprofen, indomethacin, dipyridamole, @DRUG$ and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "label": "0"}
{"id": "DDI-MedLine.d30.s1.p5", "sentence": "The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of @DRUG$ (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. ", "label": "0"}
{"id": "DDI-DrugBank.d157.s0.p0", "sentence": "Clinical interaction studies with @DRUG$ and @DRUG$ indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.", "label": "0"}
{"id": "DDI-DrugBank.d210.s1.p1", "sentence": "In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d133.s0.p5", "sentence": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.", "label": "0"}
{"id": "DDI-DrugBank.d238.s15.p12", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p348", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p545", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d440.s12.p2", "sentence": "The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or @DRUG$ was similar in patients taking @DRUG$ 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p465", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation @DRUG$;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p247", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (@DRUG$), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d18.s0.p5", "sentence": "Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d431.s1.p14", "sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as @DRUG$, antipyrine, indomethacin, ibuprofen, phenytoin, @DRUG$, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d384.s0.p21", "sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, @DRUG$, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p72", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol @DRUG$ carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) @DRUG$ lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d198.s36.p0", "sentence": "@DRUG$ and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "label": "0"}
{"id": "DDI-DrugBank.d249.s19.p10", "sentence": "Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.", "label": "0"}
{"id": "DDI-DrugBank.d251.s0.p9", "sentence": "Antiacid, clarithromycin, @DRUG$, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p983", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d328.s4.p4", "sentence": "Aspirin: Concomitant administration of @DRUG$ with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.", "label": "0"}
{"id": "DDI-DrugBank.d485.s22.p7", "sentence": "Example inducers include aminoglutethimide, @DRUG$, nafcillin, @DRUG$, phenobarbital, phenytoin, and rifamycins.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p152", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p78", "sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, @DRUG$ (TAO), and voriconazole .", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p258", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, @DRUG$, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), @DRUG$, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d107.s16.p1", "sentence": "@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "label": "0"}
{"id": "DDI-DrugBank.d546.s3.p6", "sentence": "There is limited experience with concomitant antihypertensive agents such as @DRUG$, calcium channel-blockers, @DRUG$, and diuretics (both thiazide-like and loop).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p369", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;@DRUG$;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1299", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;@DRUG$;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d463.s7.p2", "sentence": "The patient was also chronically receiving @DRUG$, phenobarbital, digoxin, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d5.s8.p4", "sentence": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., @DRUG$, phenobarbital, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d82.s12.p0", "sentence": "Caution should be used if @DRUG$ is administered simultaneously with @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d13.s0.p48", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p272", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, @DRUG$, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d404.s0.p3", "sentence": "Interactions for @DRUG$ analogues (Vitamin D2, Vitamin D3, Calcitriol, and @DRUG$): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d388.s5.p17", "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or @DRUG$ have been observed.", "label": "0"}
{"id": "DDI-DrugBank.d426.s3.p7", "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "label": "0"}
{"id": "DDI-DrugBank.d138.s0.p13", "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p84", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d424.s3.p5", "sentence": "Rifampin: Coadministration of rifampin and @DRUG$ Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d536.s3.p1", "sentence": "When such drugs are withdrawn from patients receiving @DRUG$ in combination with sulfonylureas or @DRUG$, patients should be observed closely for any evidence of hypoglycemia.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p269", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (@DRUG$), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (@DRUG$, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d531.s90.p62", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d480.s17.p1", "sentence": "@DRUG$, caffeine, and @DRUG$ may increase plasma levels of Clozapine, potentially resulting in adverse effects.", "label": "0"}
{"id": "DDI-DrugBank.d533.s7.p22", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, @DRUG$, valsartan, amlodipine, metformin, @DRUG$, atenolol, atorvastatin, ramipril or hydrochlorothiazide.", "label": "0"}
{"id": "DDI-DrugBank.d220.s9.p8", "sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "label": "0"}
{"id": "DDI-DrugBank.d533.s7.p50", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, @DRUG$, atorvastatin, @DRUG$ or hydrochlorothiazide.", "label": "0"}
{"id": "DDI-DrugBank.d437.s9.p3", "sentence": "Methadone: Coadministration of @DRUG$ and @DRUG$ can decrease plasma levels of methadone.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d533.s1.p6", "sentence": "Co-administration of @DRUG$, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, @DRUG$, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p135", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d210.s25.p3", "sentence": "Rifampin: Co-administration of @DRUG$ with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d178.s0.p6", "sentence": "The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d260.s0.p112", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d401.s0.p33", "sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the @DRUG$ and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the @DRUG$ salts, and antihistamines.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p120", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, @DRUG$, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p56", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p701", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), @DRUG$ (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d460.s3.p2", "sentence": "Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg @DRUG$ three times a day before meals for 1 day in combination with @DRUG$ 10 mg daily.", "label": "0"}
{"id": "DDI-DrugBank.d441.s6.p0", "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d395.s6.p3", "sentence": "Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with other members of the quinolone class.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p471", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p76", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d172.s8.p15", "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p282", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d192.s0.p24", "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d5.s3.p0", "sentence": "Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and cyclophosphamide).", "label": "DDI-int"}
{"id": "DDI-DrugBank.d411.s4.p463", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p199", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;@DRUG$*;ethchlorvynol;@DRUG$;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d165.s9.p0", "sentence": "In vitro data suggest that @DRUG$ also markedly inhibits the biotransformation system mainly responsible for the metabolism of @DRUG$;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d192.s0.p4", "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d165.s4.p8", "sentence": "Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.", "label": "0"}
{"id": "DDI-DrugBank.d533.s7.p33", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, @DRUG$, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p191", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d495.s7.p0", "sentence": "Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving @DRUG$ with agents known to affect sinus node function or AV nodal conduction (e.g., @DRUG$, calcium channel blockers, and beta-blockers.)", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d455.s7.p5", "sentence": "No interaction was noted with the MAO-B inhibitor @DRUG$ in two multiple-dose interaction studies when entacapone was coadministered with a @DRUG$/dopa decarboxylase inhibitor (n=29).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1236", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d485.s32.p1", "sentence": "@DRUG$: Amprenavir, @DRUG$, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p826", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, @DRUG$, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, @DRUG$, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p1029", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, @DRUG$(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d89.s3.p1", "sentence": "Based on adult data, lower doses of @DRUG$ may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., @DRUG$ and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d3.s18.p0", "sentence": "@DRUG$: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (phenytoin, carbamazepine).", "label": "0"}
{"id": "DDI-DrugBank.d379.s1.p27", "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d138.s3.p2", "sentence": "Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.", "label": "0"}
{"id": "DDI-DrugBank.d273.s0.p0", "sentence": "Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between @DRUG$ and other @DRUG$ have not been determined.", "label": "0"}
{"id": "DDI-DrugBank.d328.s33.p1", "sentence": "Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "label": "0"}
{"id": "DDI-MedLine.d132.s4.p2", "sentence": "Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "label": "0"}
{"id": "DDI-DrugBank.d195.s4.p0", "sentence": "An interaction study with @DRUG$ showed no clinically significant effect of @DRUG$ on warfarin pharmacokinetics or anticoagulant activity.", "label": "0"}
{"id": "DDI-DrugBank.d521.s3.p23", "sentence": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), @DRUG$ (Gantrisin), or @DRUG$ (Azulfidine);", "label": "0"}
{"id": "DDI-DrugBank.d488.s7.p6", "sentence": "Heparin Sodium Injection should not be mixed with @DRUG$, droperidol, @DRUG$, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p1", "sentence": "@DRUG$ (CNS) drugs including alcohol, @DRUG$, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d263.s0.p2", "sentence": "Zidovudine: There is no significant pharmacokinetic interaction between @DRUG$ and @DRUG$ which has been confirmed clinically.", "label": "0"}
{"id": "DDI-DrugBank.d457.s0.p2", "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d353.s0.p3", "sentence": "Ethanol:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of @DRUG$ and ethanol.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p501", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;@DRUG$;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d263.s7.p9", "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1185", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d171.s0.p18", "sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d400.s14.p10", "sentence": "Antacids: In a single dose study (n=6), ingestion of an @DRUG$ containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including @DRUG$, lovastatin and trimethoprim.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p66", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d374.s1.p3", "sentence": "Auranofin should not be used together with @DRUG$ (@DRUG$, Cuprimine), another arthritis medication.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p2", "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d246.s14.p0", "sentence": "Therefore, a slower onset can be anticipated if @DRUG$ is administered concomitantly with, or immediately following, a @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p926", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), @DRUG$, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d561.s11.p7", "sentence": "Lotensin has been used concomitantly with @DRUG$, calcium-channel-blocking agents, diuretics, @DRUG$, and hydralazine, without evidence of clinically important adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d485.s18.p1", "sentence": "@DRUG$: Combination hormonal contraceptives may increase the clearance of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d558.s27.p2", "sentence": "Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p171", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p127", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p98", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p828", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d95.s0.p0", "sentence": "@DRUG$ - @DRUG$ may counteract the antinaturetic effect of cyclosporin.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p54", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, @DRUG$, phenytoin, acetylsalicylic acid, tolbutamide, and @DRUG$ showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d76.s31.p1", "sentence": "Thus patients receiving oral @DRUG$ and Fluvoxamine Tablets should have their prothrombin time monitored and their @DRUG$ dose adjusted accordingly.", "label": "0"}
{"id": "DDI-DrugBank.d143.s30.p1", "sentence": "@DRUG$ taken concomitantly with quinidine increases @DRUG$ serum concentration by 33% after two days.", "label": "0"}
{"id": "DDI-DrugBank.d521.s8.p10", "sentence": "- a phenothiazine such as @DRUG$ (Thorazine), @DRUG$ (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "label": "0"}
{"id": "DDI-DrugBank.d531.s90.p12", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p130", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, @DRUG$, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p796", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d458.s21.p3", "sentence": "Because severe hypoglycemia has been reported in patients concomitantly receiving oral @DRUG$ (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an @DRUG$) can not be ruled out.", "label": "0"}
{"id": "DDI-DrugBank.d547.s0.p18", "sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, @DRUG$, @DRUG$, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p15", "sentence": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, @DRUG$), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d411.s2.p9", "sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of @DRUG$ from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, @DRUG$, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d97.s25.p0", "sentence": "Both @DRUG$ and @DRUG$ are associated with indirect (unconjugated) hyperbilirubinemia.", "label": "0"}
{"id": "DDI-DrugBank.d329.s4.p0", "sentence": "In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of @DRUG$ or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p752", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation @DRUG$;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p263", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or", "label": "0"}
{"id": "DDI-MedLine.d57.s2.p22", "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, @DRUG$, methdilazine, and tripelennamine. ", "label": "0"}
{"id": "DDI-DrugBank.d186.s5.p2", "sentence": "In 5 other schizophrenic patients treated with oral @DRUG$ and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in @DRUG$ concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d3.s4.p22", "sentence": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d533.s1.p38", "sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, @DRUG$, @DRUG$, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "label": "0"}
{"id": "DDI-DrugBank.d103.s8.p5", "sentence": "Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p364", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p41", "sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, @DRUG$, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d306.s0.p15", "sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and @DRUG$, and the antituberculosis drug rifampin.", "label": "0"}
{"id": "DDI-DrugBank.d289.s6.p11", "sentence": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d334.s12.p0", "sentence": "No clinically important pharmacokinetic interactions occurred when @DRUG$ was used concomitantly with @DRUG$ or hydrochlorothiazide.", "label": "0"}
{"id": "DDI-DrugBank.d508.s2.p1", "sentence": "Use of @DRUG$ Aspirin and @DRUG$ have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p429", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, @DRUG$, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d176.s15.p0", "sentence": "Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for Digoxin.", "label": "0"}
{"id": "DDI-DrugBank.d151.s2.p0", "sentence": "However, high doses of @DRUG$ may reduce the efficacy of intrathecally administered @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s21.p137", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d312.s5.p1", "sentence": "Due to high inter-patient variability and limited sampling, the extent of the increase in @DRUG$ levels in patients receiving concurrent irinotecan and @DRUG$ is uncertain.", "label": "0"}
{"id": "DDI-DrugBank.d307.s40.p4", "sentence": "Hormonal contraceptives Co-administration of @DRUG$ with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d86.s1.p19", "sentence": "Interactions may also occur with the following: anti-depressants/@DRUG$, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, @DRUG$, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d236.s3.p1", "sentence": "@DRUG$: Adrenergic blockers are inhibited by @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d485.s27.p5", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): @DRUG$ may decrease plasma levels of @DRUG$;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p1259", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d62.s4.p5", "sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an @DRUG$ @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d521.s4.p0", "sentence": "- a @DRUG$ (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "label": "0"}
{"id": "DDI-DrugBank.d30.s9.p4", "sentence": "As with other antihypertensive agents, the antihypertensive effect of @DRUG$ may be blunted by the non-steroidal anti-inflammatory drug @DRUG$", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d295.s1.p1", "sentence": "Coadministration of @DRUG$ with lamivudine, @DRUG$,or tenofovir disoproxil fumarate did not result in significant drug interactions.", "label": "0"}
{"id": "DDI-DrugBank.d347.s7.p3", "sentence": "@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "label": "0"}
{"id": "DDI-DrugBank.d115.s0.p4", "sentence": "Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).", "label": "0"}
{"id": "DDI-DrugBank.d187.s7.p15", "sentence": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d404.s11.p1", "sentence": "@DRUG$: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and @DRUG$, which inhibit calcium absorption.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1247", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d62.s4.p4", "sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an atypical neuroleptic @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d238.s6.p0", "sentence": "plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d103.s2.p0", "sentence": "Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p258", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d347.s7.p15", "sentence": "Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "label": "0"}
{"id": "DDI-DrugBank.d546.s3.p11", "sentence": "There is limited experience with concomitant antihypertensive agents such as alpha-blockers, @DRUG$, ACE inhibitors, and diuretics (both @DRUG$-like and loop).", "label": "0"}
{"id": "DDI-DrugBank.d541.s0.p2", "sentence": "May interact with the following: @DRUG$ (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, @DRUG$, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).", "label": "0"}
{"id": "DDI-DrugBank.d216.s9.p0", "sentence": "Other strong inhibitors of CYP3A4 (e.g., @DRUG$, @DRUG$, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.", "label": "0"}
{"id": "DDI-DrugBank.d485.s36.p7", "sentence": "Rifampin: Rifampin increases the metabolism of @DRUG$ and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "label": "0"}
{"id": "DDI-DrugBank.d132.s25.p5", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d382.s7.p5", "sentence": "5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p106", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (@DRUG$), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d143.s41.p19", "sentence": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "label": "0"}
{"id": "DDI-DrugBank.d189.s0.p26", "sentence": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.", "label": "0"}
{"id": "DDI-DrugBank.d345.s6.p1", "sentence": "However, in a follow-up study in normal subjects, single-dose administration of @DRUG$ and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of @DRUG$ absorption, but had a small yet statistically significant effect on its rate of absorption;", "label": "0"}
{"id": "DDI-DrugBank.d208.s0.p19", "sentence": "Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.", "label": "0"}
{"id": "DDI-DrugBank.d85.s9.p4", "sentence": "Naproxen and other @DRUG$ can reduce the antihypertensive effect of propranolol and other @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s1.p1", "sentence": "@DRUG$ may interact with any of the following: - Acetaminophen (e.g., @DRUG$) (with long-term, high-dose use) or", "label": "DDI-int"}
{"id": "DDI-DrugBank.d297.s2.p12", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d499.s24.p0", "sentence": "@DRUG$: @DRUG$ have been reported to increase steadystate plasma lithium levels.", "label": "0"}
{"id": "DDI-DrugBank.d420.s4.p7", "sentence": "Probenecid: As with other b-lactam antibiotics, @DRUG$ inhibits the renal excretion of @DRUG$, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d522.s8.p0", "sentence": "Also, in vitro experiments demonstrated a lack of interaction between @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d382.s41.p4", "sentence": "Diltiazem: In patients with mild to moderate hypertension, administration of @DRUG$ once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with @DRUG$ 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d246.s0.p18", "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and @DRUG$) may result in increased central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d97.s72.p10", "sentence": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as @DRUG$, fluvastatin, or @DRUG$ in combination with CRIXIVAN.", "label": "0"}
{"id": "DDI-MedLine.d76.s5.p1", "sentence": "Unmodified @DRUG$ (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) @DRUG$ conjugated with cysteine further enhanced the permeation. ", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p279", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation @DRUG$;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d263.s24.p1", "sentence": "@DRUG$: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and @DRUG$ are coadministered.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p210", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), @DRUG$ (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d207.s8.p0", "sentence": "Phase II clinical trial data, where @DRUG$ and @DRUG$ have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p104", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;@DRUG$;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;@DRUG$ under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d458.s3.p0", "sentence": "The following drug interactions have been identified involving @DRUG$ Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: @DRUG$ tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "label": "0"}
{"id": "DDI-DrugBank.d106.s4.p1", "sentence": "Coadministration of @DRUG$ with phenytoin or any known CYP3A4 inducer should be avoided and alternative @DRUG$ therapy should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p502", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d212.s21.p0", "sentence": "Coadministration of @DRUG$ did not affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1071", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation @DRUG$;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p102", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistemethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d43.s4.p7", "sentence": "Antacids: Concomitant administration of @DRUG$ containing magnesium or aluminum with @DRUG$ Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d499.s15.p2", "sentence": "Warfarin: In a short-term controlled study in 14 normal volunteers, @DRUG$ did not significantly interfere with the effect of @DRUG$ on prothrombin time.", "label": "0"}
{"id": "DDI-DrugBank.d488.s7.p4", "sentence": "@DRUG$ Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with @DRUG$ and a precipitate may form.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p957", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d20.s10.p2", "sentence": "@DRUG$ (NSAIDs)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.", "label": "0"}
{"id": "DDI-DrugBank.d245.s0.p5", "sentence": "The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d395.s23.p8", "sentence": "Warfarin: Quinolones, including @DRUG$, decrease the clearance of R-warfarin, the less active isomer of racemic @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d313.s1.p18", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d84.s3.p10", "sentence": "To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (@DRUG$, cefazolin, @DRUG$ and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ", "label": "0"}
{"id": "DDI-DrugBank.d13.s0.p21", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "label": "0"}
{"id": "DDI-DrugBank.d440.s10.p1", "sentence": "Among @DRUG$ or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with @DRUG$ 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).", "label": "0"}
{"id": "DDI-DrugBank.d567.s5.p8", "sentence": "Itraconazole @DRUG$ Erythromycin @DRUG$ Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "label": "0"}
{"id": "DDI-DrugBank.d119.s4.p0", "sentence": "@DRUG$    @DRUG$ antagonism", "label": "0"}
{"id": "DDI-DrugBank.d13.s0.p37", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$", "label": "0"}
{"id": "DDI-DrugBank.d15.s1.p11", "sentence": "In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.", "label": "0"}
{"id": "DDI-MedLine.d5.s0.p2", "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.  ", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p35", "sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d524.s0.p0", "sentence": "@DRUG$, @DRUG$, antidiabetic drugs, diuretics, digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d139.s4.p1", "sentence": "@DRUG$-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of vitamin K.", "label": "0"}
{"id": "DDI-MedLine.d115.s2.p46", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d547.s0.p17", "sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, @DRUG$, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with @DRUG$ to patients with heart failure (NYHA class II and III).", "label": "0"}
{"id": "DDI-DrugBank.d219.s19.p2", "sentence": "Phenylbutazone: @DRUG$ causes increase (by about 80%) in the free fraction of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d172.s8.p17", "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p5", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d395.s16.p1", "sentence": "or with @DRUG$ containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue @DRUG$ concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p929", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d337.s0.p2", "sentence": "Warfarin: Concomitant administration of @DRUG$ (6 mg/kg once every 24 hours for 5 days) and @DRUG$ (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.", "label": "0"}
{"id": "DDI-DrugBank.d543.s1.p0", "sentence": "@DRUG$, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p136", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, @DRUG$, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d558.s13.p2", "sentence": "@DRUG$ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with @DRUG$ (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).", "label": "0"}
{"id": "DDI-DrugBank.d103.s8.p1", "sentence": "Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p595", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d254.s0.p2", "sentence": "Other @DRUG$ (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.", "label": "0"}
{"id": "DDI-DrugBank.d53.s2.p1", "sentence": "Although a dose adjustment of @DRUG$ is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of @DRUG$, such as liver enzyme abnormalities and hearing impairment, is warranted.", "label": "0"}
{"id": "DDI-DrugBank.d138.s2.p2", "sentence": "Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), @DRUG$ and/or @DRUG$ is advised.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p118", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, @DRUG$/sulfamethoxazole or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d313.s3.p0", "sentence": "@DRUG$, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "label": "0"}
{"id": "DDI-DrugBank.d241.s0.p5", "sentence": "Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, @DRUG$, or other @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p79", "sentence": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, @DRUG$ (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p6", "sentence": "Caution should be used when administering or taking @DRUG$ with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d64.s87.p37", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d94.s8.p34", "sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, @DRUG$, rifampin, phenobarbital, Phenytoin(2), primidone, @DRUG$, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p887", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d293.s0.p15", "sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "label": "0"}
{"id": "DDI-DrugBank.d328.s46.p2", "sentence": "These increased exposures of @DRUG$ and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p67", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), @DRUG$ (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (@DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p216", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p28", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, @DRUG$, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and @DRUG$ showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p39", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p55", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d355.s3.p0", "sentence": "In diabetic patients, the metabolic effects of @DRUG$ may decrease blood glucose and therefore, @DRUG$ requirements.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d94.s4.p126", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, @DRUG$, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d527.s3.p1", "sentence": "@DRUG$, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "label": "0"}
{"id": "DDI-DrugBank.d434.s32.p7", "sentence": "Valproate: Available data suggest that there is no significant effect of @DRUG$ on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on @DRUG$  (felbamate) plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d420.s2.p1", "sentence": "There are no significant effects on @DRUG$ pharmacokinetics if the antacid is administered 2 hours before or 2 hours after @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d113.s7.p1", "sentence": "@DRUG$: Concomitant administration of aluminum and @DRUG$s does not interfere with absorption of meclofenamate sodium.", "label": "0"}
{"id": "DDI-MedLine.d12.s3.p1", "sentence": "@DRUG$ at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by @DRUG$. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p313", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (@DRUG$, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, @DRUG$, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p816", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d357.s3.p25", "sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p176", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, @DRUG$, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p205", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, @DRUG$, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d328.s27.p5", "sentence": "Fluconazole and Ketoconazole: @DRUG$ and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p47", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d521.s2.p292", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (@DRUG$), and naproxen (Anaprox, @DRUG$, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1303", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;@DRUG$;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;@DRUG$*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p263", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d141.s9.p0", "sentence": "@DRUG$: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p143", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, @DRUG$, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d316.s1.p11", "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d379.s1.p24", "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d123.s12.p8", "sentence": "Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.", "label": "0"}
{"id": "DDI-DrugBank.d76.s1.p1", "sentence": "In patients receiving another @DRUG$ in combination with monoamine oxidase inhibitors (@DRUG$), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d410.s8.p3", "sentence": "fluoxetine, @DRUG$, @DRUG$, sertraline).", "label": "0"}
{"id": "DDI-DrugBank.d335.s3.p3", "sentence": "The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, phenothiazines, @DRUG$ or other antidepressants.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d531.s90.p54", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p856", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, @DRUG$, Kaletra, Norvir, @DRUG$), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p19", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d76.s24.p0", "sentence": "Moreover, as noted with @DRUG$, the effect of @DRUG$ may even be more pronounced when it is administered at higher doses.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p480", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p822", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d568.s25.p9", "sentence": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of @DRUG$ by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d81.s10.p2", "sentence": "If rifampicin therapy is required, @DRUG$ concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d172.s21.p2", "sentence": "@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d123.s8.p48", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p110", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, @DRUG$, phenytoin, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d94.s8.p17", "sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: @DRUG$, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, @DRUG$, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d9.s0.p10", "sentence": "Azlocillin should not be administered concomitantly with amikacin, @DRUG$, gentamicin, @DRUG$, or tobramycin.", "label": "0"}
{"id": "DDI-DrugBank.d165.s3.p2", "sentence": "Coadministration of terfenadine with @DRUG$ has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.", "label": "0"}
{"id": "DDI-DrugBank.d303.s2.p0", "sentence": "Although not observed in this study, adverse effects could potentially arise from co-administration of @DRUG$ and @DRUG$ by inhibition of tubular secretion via organic cationic transporter systems.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d485.s14.p4", "sentence": "Ascorbic acid: Doses of @DRUG$ (vitamin C) 1 g/day have been reported to increase plasma concentration of @DRUG$ by ~47%, possibly by inhibiting conjugation;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d105.s0.p11", "sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d460.s11.p49", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, @DRUG$, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and @DRUG$ showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p712", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (@DRUG$), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p530", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p31", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "label": "0"}
{"id": "DDI-MedLine.d111.s14.p10", "sentence": "Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "label": "0"}
{"id": "DDI-DrugBank.d226.s0.p8", "sentence": "Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.", "label": "0"}
{"id": "DDI-DrugBank.d373.s11.p5", "sentence": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of @DRUG$ at 1000 mg per day and @DRUG$ at 40 mg per day.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d257.s0.p21", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d219.s23.p9", "sentence": "Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p208", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), @DRUG$ (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, @DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p16", "sentence": "Other Drugs: In healthy volunteers, amlodipine, @DRUG$, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), @DRUG$ (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d82.s5.p0", "sentence": "Clinical studies have shown that @DRUG$ does not influence the hypoprothrombinemia produced by @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p7", "sentence": "Caution should be used when administering or taking @DRUG$ with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d241.s3.p13", "sentence": "In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d463.s5.p0", "sentence": "In vitro, @DRUG$ does not displace tightly bound drugs like @DRUG$, propranolol, and warfarin from serum proteins.", "label": "0"}
{"id": "DDI-DrugBank.d53.s0.p0", "sentence": "Co-administration of @DRUG$ at steady-state with a single dose of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d401.s0.p40", "sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, @DRUG$, certain antiarrhythmics such as the @DRUG$ salts, and antihistamines.", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p17", "sentence": "Cholestyramine @DRUG$ may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline @DRUG$, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d77.s15.p8", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e. g., @DRUG$, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p431", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-MedLine.d57.s2.p12", "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$. ", "label": "0"}
{"id": "DDI-MedLine.d56.s1.p0", "sentence": "@DRUG$ (@DRUG$), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. ", "label": "0"}
{"id": "DDI-DrugBank.d3.s4.p2", "sentence": "Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p73", "sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and @DRUG$ preparations, estrogens and @DRUG$, and digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d224.s6.p0", "sentence": "An additive hypotensive effect has been reported with the combination of systemic @DRUG$ and @DRUG$ therapy.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s21.p21", "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d3.s20.p0", "sentence": "@DRUG$: TORADOLIV/IM has been administered concurrently with @DRUG$ in several clinical trials of postoperative pain without evidence of adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d51.s0.p2", "sentence": "@DRUG$ Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and @DRUG$, commonly used in the treatment of chronic obstructive pulmonary disease.", "label": "0"}
{"id": "DDI-DrugBank.d198.s10.p11", "sentence": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.", "label": "0"}
{"id": "DDI-DrugBank.d379.s1.p10", "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p181", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, @DRUG$), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-MedLine.d78.s2.p8", "sentence": "These agents, including norfloxacin, ciprofloxacin, @DRUG$, enoxacin, and @DRUG$, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. ", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p62", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p303", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d118.s2.p6", "sentence": "Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p487", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d324.s19.p1", "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and @DRUG$, account for only 9% of the urinary recovery of a zaleplon dose.", "label": "0"}
{"id": "DDI-DrugBank.d367.s9.p17", "sentence": "Analgesic/anti-inflammatory (e.g., @DRUG$, aspirin, codeine and codeine combinations, ibuprofen, @DRUG$).", "label": "0"}
{"id": "DDI-MedLine.d99.s9.p0", "sentence": "RESULTS: During treatment with @DRUG$, there was a statistically significant decrease in the median of the total clearance of @DRUG$, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d299.s10.p0", "sentence": "Coadministration of @DRUG$ and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d330.s5.p2", "sentence": "Oral neomycin sulfate may enhance the effect of @DRUG$ in @DRUG$ by decreasing vitamin K availability.", "label": "0"}
{"id": "DDI-DrugBank.d284.s3.p6", "sentence": "Concomitant treatment with methylxanthines (@DRUG$, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "label": "0"}
{"id": "DDI-MedLine.d8.s6.p2", "sentence": "When combined with @DRUG$, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or @DRUG$) and ofloxacin. ", "label": "0"}
{"id": "DDI-MedLine.d132.s5.p2", "sentence": "A smaller 24-week study has suggested nevirapine may be superior to the @DRUG$ @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p16", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d283.s5.p2", "sentence": "@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.", "label": "0"}
{"id": "DDI-DrugBank.d499.s10.p5", "sentence": "Diuretic: Hydrochlorothiazide, given concomitantly with @DRUG$, produces a reduction in urinary potassium and chloride excretion compared to @DRUG$ alone.", "label": "0"}
{"id": "DDI-DrugBank.d296.s0.p3", "sentence": "@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d397.s8.p80", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p61", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.", "label": "0"}
{"id": "DDI-DrugBank.d561.s7.p2", "sentence": "@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.", "label": "0"}
{"id": "DDI-DrugBank.d143.s8.p0", "sentence": "Since @DRUG$ is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d551.s4.p4", "sentence": "In clinical studies, coadministration of WelChol  with @DRUG$, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.", "label": "0"}
{"id": "DDI-DrugBank.d13.s0.p13", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "label": "0"}
{"id": "DDI-DrugBank.d324.s13.p0", "sentence": "However, the pharmacodynamics of coadministration of @DRUG$ and @DRUG$ have not been evaluated.", "label": "0"}
{"id": "DDI-DrugBank.d485.s8.p4", "sentence": "Antibiotics (@DRUG$, @DRUG$): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "label": "0"}
{"id": "DDI-DrugBank.d485.s16.p0", "sentence": "@DRUG$: @DRUG$ increases the AUC for norethindrone and ethinyl estradiol.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p204", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), @DRUG$ (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (@DRUG$), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d277.s15.p6", "sentence": "Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p51", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-MedLine.d132.s4.p12", "sentence": "Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz. ", "label": "0"}
{"id": "DDI-DrugBank.d367.s15.p1", "sentence": "Cardiovascular agents (e.g., @DRUG$, hydrochlorothiazide, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d526.s4.p0", "sentence": "@DRUG$ enhanced possibility of arrhythmias or @DRUG$ toxicity associated with hypokalemia.", "label": "0"}
{"id": "DDI-DrugBank.d297.s2.p31", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d94.s16.p1", "sentence": "Additionally, @DRUG$, such as chloroquine and @DRUG$, may antagonize the activity of carbamazepine.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p118", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p59", "sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), @DRUG$ (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d321.s6.p1", "sentence": "@DRUG$: The pharmacokinetics of theophylline (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p208", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d257.s6.p13", "sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.", "label": "0"}
{"id": "DDI-DrugBank.d237.s14.p2", "sentence": "@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as sotalol);", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d306.s0.p12", "sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p33", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: @DRUG$;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;@DRUG$;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d411.s2.p11", "sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of @DRUG$ from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, @DRUG$, soybean flour (e.g., infant formula), sucralfate.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d48.s1.p24", "sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, @DRUG$, erythromycin, @DRUG$, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p253", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d62.s0.p34", "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p72", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d288.s12.p5", "sentence": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p42", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, @DRUG$, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, @DRUG$, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d506.s4.p0", "sentence": "In healthy subjects, no significant drug-drug interaction was observed when @DRUG$ was coadministered with either @DRUG$ or diazepam.", "label": "0"}
{"id": "DDI-DrugBank.d522.s24.p14", "sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including @DRUG$, hexobarbital, carbamazepine, alfentanil, disopyramide, @DRUG$, bromocriptine, valproate, astemizole, and lovastatin.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p3", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d318.s8.p34", "sentence": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d211.s2.p3", "sentence": "@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.", "label": "0"}
{"id": "DDI-DrugBank.d386.s14.p0", "sentence": "Concomitant use of @DRUG$ with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.", "label": "0"}
{"id": "DDI-DrugBank.d464.s0.p7", "sentence": "Codeine in combination with other @DRUG$, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p801", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p297", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (@DRUG$, @DRUG$, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p207", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, @DRUG$, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p200", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d328.s43.p4", "sentence": "Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).", "label": "0"}
{"id": "DDI-DrugBank.d260.s3.p33", "sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.", "label": "0"}
{"id": "DDI-DrugBank.d220.s11.p4", "sentence": "In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p177", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d395.s6.p2", "sentence": "@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d98.s2.p4", "sentence": "@DRUG$/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of @DRUG$/ergocalcitriol by accelerating metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d382.s23.p3", "sentence": "The potential effects of increased plasma concentrations of @DRUG$ or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-MedLine.d15.s0.p2", "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h@DRUG$(0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "label": "0"}
{"id": "DDI-DrugBank.d477.s1.p0", "sentence": "@DRUG$ should not be used concomitantly with other @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d506.s0.p3", "sentence": "If phenytoin or other hepatic enzyme inducers are taken concurrently with @DRUG$ or @DRUG$, lower plasma levels of disopyramide may occur.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p52", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, @DRUG$, beta-blockers), motion sickness medications, @DRUG$, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p15", "sentence": "Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d521.s5.p27", "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (@DRUG$), metoprolol (Lopressor), and others;", "label": "0"}
{"id": "DDI-DrugBank.d333.s5.p5", "sentence": "Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d558.s25.p55", "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d423.s4.p7", "sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as @DRUG$ (@DRUG$) and dihydroergotamine.", "label": "0"}
{"id": "DDI-DrugBank.d568.s10.p6", "sentence": "Lithium - Coadministration of racemic @DRUG$ (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d413.s11.p0", "sentence": "Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on @DRUG$ alone or in combination with @DRUG$, the possibility should be kept in mind.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p60", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, @DRUG$, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d488.s7.p0", "sentence": "@DRUG$ Injection should not be mixed with @DRUG$, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "label": "0"}
{"id": "DDI-DrugBank.d114.s2.p13", "sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.", "label": "0"}
{"id": "DDI-DrugBank.d5.s22.p0", "sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of @DRUG$ and agents (e.g., @DRUG$, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d509.s0.p3", "sentence": "Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when @DRUG$ is taken in combination with other @DRUG$ and alcohol.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d456.s1.p44", "sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (@DRUG$), and voriconazole .", "label": "0"}
{"id": "DDI-MedLine.d45.s5.p0", "sentence": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in @DRUG$, but not in @DRUG$ and tripelennamine, addicts) were completely inhibited by the drug combination. ", "label": "0"}
{"id": "DDI-DrugBank.d388.s5.p6", "sentence": "No significant interactions with digoxin, @DRUG$, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.", "label": "0"}
{"id": "DDI-DrugBank.d225.s0.p12", "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p27", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, @DRUG$ (e.g., @DRUG$), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d413.s9.p3", "sentence": "Uricosuric Agents: Since the excretion of @DRUG$ is similar to that of urate, @DRUG$, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.", "label": "0"}
{"id": "DDI-DrugBank.d459.s0.p1", "sentence": "The daily dose of @DRUG$ should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, @DRUG$, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d64.s87.p649", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;@DRUG$;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d124.s23.p2", "sentence": "@DRUG$/Hypnotics: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.", "label": "0"}
{"id": "DDI-DrugBank.d231.s7.p0", "sentence": "Potentiation occurs with @DRUG-DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d393.s0.p8", "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, ketoconazole, erythromycin and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p197", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d8.s6.p5", "sentence": "When combined with ofloxacin, @DRUG$ exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or @DRUG$) and ofloxacin. ", "label": "0"}
{"id": "DDI-MedLine.d111.s5.p51", "sentence": "acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p825", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, @DRUG$, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d81.s11.p4", "sentence": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between @DRUG$ and racemic @DRUG$ was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "label": "0"}
{"id": "DDI-DrugBank.d249.s11.p1", "sentence": "There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral hypoglycemic agents in the presence of @DRUG$ that necessitated changes in the doses of such agents.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d187.s7.p0", "sentence": "@DRUG$: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "label": "0"}
{"id": "DDI-DrugBank.d75.s2.p21", "sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, @DRUG$, iron, ranitidine, hydroxyurea, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p42", "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d81.s7.p5", "sentence": "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of @DRUG$ on the sixth day showed an increase in @DRUG$ mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "label": "0"}
{"id": "DDI-DrugBank.d131.s10.p20", "sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d567.s9.p5", "sentence": "Gemfibrozil Other fibrates @DRUG$ (@DRUG$) (=1 g/day)", "label": "0"}
{"id": "DDI-DrugBank.d345.s13.p18", "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d456.s6.p7", "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, @DRUG$, @DRUG$, phenobarbital and St. Johns Wort.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p537", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d117.s0.p0", "sentence": "Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p66", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p7", "sentence": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d143.s22.p5", "sentence": "Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.", "label": "0"}
{"id": "DDI-DrugBank.d476.s3.p25", "sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the @DRUG$ [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as @DRUG$, are used concurrently.", "label": "0"}
{"id": "DDI-DrugBank.d509.s23.p5", "sentence": "No clinically significant effect of famotidine, valproate, or @DRUG$ was seen on the pharmacokinetics of @DRUG$ (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p97", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p191", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d114.s10.p10", "sentence": "Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d72.s4.p0", "sentence": "Because @DRUG$ is eliminated from the body via conjugation with glutathione, use of @DRUG$ prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "label": "0"}
{"id": "DDI-DrugBank.d178.s7.p3", "sentence": "A possible interaction between glyburide and @DRUG$, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p633", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d382.s7.p2", "sentence": "@DRUG$: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d318.s8.p8", "sentence": "Imidazoles (e. g., @DRUG$, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "label": "0"}
{"id": "DDI-DrugBank.d138.s0.p0", "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d144.s1.p19", "sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d521.s2.p31", "sentence": "- a nonsteroidal anti-inflammatory drug (@DRUG$) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, @DRUG$), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d179.s34.p0", "sentence": "- @DRUG$ (@DRUG$s) or", "label": "0"}
{"id": "DDI-DrugBank.d382.s5.p0", "sentence": "Coadministration of @DRUG$ with these drugs or other drugs that are known to be metabolized by CYP2C9, such as @DRUG$, may result in lower plasma concentrations of these drugs.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d15.s0.p1", "sentence": "In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "label": "0"}
{"id": "DDI-DrugBank.d26.s0.p18", "sentence": "Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d404.s2.p8", "sentence": "Phenytoin/@DRUG$: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of @DRUG$/ergocalcitriol by accelerating metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d43.s9.p2", "sentence": "In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when @DRUG$ was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s3.p86", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d249.s19.p33", "sentence": "Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.", "label": "0"}
{"id": "DDI-MedLine.d115.s5.p0", "sentence": "@DRUG$ regimens consisted of two @DRUG$ and one protease inhibitor. ", "label": "0"}
{"id": "DDI-DrugBank.d480.s8.p2", "sentence": "Although it has not been established that there is an interaction between @DRUG$ and benzodiazepines or other psychotropics, caution is advised when @DRUG$ is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "label": "0"}
{"id": "DDI-DrugBank.d521.s4.p3", "sentence": "- a @DRUG$ (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil);", "label": "0"}
{"id": "DDI-DrugBank.d288.s0.p2", "sentence": "In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).", "label": "0"}
{"id": "DDI-DrugBank.d237.s14.p1", "sentence": "@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as sotalol);", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d274.s3.p32", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d297.s2.p10", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d132.s27.p5", "sentence": "Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "label": "0"}
{"id": "DDI-DrugBank.d94.s18.p1", "sentence": "Because of its primary CNS effect, caution should be used when @DRUG$ is taken with other centrally acting drugs and @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d347.s0.p1", "sentence": "Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1314", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p29", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: @DRUG$;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;@DRUG$;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d171.s0.p30", "sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d328.s31.p2", "sentence": "Coadministration of valdecoxib (10 mg BID for 7 days) with @DRUG$ (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p9", "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p832", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d15.s0.p5", "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a@DRUG$in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "label": "0"}
{"id": "DDI-DrugBank.d425.s1.p39", "sentence": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a @DRUG$) @DRUG$ There has been concern about the interaction between vitamin B12 and folic acid.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p23", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p1049", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d244.s0.p20", "sentence": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d111.s5.p40", "sentence": "acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p196", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d60.s6.p7", "sentence": "Isoflurane or @DRUG$ administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of @DRUG$ and decrease the required infusion rate of NIMBEX.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d241.s3.p28", "sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p90", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d123.s8.p34", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p731", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d77.s14.p7", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).", "label": "0"}
{"id": "DDI-DrugBank.d297.s2.p36", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p35", "sentence": "Chlorotrianisene may interact with antidepressants, @DRUG$, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d187.s7.p7", "sentence": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "label": "0"}
{"id": "DDI-DrugBank.d236.s14.p0", "sentence": "@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p19", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p946", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, @DRUG$ (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p39", "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p68", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d307.s40.p8", "sentence": "Hormonal contraceptives Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p86", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, @DRUG$, cabergoline, lithium, @DRUG$ pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d386.s23.p13", "sentence": "If desipramine hydrochloride is to be combined with other @DRUG$ such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., @DRUG$ or diazepam) are additive.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p564", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;@DRUG$;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d172.s7.p0", "sentence": "Experience with @DRUG$ (@DRUG$) suggests the potential for interactions with furosemide and ACE inhibitors.", "label": "0"}
{"id": "DDI-DrugBank.d313.s10.p1", "sentence": "Because there are no data on the compatibility of @DRUG$ and crystalline zinc insulin preparations, @DRUG$ should not be mixed with these preparations.", "label": "0"}
{"id": "DDI-DrugBank.d413.s2.p2", "sentence": "@DRUG$/Azathioprine: Allopurinol inhibits the enzymatic oxidation of @DRUG$ and azathioprine to 6-thiouric acid.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p25", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: @DRUG$;alcohol*;antacids;@DRUG$;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d345.s13.p14", "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d162.s4.p9", "sentence": "Cholestyramine and colestipol resins: Absorption of @DRUG$ is impaired in the presence of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d179.s3.p29", "sentence": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p151", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p22", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p81", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d320.s6.p6", "sentence": "and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d321.s6.p3", "sentence": "Theophylline: The pharmacokinetics of @DRUG$ (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d297.s2.p52", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p783", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d562.s8.p3", "sentence": "Quinolones, including @DRUG$, may enhance the effects of oral @DRUG$, such as warfarin or its derivatives.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d123.s8.p5", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d446.s0.p46", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, @DRUG$, @DRUG$ supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d492.s1.p11", "sentence": "Antihistamines may have additive effects with alcohol and other @DRUG$, e.g., @DRUG$, sedatives, tranquilizers, antianxiety agents.", "label": "0"}
{"id": "DDI-DrugBank.d78.s3.p8", "sentence": "Caffeine @DRUG$ Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d48.s1.p73", "sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, @DRUG$, saquinavir, @DRUG$) may increase exposure to dasatinib and should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d345.s13.p33", "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d328.s12.p5", "sentence": "Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s4.p452", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p89", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d360.s1.p17", "sentence": "A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.", "label": "0"}
{"id": "DDI-MedLine.d115.s0.p7", "sentence": "Concomitant cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.", "label": "0"}
{"id": "DDI-DrugBank.d140.s3.p1", "sentence": "@DRUG$: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.", "label": "0"}
{"id": "DDI-MedLine.d115.s2.p12", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p561", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d338.s1.p5", "sentence": "The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d94.s11.p830", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d131.s5.p1", "sentence": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p71", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d476.s3.p10", "sentence": "ZEBETA should be used with care when @DRUG$ or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [@DRUG$] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "label": "0"}
{"id": "DDI-DrugBank.d123.s8.p4", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d559.s1.p0", "sentence": "@DRUG$, @DRUG$ and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "label": "0"}
{"id": "DDI-MedLine.d103.s1.p5", "sentence": "Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. ", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p160", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;@DRUG$;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;@DRUG$;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-MedLine.d81.s6.p0", "sentence": "Maximal hypotension was found 120 minutes post @DRUG$, and returned to normal 300 minutes after @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d485.s18.p0", "sentence": "@DRUG$: Combination @DRUG$ may increase the clearance of clofibric acid.", "label": "0"}
{"id": "DDI-MedLine.d15.s2.p2", "sentence": "It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration. ", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p6", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of @DRUG$ are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, @DRUG$, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s4.p339", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p692", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, @DRUG$), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p429", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p32", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d413.s2.p11", "sentence": "Mercaptopurine/Azathioprine: @DRUG$ inhibits the enzymatic oxidation of mercaptopurine and azathioprine to @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d145.s0.p0", "sentence": "Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d537.s0.p52", "sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., @DRUG$), local anesthetics (e.g., benzocaine and @DRUG$), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "label": "0"}
{"id": "DDI-DrugBank.d178.s0.p28", "sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p12", "sentence": "Caution should be used when administering or taking @DRUG$ with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and @DRUG$ .", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d94.s11.p781", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d434.s37.p3", "sentence": "Effects of @DRUG$  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg @DRUG$ for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p727", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d138.s0.p10", "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, or @DRUG$) should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d107.s10.p6", "sentence": "Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p33", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p16", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d237.s10.p9", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d508.s1.p14", "sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and @DRUG$) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d364.s4.p0", "sentence": "Concomitant administration of @DRUG$ and @DRUG$ is contraindicated.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d179.s21.p166", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d41.s15.p1", "sentence": "Because of the potential for @DRUG$ levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p773", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d485.s17.p10", "sentence": "Benzodiazepines: Combination @DRUG$ may decrease the clearance of some benzodiazepines (alprazolam, @DRUG$, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p1234", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;@DRUG$;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d111.s14.p2", "sentence": "Coingestion of @DRUG$ with theophylline, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "label": "0"}
{"id": "DDI-DrugBank.d543.s1.p6", "sentence": "MAO inhibitors, @DRUG$ (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.", "label": "0"}
{"id": "DDI-DrugBank.d288.s5.p2", "sentence": "Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when paclitaxel and @DRUG$ are used in combination.", "label": "0"}
{"id": "DDI-DrugBank.d258.s4.p2", "sentence": "Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of @DRUG$ relative to that observed with @DRUG$ alone.", "label": "0"}
{"id": "DDI-DrugBank.d124.s14.p9", "sentence": "Antiarrhythmics: Amiodarone, @DRUG$, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.", "label": "0"}
{"id": "DDI-MedLine.d111.s9.p0", "sentence": "@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d397.s8.p2", "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d15.s0.p12", "sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "label": "0"}
{"id": "DDI-DrugBank.d533.s7.p38", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, @DRUG$, metformin, celecoxib, atenolol, atorvastatin, @DRUG$ or hydrochlorothiazide.", "label": "0"}
{"id": "DDI-DrugBank.d527.s1.p36", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, @DRUG$, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p125", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, @DRUG$, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and @DRUG$ (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d208.s0.p29", "sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.", "label": "0"}
{"id": "DDI-DrugBank.d531.s90.p28", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d313.s1.p47", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.", "label": "0"}
{"id": "DDI-DrugBank.d423.s0.p1", "sentence": "In patients receiving nonselective @DRUG$ (MAOIs) (e.g., @DRUG$) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "label": "0"}
{"id": "DDI-DrugBank.d531.s50.p0", "sentence": "Plasma concentrations increased by @DRUG$ (@DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d463.s0.p6", "sentence": "It is recommended that buspirone hydrochloride not be used concomitantly with @DRUG$ Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of @DRUG$ with other CNS-active drugs should be approached with caution.", "label": "0"}
{"id": "DDI-DrugBank.d237.s11.p2", "sentence": "The gastrointestinal absorption of cimetidine and @DRUG$ is accelerated when they are coadministered with @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d484.s0.p509", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p51", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants @DRUG$ antihistamines carbamazepine (Tegretol) @DRUG$ (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p103", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p79", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (@DRUG$, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (@DRUG$), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d434.s37.p11", "sentence": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral @DRUG$ regimen containing 30 mg @DRUG$ and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p228", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p11", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, @DRUG$, @DRUG$, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d87.s6.p0", "sentence": "The effects of concomitant administration of @DRUG$ and @DRUG$ on the PR interval were less than additive.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p53", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d198.s5.p0", "sentence": "@DRUG$ (500 mg t.i.d) produced a 4-fold increase in @DRUG$ AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s29.p69", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;@DRUG$;antihistamines;barbiturates;carbamazepine;@DRUG$*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d284.s6.p2", "sentence": "@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d566.s2.p10", "sentence": "Cholestyramine @DRUG$ may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d98.s0.p11", "sentence": "Interactions for vitamin D analogues (@DRUG$, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: @DRUG$ has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d77.s15.p2", "sentence": "While all the @DRUG$ (SSRIs), e. g., fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1269", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d20.s4.p16", "sentence": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (@DRUG$/ARB).", "label": "0"}
{"id": "DDI-DrugBank.d413.s20.p4", "sentence": "Chlorpropamide: @DRUG$s plasma half-life may be prolonged by @DRUG$, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d9.s0.p14", "sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, @DRUG$, or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d178.s4.p14", "sentence": "These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d171.s3.p1", "sentence": "Interaction with @DRUG$, lidocaine and @DRUG$ has also been reported to produce adverse clinical effects.", "label": "0"}
{"id": "DDI-DrugBank.d535.s1.p3", "sentence": "Antiretroviral Agents: No drug interactions with other @DRUG$ have been identified that would warrant alteration of either the @DRUG$ dose or the dose of the other antiretroviral medication.", "label": "0"}
{"id": "DDI-DrugBank.d567.s5.p17", "sentence": "Itraconazole Ketoconazole @DRUG$ Clarithromycin Telithromycin HIV protease inhibitors Nefazodone @DRUG$ Large quantities of grapefruit juice ( 1 quart daily)", "label": "0"}
{"id": "DDI-DrugBank.d198.s28.p2", "sentence": "Alpha-blockers: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d299.s6.p24", "sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d466.s4.p0", "sentence": "No differences in adverse events or QTc interval were observed when subjects were administered @DRUG$ alone or in combination with either @DRUG$ or ketoconazole.", "label": "0"}
{"id": "DDI-DrugBank.d561.s7.p0", "sentence": "@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "label": "0"}
{"id": "DDI-DrugBank.d213.s1.p2", "sentence": "Serum concentration of digoxin and @DRUG$ may increase when patients take @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d260.s0.p83", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d176.s9.p22", "sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.", "label": "0"}
{"id": "DDI-DrugBank.d5.s22.p6", "sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., @DRUG$, other antidepressants, theophylline, systemic @DRUG$, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p17", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of @DRUG$, carbamazepine, cetirizine, @DRUG$, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d178.s0.p35", "sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d495.s5.p0", "sentence": "The effects of @DRUG$ on @DRUG$s analgesic actions are not known.", "label": "0"}
{"id": "DDI-DrugBank.d357.s1.p3", "sentence": "Antihypertensive Medications and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p105", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d357.s3.p4", "sentence": "@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p41", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, @DRUG$, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, @DRUG$, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d338.s1.p32", "sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.", "label": "0"}
{"id": "DDI-MedLine.d137.s9.p2", "sentence": "Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions. ", "label": "0"}
{"id": "DDI-DrugBank.d324.s19.p3", "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and @DRUG$, account for only 9% of the urinary recovery of a zaleplon dose.", "label": "0"}
{"id": "DDI-DrugBank.d154.s11.p5", "sentence": "In patients receiving Nalfon and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p459", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, @DRUG$, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, @DRUG$ (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d353.s7.p0", "sentence": "It is not known whether other @DRUG$, such as implants and injectables, are adequate methods of contraception during @DRUG$ therapy.", "label": "0"}
{"id": "DDI-DrugBank.d522.s24.p1", "sentence": "Other drugs Drug interactions have been reported with concomitant administration of @DRUG$ and other medications, including cyclosporine, @DRUG$, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d172.s8.p19", "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.", "label": "0"}
{"id": "DDI-MedLine.d57.s2.p7", "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. ", "label": "0"}
{"id": "DDI-DrugBank.d15.s0.p26", "sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "label": "0"}
{"id": "DDI-DrugBank.d371.s1.p6", "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, @DRUG$, erythromycin, and troleandomycin.", "label": "0"}
{"id": "DDI-DrugBank.d249.s19.p30", "sentence": "Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p134", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, @DRUG$, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d81.s12.p0", "sentence": "Neither racemic @DRUG$ nor @DRUG$ binding to plasma proteins in vitro was altered by the addition of the other drug.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p78", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, @DRUG$, quinidine, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p88", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d237.s10.p3", "sentence": "@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p353", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p838", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, @DRUG$, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d533.s9.p1", "sentence": "@DRUG$: When aliskiren was co-administered with @DRUG$, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d522.s12.p0", "sentence": "@DRUG$: Following co-administration of two 250-mg @DRUG$ tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.", "label": "0"}
{"id": "DDI-DrugBank.d522.s24.p3", "sentence": "Other drugs Drug interactions have been reported with concomitant administration of @DRUG$ and other medications, including cyclosporine, hexobarbital, carbamazepine, @DRUG$, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d521.s4.p21", "sentence": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (@DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p109", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d3.s1.p12", "sentence": "Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "label": "0"}
{"id": "DDI-DrugBank.d225.s0.p15", "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.", "label": "0"}
{"id": "DDI-DrugBank.d382.s9.p1", "sentence": "@DRUG$: Dexamethasone: @DRUG$, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p159", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-MedLine.d82.s8.p0", "sentence": "@DRUG$ administration to rachitic chicks was effective in significantly elevating duodenal @DRUG$ absorption, acting primarily to enhance serosal transport.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d11.s0.p9", "sentence": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "label": "0"}
{"id": "DDI-DrugBank.d392.s2.p2", "sentence": "Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic @DRUG$, including protease inhibitors, macrolide antibiotics, and @DRUG$, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p185", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p293", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p159", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (@DRUG$, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (@DRUG$), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p89", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d186.s3.p0", "sentence": "As with other @DRUG$, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1180", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d558.s5.p24", "sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, @DRUG$, or antacids (aluminum and magnesium hydroxides) be used as alternatives to @DRUG$, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d141.s9.p5", "sentence": "WARFARIN: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.", "label": "0"}
{"id": "DDI-DrugBank.d105.s0.p7", "sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.", "label": "0"}
{"id": "DDI-MedLine.d30.s10.p1", "sentence": "In pigeons, @DRUG$ did not systematically alter the effects of (-)-NANM, @DRUG$ or PCP. ", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p743", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d43.s2.p0", "sentence": "@DRUG$: The AUC of @DRUG$ was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).", "label": "0"}
{"id": "DDI-DrugBank.d558.s35.p37", "sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, @DRUG$, sulphonylureas, loop diuretics, @DRUG$, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1337", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;@DRUG$;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d347.s1.p16", "sentence": "Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "label": "0"}
{"id": "DDI-DrugBank.d360.s1.p5", "sentence": "A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p47", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p58", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p79", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, @DRUG$, dantrolene, nicotine, somatropin, @DRUG$, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d167.s2.p22", "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, @DRUG$, lithium carbonate, and terbutaline.", "label": "0"}
{"id": "DDI-DrugBank.d400.s4.p2", "sentence": "ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d235.s4.p40", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d536.s6.p6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, propranolol, or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p67", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d32.s7.p0", "sentence": "however, 150 mg of @DRUG$ q12h for 3 days increased the @DRUG$ C max by 23% and ceftibuten AUC by 16%.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d484.s0.p532", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (@DRUG$, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d558.s35.p28", "sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, @DRUG$, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, @DRUG$, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p61", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d123.s15.p5", "sentence": "Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p968", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, @DRUG$ (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d210.s1.p5", "sentence": "In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.", "label": "0"}
{"id": "DDI-DrugBank.d60.s13.p2", "sentence": "Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p192", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, @DRUG$), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (@DRUG$, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p849", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d224.s1.p14", "sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, @DRUG$) should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d288.s4.p11", "sentence": "Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p352", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d533.s7.p41", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, @DRUG$, celecoxib, @DRUG$, atorvastatin, ramipril or hydrochlorothiazide.", "label": "0"}
{"id": "DDI-DrugBank.d132.s11.p3", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d426.s3.p12", "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p500", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d139.s1.p4", "sentence": "@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p166", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, @DRUG$, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, @DRUG$, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p281", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p43", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d210.s24.p2", "sentence": "@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.", "label": "0"}
{"id": "DDI-DrugBank.d424.s2.p0", "sentence": "The extent of plasma protein binding of @DRUG$ in human plasma is not affected by the presence of therapeutic concentrations of @DRUG$ (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p37", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, @DRUG$ (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing @DRUG$ (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d277.s10.p10", "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.", "label": "0"}
{"id": "DDI-DrugBank.d219.s0.p2", "sentence": "ACE-inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p686", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d478.s4.p8", "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.", "label": "0"}
{"id": "DDI-DrugBank.d558.s12.p0", "sentence": "@DRUG$ (@DRUG$) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.", "label": "0"}
{"id": "DDI-DrugBank.d316.s1.p3", "sentence": "Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p28", "sentence": "Chlorotrianisene may interact with antidepressants, @DRUG$, barbiturates, bromocriptine, calcium supplements, @DRUG$, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p145", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, @DRUG$, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p882", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d224.s1.p1", "sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d558.s35.p38", "sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, @DRUG$, sulphonylureas, loop diuretics, potassium sparing diuretics, @DRUG$, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p969", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;@DRUG$;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p466", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p439", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;@DRUG$*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;@DRUG$*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p796", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as @DRUG$ (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, @DRUG$, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p100", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p310", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p71", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;@DRUG$;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;@DRUG$;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p74", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, @DRUG$, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., @DRUG$), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p112", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (@DRUG$) estrogens fluoxetine (Prozac) intraconazole (Sporanox) @DRUG$ (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d107.s3.p4", "sentence": "Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d546.s3.p3", "sentence": "There is limited experience with concomitant @DRUG$ such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and @DRUG$ (both thiazide-like and loop).", "label": "0"}
{"id": "DDI-DrugBank.d81.s1.p0", "sentence": "@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p738", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d83.s1.p0", "sentence": "@DRUG$, a @DRUG$, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "label": "0"}
{"id": "DDI-DrugBank.d288.s0.p11", "sentence": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d415.s8.p0", "sentence": "H-2 Antagonists: In studies with human volunteers, co-administration of @DRUG$ or @DRUG$ with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d536.s1.p18", "sentence": "These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel-blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p9", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d434.s37.p1", "sentence": "Effects of @DRUG$  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral @DRUG$ regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p42", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d103.s4.p17", "sentence": "Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d242.s1.p9", "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p910", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p19", "sentence": "Cholestyramine @DRUG$ may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and @DRUG$ preparations, estrogens and progestins, and digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d78.s1.p56", "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d312.s1.p5", "sentence": "In Study 1, patients with colorectal cancer were given irinotecan/5-FU/@DRUG$ (bolus-IFL) with or without @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d458.s11.p5", "sentence": "Dosage adjustment may be required if cyclosporine, tacrolimus, or @DRUG$ are given concomitantly with @DRUG$  Tablets.", "label": "0"}
{"id": "DDI-DrugBank.d291.s0.p7", "sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and @DRUG$ may enhance the action of anticoagulants of the coumarin type.", "label": "0"}
{"id": "DDI-DrugBank.d143.s41.p11", "sentence": "Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p65", "sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and @DRUG$ did not affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d456.s6.p8", "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, @DRUG$, carbamazepine, @DRUG$ and St. Johns Wort.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p228", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), @DRUG$, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, @DRUG$(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d162.s5.p1", "sentence": "Single doses of either @DRUG$ or colestipol @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p41", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, @DRUG$, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, @DRUG$, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1285", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;@DRUG$;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d310.s3.p2", "sentence": "A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of @DRUG$ at 1,000 mg/day and @DRUG$ at 90 mg/day.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d281.s0.p2", "sentence": "Probenecid may decrease renal tubular secretion of @DRUG$ when used concurrently, resulting in increased and more prolonged @DRUG$ blood levels.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p769", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p46", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p1427", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;@DRUG$;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d394.s0.p0", "sentence": "The hypotensive effect of @DRUG$ is augmented by that of most other @DRUG$, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d74.s6.p1", "sentence": "@DRUG$, in the absence of glucose or @DRUG$, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ", "label": "0"}
{"id": "DDI-DrugBank.d499.s6.p8", "sentence": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased @DRUG$ plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d212.s19.p0", "sentence": "@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d347.s7.p38", "sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d175.s14.p3", "sentence": "@DRUG$ such as spironolactone, triamterene, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d5.s20.p9", "sentence": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p667", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p44", "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d558.s35.p36", "sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, @DRUG$, sulphonylureas, @DRUG$, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "label": "0"}
{"id": "DDI-DrugBank.d226.s0.p1", "sentence": "Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.", "label": "0"}
{"id": "DDI-DrugBank.d47.s2.p4", "sentence": "@DRUG$ (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d521.s7.p22", "sentence": "- a steroid medicine such as prednisone (Deltasone, @DRUG$, others), methylprednisolone (@DRUG$, others), prednisolone (Prelone, Pediapred, others), and others;", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p2", "sentence": "- a @DRUG$ (NSAID) such as ibuprofen (@DRUG$, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p56", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, @DRUG$), motion sickness medications, @DRUG$, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d532.s2.p26", "sentence": "These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral @DRUG$, ticlopidine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p5", "sentence": "Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d90.s9.p2", "sentence": "At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for @DRUG$ plus @DRUG$. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d257.s0.p73", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d249.s18.p5", "sentence": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d313.s2.p35", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p512", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-MedLine.d95.s4.p1", "sentence": "@DRUG$ (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or @DRUG$ (125 mmol/l) from both lean and dietary-obese rats. ", "label": "0"}
{"id": "DDI-DrugBank.d486.s0.p1", "sentence": "No drug interaction studies have been conducted for @DRUG$, however the use of orally administered antibiotics could, theoretically, interfere with the release of @DRUG$ in the colon.", "label": "0"}
{"id": "DDI-DrugBank.d522.s7.p0", "sentence": "The mean QT c interval (msec) was 369 with @DRUG$ alone and 367 with @DRUG$ plus dirithromycin.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1089", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p5", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d199.s0.p0", "sentence": "@DRUG$: When coadministered with @DRUG$, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "label": "0"}
{"id": "DDI-DrugBank.d468.s10.p12", "sentence": "When therapeutic concentrations of furosemide, propranolol, @DRUG$, warfarin, @DRUG$, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "label": "0"}
{"id": "DDI-DrugBank.d3.s19.p13", "sentence": "Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d554.s0.p1", "sentence": "Certain @DRUG$, cisplatin, @DRUG$, diuretic, foscarnet, and vaccines.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p18", "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p75", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d400.s14.p5", "sentence": "@DRUG$: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, @DRUG$ and trimethoprim.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p87", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d285.s1.p1", "sentence": "A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p143", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), @DRUG$ such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (@DRUG$), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p30", "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d241.s3.p4", "sentence": "In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d437.s4.p2", "sentence": "HIV Protease Inhibitors: The effect of @DRUG$ on total drug concentrations of other @DRUG$ in subjects receiving both agents was evaluated using comparisons to historical data.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p24", "sentence": "- Phenothiazines (@DRUG$ [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d460.s12.p15", "sentence": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, @DRUG$, nicardipine, warfarin, @DRUG$, acetylsalicylic acid, and tolbutamide in vitro .", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p255", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), @DRUG$ (@DRUG$), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d226.s0.p7", "sentence": "Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.", "label": "0"}
{"id": "DDI-DrugBank.d183.s1.p9", "sentence": "INOmax has been administered with tolazoline, @DRUG$, @DRUG$, steroids, surfactant, and high-frequency ventilation.", "label": "0"}
{"id": "DDI-DrugBank.d289.s32.p16", "sentence": "Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "label": "0"}
{"id": "DDI-DrugBank.d382.s36.p6", "sentence": "Ketoconazole: When a single 125-mg dose of @DRUG$ was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of @DRUG$ increased approximately 3-fold.", "label": "0"}
{"id": "DDI-DrugBank.d506.s2.p12", "sentence": "Other antiarrhythmic drugs (eg, quinidine, procainamide, @DRUG$, @DRUG$) have occasionally been used concurrently with Norpace.", "label": "0"}
{"id": "DDI-DrugBank.d395.s16.p0", "sentence": "or with @DRUG$ containing @DRUG$ may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d467.s4.p0", "sentence": "Concomitant administration of @DRUG$ capsules and @DRUG$ resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d184.s0.p39", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d43.s11.p2", "sentence": "In a single subject given one dose of ciprofloxacin 2 hours after a dose of @DRUG$-placebo tablets, a greater than 50% reduction in the AUC of @DRUG$ was observed.", "label": "0"}
{"id": "DDI-DrugBank.d424.s5.p0", "sentence": "@DRUG$, another @DRUG$, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.", "label": "0"}
{"id": "DDI-DrugBank.d522.s24.p25", "sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, @DRUG$, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, @DRUG$, and lovastatin.", "label": "0"}
{"id": "DDI-DrugBank.d328.s43.p6", "sentence": "Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p225", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;@DRUG$;griseofulvin;haloperidol;meprobamate;oral contraceptives;@DRUG$;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d386.s23.p4", "sentence": "If @DRUG$ is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of @DRUG$ and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "label": "0"}
{"id": "DDI-DrugBank.d424.s2.p1", "sentence": "The extent of plasma protein binding of @DRUG$ in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of @DRUG$ affected by the presence of atovaquone.", "label": "0"}
{"id": "DDI-DrugBank.d565.s35.p1", "sentence": "These pharmacokinetic effects seen during @DRUG$ coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d236.s16.p0", "sentence": "@DRUG$: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.", "label": "0"}
{"id": "DDI-DrugBank.d216.s6.p0", "sentence": "Drugs That Inhibit CYP3A4 (@DRUG$) CYP3A4 is a major metabolic pathway for elimination of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d382.s24.p3", "sentence": "In another study with intravenous administration of midazolam, @DRUG$ was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and @DRUG$ 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "label": "0"}
{"id": "DDI-DrugBank.d187.s7.p5", "sentence": "@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "label": "0"}
{"id": "DDI-DrugBank.d288.s1.p0", "sentence": "Pharmacokinetic data from these patients demonstrated a decrease in @DRUG$ clearance of approximately 33% when @DRUG$ was administered following cisplatin.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p250", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d410.s5.p10", "sentence": "Macrolide Antibiotics (e. g. @DRUG$ and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (@DRUG$) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p119", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and @DRUG$ without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d20.s4.p4", "sentence": "@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).", "label": "0"}
{"id": "DDI-DrugBank.d17.s9.p5", "sentence": "Amphotericin B or Corticosteroids or @DRUG$ (@DRUG$)", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p122", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;@DRUG$;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p38", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d467.s3.p5", "sentence": "Furthermore, rifampin, phenytoin, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d115.s2.p37", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-MedLine.d111.s14.p5", "sentence": "Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "label": "0"}
{"id": "DDI-DrugBank.d9.s0.p8", "sentence": "Azlocillin should not be administered concomitantly with @DRUG$, ciprofloxacin, gentamicin, netilmicin, or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d223.s8.p16", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p77", "sentence": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-MedLine.d130.s3.p3", "sentence": "To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin. ", "label": "0"}
{"id": "DDI-DrugBank.d334.s20.p1", "sentence": "It is recommended that serum @DRUG$ levels be monitored frequently if PRINIVIL is administered concomitantly with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p394", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d205.s0.p10", "sentence": "Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).", "label": "0"}
{"id": "DDI-DrugBank.d76.s7.p4", "sentence": "Terfenadine, @DRUG$ and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that @DRUG$, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p98", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d501.s10.p6", "sentence": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of @DRUG$, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these @DRUG$ with EXTRANEAL.", "label": "0"}
{"id": "DDI-DrugBank.d455.s10.p6", "sentence": "These include probenecid, @DRUG$, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).", "label": "0"}
{"id": "DDI-DrugBank.d404.s4.p0", "sentence": "@DRUG$: @DRUG$ are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "label": "0"}
{"id": "DDI-DrugBank.d521.s10.p0", "sentence": "- @DRUG$ (@DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p137", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;@DRUG$;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d223.s7.p11", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p298", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., @DRUG$]) or", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p7", "sentence": "@DRUG$ (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, @DRUG$, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p81", "sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$, troleandomycin (TAO), and voriconazole .", "label": "0"}
{"id": "DDI-DrugBank.d393.s0.p10", "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, @DRUG$ and azithromycin.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p85", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, @DRUG$, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, @DRUG$, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d137.s9.p7", "sentence": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1142", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d568.s31.p0", "sentence": "In addition, steady state levels of racemic @DRUG$ were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of @DRUG$, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d78.s1.p44", "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p82", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, @DRUG$, quinidine, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p32", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d175.s18.p8", "sentence": "Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.", "label": "0"}
{"id": "DDI-DrugBank.d357.s3.p33", "sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.", "label": "0"}
{"id": "DDI-DrugBank.d84.s1.p12", "sentence": "Although deferasirox has a lower affinity for aluminum than for iron, @DRUG$ should not be taken with @DRUG$-containing antacid preparations.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d186.s4.p2", "sentence": "In a study of 12 schizophrenic patients coadministered oral haloperidol and @DRUG$, plasma @DRUG$ levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p162", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d115.s0.p5", "sentence": "Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p53", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d568.s1.p12", "sentence": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other @DRUG$, the use of @DRUG$ by patients taking LEXAPRO is not recommended.", "label": "0"}
{"id": "DDI-DrugBank.d216.s16.p7", "sentence": "Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG-DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p56", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, @DRUG$ supplements, corticosteroids, @DRUG$, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p493", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p44", "sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, @DRUG$, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d333.s3.p0", "sentence": "In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s29.p147", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;@DRUG$*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;@DRUG$;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d382.s4.p2", "sentence": "Aprepitant has been shown to induce the metabolism of @DRUG$ and @DRUG$, which are metabolized through CYP2C9.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p30", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d485.s17.p25", "sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (@DRUG$, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d151.s0.p4", "sentence": "Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p234", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p576", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;@DRUG$;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d83.s4.p0", "sentence": "The 1-year risk of relapse (rehospitalisation) was significantly lower with @DRUG$ than with @DRUG$ treatment. ", "label": "0"}
{"id": "DDI-DrugBank.d549.s3.p4", "sentence": "During clinical trials, @DRUG$ was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, @DRUG$, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.", "label": "0"}
{"id": "DDI-DrugBank.d395.s8.p3", "sentence": "If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p9", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;@DRUG$;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d360.s1.p2", "sentence": "A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.", "label": "0"}
{"id": "DDI-DrugBank.d342.s0.p21", "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d277.s15.p1", "sentence": "Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "label": "0"}
{"id": "DDI-DrugBank.d528.s0.p4", "sentence": "Acetaminophen and @DRUG$ - @DRUG$ may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "label": "0"}
{"id": "DDI-DrugBank.d3.s1.p16", "sentence": "Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "label": "0"}
{"id": "DDI-DrugBank.d131.s0.p9", "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p104", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (@DRUG$), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d205.s0.p11", "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "label": "0"}
{"id": "DDI-DrugBank.d287.s0.p0", "sentence": "@DRUG$ should be administered with caution to patients taking @DRUG$, because of the possibility of conduction disturbances.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d165.s26.p0", "sentence": "Severe hypoglycemia has been reported in patients concomitantly receiving @DRUG$ and oral @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d411.s4.p552", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d272.s2.p0", "sentence": "Compounds in these categories result in a decreased efficacy of @DRUG$: @DRUG$, haloperidol, metoclopramide, pimozide.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d434.s32.p10", "sentence": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of @DRUG$  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on @DRUG$  (felbamate) plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d441.s4.p2", "sentence": "Initial doses of adrenergic agents, such as @DRUG$ or @DRUG$, should be reduced and titrated to achieve the desired response.", "label": "0"}
{"id": "DDI-DrugBank.d78.s16.p9", "sentence": "include terfenadine, astemizole, cisapride, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d558.s5.p35", "sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to @DRUG$, as these agents have no effect on the pharmacokinetic profile of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p96", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistemethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d487.s1.p1", "sentence": "Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "label": "0"}
{"id": "DDI-DrugBank.d82.s25.p0", "sentence": "(@DRUG$) @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "label": "0"}
{"id": "DDI-DrugBank.d219.s20.p0", "sentence": "Although in vivo studies have not been done to see if @DRUG$ clearance is changed by coadministration of @DRUG$, it is not recommended that they be coadministered.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d431.s1.p27", "sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, @DRUG$, @DRUG$, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p124", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d192.s0.p10", "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d488.s4.p0", "sentence": "Thus in order to avoid bleeding, reduced dosage of @DRUG$ is recommended during treatment with @DRUG$ (human).", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d492.s1.p5", "sentence": "@DRUG$ may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d531.s90.p41", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d208.s0.p7", "sentence": "@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d20.s3.p2", "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d239.s2.p14", "sentence": "The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).", "label": "0"}
{"id": "DDI-DrugBank.d356.s4.p5", "sentence": "In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d485.s36.p0", "sentence": "@DRUG$: @DRUG$ increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p80", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (@DRUG$, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), @DRUG$ (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p403", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d307.s48.p0", "sentence": "Results with @DRUG$ wshow no evidence of interaction with either single or repeated doses of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d141.s13.p5", "sentence": "OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d186.s3.p13", "sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d170.s3.p4", "sentence": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "label": "0"}
{"id": "DDI-DrugBank.d124.s28.p0", "sentence": "Since @DRUG$ is coadministered with @DRUG$, the ritonavir label should be reviewed for additional drugs that should not be coadministered.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d64.s87.p811", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d111.s14.p11", "sentence": "Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug. ", "label": "0"}
{"id": "DDI-DrugBank.d198.s16.p1", "sentence": "Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and ranitidine.", "label": "0"}
{"id": "DDI-MedLine.d12.s2.p2", "sentence": "Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d139.s1.p18", "sentence": "Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p16", "sentence": "Chlorotrianisene may interact with @DRUG$, aspirin, barbiturates, bromocriptine, @DRUG$ supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p480", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d333.s3.p12", "sentence": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "label": "0"}
{"id": "DDI-DrugBank.d236.s8.p7", "sentence": "d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p85", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, @DRUG$, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p333", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p179", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p167", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;@DRUG$;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p3", "sentence": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d64.s87.p1136", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d277.s12.p0", "sentence": "@DRUG$ (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "label": "0"}
{"id": "DDI-DrugBank.d345.s13.p8", "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d492.s1.p17", "sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., @DRUG$, sedatives, tranquilizers, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p203", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;@DRUG$*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral @DRUG$;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d457.s0.p10", "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.", "label": "0"}
{"id": "DDI-MedLine.d114.s8.p0", "sentence": "In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes.", "label": "0"}
{"id": "DDI-DrugBank.d99.s8.p0", "sentence": "While all the selective @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d434.s37.p0", "sentence": "Effects of @DRUG$  on Low-Dose @DRUG$ A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p99", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, @DRUG$(1), dalfopristin, @DRUG$, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d277.s24.p0", "sentence": "Oral @DRUG$: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.", "label": "0"}
{"id": "DDI-DrugBank.d321.s4.p2", "sentence": "@DRUG$: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p172", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p71", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d324.s20.p1", "sentence": "Coadministration of single, oral doses of @DRUG$ with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in @DRUG$s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p52", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d140.s3.p5", "sentence": "Antipyrine: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p331", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d176.s9.p20", "sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "label": "0"}
{"id": "DDI-DrugBank.d228.s2.p1", "sentence": "Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, ketoconazole), though this has not been studied", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d463.s7.p4", "sentence": "The patient was also chronically receiving phenytoin, @DRUG$, digoxin, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d425.s1.p36", "sentence": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) @DRUG$ (a diuretic) @DRUG$ There has been concern about the interaction between vitamin B12 and folic acid.", "label": "0"}
{"id": "DDI-DrugBank.d47.s2.p13", "sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, @DRUG$) and isoniazid may reduce the therapeutic effects of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d333.s7.p35", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d171.s2.p0", "sentence": "therefore, close monitoring of prothrombin time is recommended, and adjustment of the @DRUG$ dose may be necessary when @DRUG$ is administered concomitantly.", "label": "DDI-advise"}
{"id": "DDI-MedLine.d47.s4.p1", "sentence": "@DRUG$ may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d530.s2.p3", "sentence": "Selegiline - @DRUG$ and the @DRUG$ selegiline may have synergistic antidepressant activity if used concomitantly.", "label": "0"}
{"id": "DDI-DrugBank.d163.s13.p0", "sentence": "No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d313.s1.p54", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d139.s1.p23", "sentence": "Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.", "label": "0"}
{"id": "DDI-DrugBank.d467.s3.p1", "sentence": "Furthermore, @DRUG$, phenytoin, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d123.s14.p1", "sentence": "@DRUG$: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d94.s12.p1", "sentence": "The uptake inhibitors @DRUG$ and desipramine (3 mumol/liter) potentiated the positive inotropic effects of @DRUG$ in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d226.s0.p14", "sentence": "Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and @DRUG$, without any change in the adverse reaction profile.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p801", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1385", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p771", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, @DRUG$), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), @DRUG$, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-MedLine.d124.s1.p0", "sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine. ", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p200", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;@DRUG$;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d485.s22.p3", "sentence": "Example inducers include @DRUG$, carbamazepine, nafcillin, nevirapine, @DRUG$, phenytoin, and rifamycins.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p39", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, @DRUG$, bromocriptine, calcium supplements, corticosteroids, @DRUG$, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p652", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (@DRUG$), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), @DRUG$ (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p87", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d140.s9.p0", "sentence": "@DRUG$: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.", "label": "0"}
{"id": "DDI-DrugBank.d499.s3.p3", "sentence": "@DRUG$: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p37", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, @DRUG$, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and @DRUG$", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p100", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d220.s11.p12", "sentence": "In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "label": "0"}
{"id": "DDI-DrugBank.d140.s9.p1", "sentence": "@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.", "label": "0"}
{"id": "DDI-DrugBank.d245.s0.p4", "sentence": "The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d250.s2.p9", "sentence": "Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p617", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d170.s2.p4", "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d431.s1.p4", "sentence": "Studies have shown that @DRUG$ does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, @DRUG$, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d47.s2.p5", "sentence": "Dopamine D2 receptor antagonists (e.g., @DRUG$, @DRUG$, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.", "label": "0"}
{"id": "DDI-DrugBank.d78.s1.p30", "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d171.s0.p26", "sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.", "label": "0"}
{"id": "DDI-MedLine.d118.s3.p4", "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "label": "0"}
{"id": "DDI-DrugBank.d97.s84.p0", "sentence": "Dose reduction of @DRUG$ to half the standard dose and a dose increase of @DRUG$ to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "label": "0"}
{"id": "DDI-DrugBank.d410.s5.p6", "sentence": "@DRUG$ (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the @DRUG$, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "label": "0"}
{"id": "DDI-DrugBank.d316.s19.p2", "sentence": "Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p11", "sentence": "Before taking @DRUG$, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (@DRUG$);", "label": "DDI-advise"}
{"id": "DDI-MedLine.d140.s2.p0", "sentence": "METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and prednisone. ", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p114", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p290", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (@DRUG$), and @DRUG$ (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d457.s0.p7", "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1225", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p207", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), @DRUG$ (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, @DRUG$, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d263.s0.p1", "sentence": "@DRUG$: There is no significant pharmacokinetic interaction between ZDV and @DRUG$ which has been confirmed clinically.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p21", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d202.s16.p1", "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "label": "DDI-advise"}
{"id": "DDI-MedLine.d54.s2.p0", "sentence": "Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of @DRUG$ on these components may help to trace pathways which are affected by @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1326", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p75", "sentence": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p81", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, @DRUG$, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p377", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p95", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p36", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p23", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d485.s27.p2", "sentence": "@DRUG$ (NNRTIs): Nevirapine may decrease plasma levels of @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p214", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d20.s9.p0", "sentence": "Serum @DRUG$ levels should be monitored frequently if @DRUG$ is administered concomitantly with lithium.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p76", "sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, @DRUG$, @DRUG$, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d404.s7.p2", "sentence": "Digitalis: @DRUG$ dosage must be determined with care in patients undergoing treatment with @DRUG$, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d94.s11.p927", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p0", "sentence": "@DRUG$ may interact with @DRUG$, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d484.s0.p267", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d474.s1.p1", "sentence": "These agents include medications such as: @DRUG$, platelet inhibitors including @DRUG$, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p212", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d123.s14.p0", "sentence": "@DRUG$: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p170", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p212", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d107.s13.p14", "sentence": "Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d506.s4.p2", "sentence": "In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d533.s7.p53", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, @DRUG$, ramipril or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p0", "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p2", "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d499.s19.p2", "sentence": "@DRUG$: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of @DRUG$ to about one-third, as well as decreasing its protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d521.s4.p19", "sentence": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (@DRUG$), or phenelzine (Nardil);", "label": "0"}
{"id": "DDI-DrugBank.d333.s3.p13", "sentence": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.", "label": "0"}
{"id": "DDI-DrugBank.d386.s23.p2", "sentence": "If @DRUG$ is to be combined with other psychotropic agents such as tranquilizers or @DRUG$/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d133.s0.p4", "sentence": "Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.", "label": "0"}
{"id": "DDI-DrugBank.d568.s17.p1", "sentence": "If concomitant treatment with @DRUG$ and an SSRI (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d449.s2.p8", "sentence": "Fluoxetine, OCs, @DRUG$, diltiazem, @DRUG$ (exercise caution).", "label": "0"}
{"id": "DDI-DrugBank.d380.s2.p18", "sentence": "ketoconazole), macrolide antibiotics (e.g. @DRUG$), and HIV protease inhibitors (e.g. ritonavir, indinavir and @DRUG$) should have their dose of SUBUTEX or SUBOXONE adjusted.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p85", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-MedLine.d111.s14.p12", "sentence": "Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "label": "0"}
{"id": "DDI-DrugBank.d97.s73.p0", "sentence": "@DRUG$: @DRUG$, tacrolimus, sirolimus", "label": "0"}
{"id": "DDI-DrugBank.d380.s2.p30", "sentence": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, @DRUG$ and @DRUG$) should have their dose of SUBUTEX or SUBOXONE adjusted.", "label": "0"}
{"id": "DDI-DrugBank.d275.s1.p0", "sentence": "Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either @DRUG$ or @DRUG$ when the two agents were administered together.", "label": "0"}
{"id": "DDI-DrugBank.d46.s20.p2", "sentence": "Therefore, when chlorothiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p0", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p428", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, @DRUG$, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d468.s10.p14", "sentence": "When therapeutic concentrations of furosemide, propranolol, @DRUG$, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of @DRUG$ was not altered.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p831", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p18", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p365", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d431.s1.p32", "sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, @DRUG$, ibuprofen, phenytoin, propranolol, prednisone, diazepam, @DRUG$, or terfenadine in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p271", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d460.s14.p5", "sentence": "Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d94.s11.p45", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p99", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p15", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, @DRUG$, captopril, nicardipine, pravastatin, glyburide, @DRUG$, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-MedLine.d133.s1.p4", "sentence": "BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "label": "0"}
{"id": "DDI-DrugBank.d179.s7.p0", "sentence": "- @DRUG$ (e.g., @DRUG$) or", "label": "0"}
{"id": "DDI-DrugBank.d434.s32.p3", "sentence": "@DRUG$: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on @DRUG$  (felbamate) plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p11", "sentence": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d238.s6.p9", "sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p42", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d364.s18.p0", "sentence": "A clinical interaction study was also conducted with @DRUG$ and the CYP3A4 substrate @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d526.s17.p1", "sentence": "@DRUG$, phenytoin, or @DRUG$ increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p102", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, @DRUG$ (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d179.s3.p7", "sentence": "- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or", "label": "0"}
{"id": "DDI-DrugBank.d163.s10.p1", "sentence": "@DRUG$: Accutane has not been shown to alter the pharmacokinetics of @DRUG$ in a study in seven healthy volunteers.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p119", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p52", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), @DRUG$ (Disalcid, others), choline salicylate (@DRUG$), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p71", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p580", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, @DRUG$, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, @DRUG$, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d210.s30.p1", "sentence": "Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, tacrine, and @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d367.s11.p1", "sentence": "@DRUG$ (e.g., erythromycin, @DRUG$ and sulfamethoxazole, amoxicillin).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p679", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d522.s23.p0", "sentence": "@DRUG$: Concurrent use of @DRUG$ and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p262", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p335", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p748", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d269.s1.p10", "sentence": "poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p188", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in @DRUG$;diuretics*;ethchlorvynol;glutethimide;@DRUG$;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d76.s14.p9", "sentence": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when @DRUG$ was administered alone;", "label": "0"}
{"id": "DDI-DrugBank.d223.s8.p13", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p382", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d253.s2.p1", "sentence": "@DRUG$ (such as flecainide, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p131", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, @DRUG$, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p608", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d183.s2.p1", "sentence": "Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p53", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d46.s16.p0", "sentence": "@DRUG$ reduce the renal clearance of @DRUG$ and add a high risk of lithium toxicity.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d440.s1.p1", "sentence": "Products containing @DRUG$ and other multivalent cations (such as aluminum, @DRUG$, iron) are likely to interfere with absorption of Ibandronate.", "label": "0"}
{"id": "DDI-DrugBank.d66.s5.p0", "sentence": "@DRUG$ - There is one report that @DRUG$ may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p7", "sentence": "Before taking @DRUG$, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (@DRUG$), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d179.s21.p230", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d257.s0.p47", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d277.s3.p0", "sentence": "@DRUG$ is considered to be a non-enzyme inducing @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d30.s8.p8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, @DRUG$, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p62", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, @DRUG$, guanethidine, guanadrel, @DRUG$, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p878", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d467.s2.p3", "sentence": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "label": "0"}
{"id": "DDI-MedLine.d56.s2.p0", "sentence": "In the presence of @DRUG$ (10(-5) M), @DRUG$ (10(-8) M) failed to cause the first contraction; ", "label": "DDI-effect"}
{"id": "DDI-MedLine.d132.s4.p7", "sentence": "Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz. ", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p858", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d237.s14.p7", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and @DRUG$) and Class III (such as sotalol);", "label": "0"}
{"id": "DDI-DrugBank.d225.s6.p39", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p118", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-MedLine.d76.s9.p5", "sentence": "Formulation of fluorescence labelled bacitracin and insulin in unconjugated @DRUG$ (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) @DRUG$7.3 a significantly improved permeation was observed (R= 1.3). ", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p29", "sentence": "Chlorotrianisene may interact with antidepressants, @DRUG$, barbiturates, bromocriptine, calcium supplements, corticosteroids, @DRUG$, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d514.s2.p3", "sentence": "Toxicology studies of @DRUG$-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as @DRUG$ (Valium), and, to a rising degree, methadone.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p834", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, @DRUG$, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, @DRUG$ (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p56", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), @DRUG$ (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (@DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p766", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d97.s72.p6", "sentence": "Use lowest possible dose of atorvastatin with careful monitoring, or consider @DRUG$ that are not primarily metabolized by CYP3A4, such as pravastatin, @DRUG$, or rosuvastatin in combination with CRIXIVAN.", "label": "0"}
{"id": "DDI-MedLine.d135.s8.p0", "sentence": "Since chronic dosing is required for therapeutic efficacy of @DRUG$, future studies should focus on investigation of chronic dosing effects of these drugs in combination with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1278", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p177", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p79", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d205.s0.p3", "sentence": "Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p70", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d485.s32.p10", "sentence": "Protease inhibitors: Amprenavir, @DRUG$, nelfinavir, and @DRUG$ have been shown to decrease plasma levels of combination hormonal contraceptives;", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p69", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d466.s3.p0", "sentence": "In 2 separate studies, @DRUG$ 120 mg twice daily (240 mg total daily dose) was co-administered with either @DRUG$ 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).", "label": "0"}
{"id": "DDI-DrugBank.d54.s24.p6", "sentence": "Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on @DRUG$ therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d26.s0.p20", "sentence": "Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d460.s11.p16", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, @DRUG$, captopril, nicardipine, pravastatin, glyburide, warfarin, @DRUG$, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d357.s0.p6", "sentence": "@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .", "label": "0"}
{"id": "DDI-DrugBank.d143.s52.p1", "sentence": "Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (@DRUG$ substrate) given for local anesthesia.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1104", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d536.s1.p24", "sentence": "These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p329", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p278", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p213", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), @DRUG$, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d299.s6.p2", "sentence": "@DRUG$ (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "label": "0"}
{"id": "DDI-DrugBank.d11.s0.p5", "sentence": "Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "label": "0"}
{"id": "DDI-DrugBank.d415.s9.p0", "sentence": "@DRUG$: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.", "label": "0"}
{"id": "DDI-DrugBank.d488.s6.p3", "sentence": "Drugs Decreasing @DRUG$ Effect: Digitalis, tetracyclines, nicotine, or @DRUG$ may partially counteract the anticoagulant action of heparin sodium.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p45", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p10", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d395.s23.p4", "sentence": "Warfarin: @DRUG$, including @DRUG$, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d559.s1.p34", "sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, @DRUG$, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other @DRUG$, causing increased CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d246.s0.p9", "sentence": "Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d531.s39.p1", "sentence": "When @DRUG$ at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the @DRUG$ AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "label": "0"}
{"id": "DDI-DrugBank.d342.s0.p8", "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p846", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p13", "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "label": "0"}
{"id": "DDI-MedLine.d3.s0.p0", "sentence": "Pharmacokinetic Interaction between @DRUG$ and @DRUG$ or rifampin in healthy males. ", "label": "0"}
{"id": "DDI-DrugBank.d198.s12.p3", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.", "label": "0"}
{"id": "DDI-DrugBank.d440.s13.p6", "sentence": "However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.", "label": "0"}
{"id": "DDI-DrugBank.d512.s2.p1", "sentence": "Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., @DRUG$, vinblastine, @DRUG$ and most tricyclic antidepressants) may be required.", "label": "0"}
{"id": "DDI-DrugBank.d423.s0.p23", "sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with @DRUG$ (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p111", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, @DRUG$, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d460.s12.p1", "sentence": "Similarly, @DRUG$ had no influence on the serum protein binding of propranolol, @DRUG$, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p63", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p20", "sentence": "Caution should be used when administering or taking TARCEVA with @DRUG$ and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "0"}
{"id": "DDI-MedLine.d132.s1.p3", "sentence": "The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p301", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p59", "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p62", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p182", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), @DRUG$ (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d123.s5.p0", "sentence": "@DRUG$ Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.", "label": "0"}
{"id": "DDI-MedLine.d111.s5.p18", "sentence": "acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-MedLine.d90.s8.p2", "sentence": "Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for @DRUG$ plus @DRUG$. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d226.s0.p6", "sentence": "Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.", "label": "0"}
{"id": "DDI-DrugBank.d277.s10.p11", "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d318.s8.p7", "sentence": "@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p16", "sentence": "Cholestyramine @DRUG$ may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as @DRUG$ penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p63", "sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p308", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (@DRUG$, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p201", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d72.s2.p0", "sentence": "@DRUG$ increases the clearance of @DRUG$ by 15% or more, possibly due to the induction of glutathione-S-transferase.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d267.s5.p9", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d236.s1.p5", "sentence": "Urinary acidifying agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p249", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p346", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p37", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, @DRUG$, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, @DRUG$ (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d76.s14.p7", "sentence": "Alprazolam: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;", "label": "0"}
{"id": "DDI-DrugBank.d104.s1.p0", "sentence": "Other @DRUG$ should be used with caution in patients taking @DRUG$, since the effects may be additive.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d210.s24.p9", "sentence": "Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p984", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, @DRUG$, @DRUG$ (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p0", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d522.s19.p3", "sentence": "Triazolam: @DRUG$ has been reported to decrease the clearance of @DRUG$ and, thus, may increase the pharmacologic effect of triazolam.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d46.s7.p19", "sentence": "- Cholestyramine and colestipol resins: @DRUG$ and colestipol @DRUG$ have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "label": "0"}
{"id": "DDI-DrugBank.d566.s2.p2", "sentence": "@DRUG$ resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine @DRUG$ could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p759", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d558.s7.p2", "sentence": "Co-administration of @DRUG$ with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to @DRUG$ was not significantly increased.", "label": "0"}
{"id": "DDI-DrugBank.d499.s6.p1", "sentence": "however, in a study of 12 normal subjects, concurrent administration of @DRUG$ decreased ketoprofen protein binding and increased @DRUG$ plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d211.s5.p2", "sentence": "Probenecid: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or @DRUG$ toxicity.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p17", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p795", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d203.s2.p1", "sentence": "Compounds tested in man include @DRUG$, theophylline, @DRUG$, diazepam, aminopyrine and antipyrine.", "label": "0"}
{"id": "DDI-DrugBank.d400.s8.p0", "sentence": "During concomitant therapy of @DRUG$ with @DRUG$, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d123.s12.p4", "sentence": "Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1035", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d289.s32.p25", "sentence": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and @DRUG$ has no significant effect on plasma levels of bosentan.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p135", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d18.s1.p30", "sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p437", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;@DRUG$*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d45.s5.p1", "sentence": "Concomitant Crohn s disease medications were @DRUG$, antivirals, @DRUG$, 6-MP/AZA and aminosalicylates.", "label": "0"}
{"id": "DDI-DrugBank.d322.s0.p0", "sentence": "@DRUG$, @DRUG$, and MAOIs may increase anticholinergic effect of clidinium.", "label": "0"}
{"id": "DDI-DrugBank.d524.s0.p4", "sentence": "Albuterol, @DRUG$, @DRUG$, diuretics, digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d89.s3.p20", "sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and @DRUG$) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., @DRUG$ and phenytoin).", "label": "0"}
{"id": "DDI-DrugBank.d237.s10.p8", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d289.s25.p0", "sentence": "@DRUG$ and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "label": "0"}
{"id": "DDI-DrugBank.d459.s0.p13", "sentence": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, @DRUG$, nelfinavir, @DRUG$ and nefazadone) .", "label": "0"}
{"id": "DDI-DrugBank.d462.s0.p0", "sentence": "@DRUG$: The mixing of @DRUG$ with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.", "label": "0"}
{"id": "DDI-DrugBank.d124.s14.p6", "sentence": "Antiarrhythmics: @DRUG$, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p11", "sentence": "Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d342.s0.p6", "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p50", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d178.s4.p32", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d237.s18.p0", "sentence": "@DRUG$, @DRUG$, sparfloxacin, and terodiline.", "label": "0"}
{"id": "DDI-DrugBank.d521.s7.p30", "sentence": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (@DRUG$, others), @DRUG$ (Prelone, Pediapred, others), and others;", "label": "0"}
{"id": "DDI-DrugBank.d131.s8.p58", "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "label": "0"}
{"id": "DDI-DrugBank.d236.s27.p1", "sentence": "@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.", "label": "0"}
{"id": "DDI-DrugBank.d245.s0.p25", "sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p652", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p9", "sentence": "@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d205.s0.p14", "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p385", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p19", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d397.s10.p0", "sentence": "@DRUG$ has been reported to significantly alter the metabolism of nonsedating @DRUG$ terfenadine and astemizole when taken concomitantly.", "label": "0"}
{"id": "DDI-DrugBank.d358.s3.p0", "sentence": "@DRUG$ does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on @DRUG$, a drug with metabolism very sensitive to C.P.A. inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d289.s6.p19", "sentence": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "label": "0"}
{"id": "DDI-MedLine.d111.s5.p22", "sentence": "acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-DrugBank.d216.s0.p3", "sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and @DRUG$ 0.70 g/kg for up to 4 hours after ethanol administration.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d549.s3.p32", "sentence": "During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, @DRUG$, antipyretics, nonsteroidal antiinflammatories, @DRUG$, and other medications.", "label": "0"}
{"id": "DDI-DrugBank.d401.s0.p34", "sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the @DRUG$ and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p710", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, @DRUG$, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d431.s9.p0", "sentence": "In clinical trials, @DRUG$ were administered concomitantly with @DRUG$ delayed-release capsules;", "label": "0"}
{"id": "DDI-DrugBank.d488.s6.p10", "sentence": "Drugs Decreasing Heparin Effect: Digitalis, @DRUG$, nicotine, or @DRUG$ may partially counteract the anticoagulant action of heparin sodium.", "label": "0"}
{"id": "DDI-DrugBank.d60.s5.p5", "sentence": "Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or @DRUG$ were administered following varying degrees of recovery from single doses or infusions of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d223.s7.p9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).", "label": "0"}
{"id": "DDI-DrugBank.d482.s3.p0", "sentence": "Caution should be exercised when taking this medicine certain @DRUG$, such as @DRUG$, clarithromycin, or azithromycin.", "label": "0"}
{"id": "DDI-DrugBank.d107.s10.p15", "sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-MedLine.d39.s3.p2", "sentence": "The serum estrogen concentrations of estradiol + @DRUG$-treated rats decreased by 50%, while those of the @DRUG$-treated rats increased (2- to 5-fold). ", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p12", "sentence": "Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d179.s3.p33", "sentence": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], @DRUG$ [e.g., Winstrol]) or", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p162", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, @DRUG$, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d263.s20.p6", "sentence": "Probenecid or @DRUG$: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.", "label": "0"}
{"id": "DDI-DrugBank.d443.s3.p9", "sentence": "Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly @DRUG$): Concomitant administration with @DRUG$ may increase the risk of gastrointestinal ulceration.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d392.s2.p4", "sentence": "Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including @DRUG$, @DRUG$, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.", "label": "0"}
{"id": "DDI-DrugBank.d522.s20.p1", "sentence": "@DRUG$: Concomitant administration of erythromycin and @DRUG$ has been reported to result in elevated digoxin serum levels.", "label": "0"}
{"id": "DDI-DrugBank.d458.s9.p0", "sentence": "Therefore concomitant administration of @DRUG$ tablets with @DRUG$ is contraindicated.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d411.s3.p46", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d114.s1.p0", "sentence": "Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).", "label": "0"}
{"id": "DDI-DrugBank.d76.s12.p13", "sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, @DRUG$, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d290.s1.p1", "sentence": "Standard therapy includes @DRUG$, such as penicillin and @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p145", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) @DRUG$ (Nizoral) levodopa @DRUG$ muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p978", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;@DRUG$*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p14", "sentence": "Other Drugs: In healthy volunteers, amlodipine, @DRUG$, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated @DRUG$ and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p27", "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p23", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d566.s2.p11", "sentence": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of @DRUG$ @DRUG$ could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "label": "0"}
{"id": "DDI-DrugBank.d82.s21.p2", "sentence": "INDOCIN given concomitantly with @DRUG$ has been reported to increase the serum concentration and prolong the half-life of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1367", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d549.s3.p31", "sentence": "During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, @DRUG$, antipyretics, @DRUG$, corticosteroids, and other medications.", "label": "0"}
{"id": "DDI-MedLine.d47.s4.p2", "sentence": "Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either @DRUG$ or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p621", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), @DRUG$ (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, @DRUG$, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p468", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d129.s2.p1", "sentence": "Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d103.s3.p9", "sentence": "It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation. ", "label": "0"}
{"id": "DDI-DrugBank.d202.s16.p8", "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "label": "0"}
{"id": "DDI-DrugBank.d324.s19.p0", "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p407", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p300", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, @DRUG$, niacinamide, nicotinamide, protease inhibitors, propoxyphene, @DRUG$, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-MedLine.d3.s5.p0", "sentence": "Serial plasma and urine samples for measurement of @DRUG$, @DRUG$, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p75", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p233", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, @DRUG$, grapefruit juice, isoniazid, itraconazole, @DRUG$, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p2", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d333.s7.p14", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d521.s6.p9", "sentence": "- a diuretic (water pill) such as hydrochlorothiazide (@DRUG$, @DRUG$), chlorothiazide (Diuril), and others;", "label": "0"}
{"id": "DDI-DrugBank.d333.s5.p9", "sentence": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.", "label": "0"}
{"id": "DDI-DrugBank.d124.s15.p1", "sentence": "@DRUG$: astemizole*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p65", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, @DRUG$, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d434.s31.p13", "sentence": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of @DRUG$ results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of @DRUG$  given as monotherapy.", "label": "0"}
{"id": "DDI-DrugBank.d78.s1.p11", "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p495", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d303.s0.p1", "sentence": "@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p880", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d531.s5.p1", "sentence": "Drugs which induce CYP3A4 activity (eg, @DRUG$, rifampin, @DRUG$) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p71", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d123.s8.p31", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "label": "0"}
{"id": "DDI-MedLine.d132.s3.p2", "sentence": "No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, @DRUG$ or @DRUG$). ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p196", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d277.s17.p0", "sentence": "@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of tiagabine given as a single dose.", "label": "0"}
{"id": "DDI-DrugBank.d568.s9.p2", "sentence": "@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and @DRUG$ (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p196", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), @DRUG$ (Voltaren, @DRUG$), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d509.s25.p11", "sentence": "In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (@DRUG$), CYP2C19 (omeprazole, warfarin), and CYP3A4 (@DRUG$) substrates.", "label": "0"}
{"id": "DDI-DrugBank.d313.s1.p35", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p4", "sentence": "@DRUG$ (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (@DRUG$, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d386.s23.p31", "sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of @DRUG$ and benzodiazepines (e.g., @DRUG$ or diazepam) are additive.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d187.s10.p0", "sentence": "To avoid @DRUG$ intoxication, appropriate adjustment of the @DRUG$ should be made.", "label": "0"}
{"id": "DDI-DrugBank.d64.s93.p0", "sentence": "Drug/Laboratory Test Interferences: @DRUG$ and @DRUG$, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.", "label": "0"}
{"id": "DDI-DrugBank.d373.s11.p2", "sentence": "@DRUG$: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and @DRUG$ at 40 mg per day.", "label": "0"}
{"id": "DDI-DrugBank.d353.s4.p2", "sentence": "Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d123.s8.p26", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d84.s0.p0", "sentence": "The concomitant administration of @DRUG$ and @DRUG$-containing antacid preparations has not been formally studied.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p6", "sentence": "@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d521.s4.p1", "sentence": "- a @DRUG$ (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "label": "0"}
{"id": "DDI-MedLine.d82.s5.p0", "sentence": "However, total mucosal accumulation of @DRUG$ and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d560.s2.p0", "sentence": "This allows @DRUG$ to open air passages, increasing the effectiveness of the @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d175.s18.p5", "sentence": "Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p21", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d423.s0.p27", "sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "label": "0"}
{"id": "DDI-DrugBank.d568.s10.p0", "sentence": "@DRUG$ - Coadministration of racemic @DRUG$ (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "label": "0"}
{"id": "DDI-MedLine.d83.s13.p1", "sentence": "In comparison with @DRUG$, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with @DRUG$, only bodyweight gain occurred significantly more frequently with olanzapine. ", "label": "0"}
{"id": "DDI-DrugBank.d277.s12.p5", "sentence": "Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "label": "0"}
{"id": "DDI-DrugBank.d47.s3.p1", "sentence": "In addition, the beneficial effects of @DRUG$ in Parkinsons disease have been reported to be reversed by phenytoin and @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d47.s2.p14", "sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and @DRUG$ may reduce the therapeutic effects of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d411.s3.p21", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-MedLine.d132.s5.p0", "sentence": "A smaller 24-week study has suggested @DRUG$ may be superior to the @DRUG$ nelfinavir. ", "label": "0"}
{"id": "DDI-DrugBank.d76.s4.p1", "sentence": "Therefore, it is recommended that @DRUG$ Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d484.s0.p165", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), @DRUG$ such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (@DRUG$), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d3.s4.p10", "sentence": "Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p156", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d289.s31.p6", "sentence": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p36", "sentence": "- a nonsteroidal anti-inflammatory drug (@DRUG$) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (@DRUG$), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d505.s2.p1", "sentence": "@DRUG$: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p307", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, @DRUG$, nicotinamide, @DRUG$, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d258.s0.p1", "sentence": "@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.", "label": "0"}
{"id": "DDI-DrugBank.d223.s8.p3", "sentence": "While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "label": "0"}
{"id": "DDI-DrugBank.d143.s18.p1", "sentence": "@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and CYP3A4.", "label": "0"}
{"id": "DDI-DrugBank.d568.s7.p4", "sentence": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p36", "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d413.s12.p0", "sentence": "@DRUG$: The reports that the concomitant use of @DRUG$ and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "label": "0"}
{"id": "DDI-DrugBank.d328.s33.p9", "sentence": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p230", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;@DRUG$;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;@DRUG$ under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d238.s17.p0", "sentence": "@DRUG$ has also been shown to inhibit P450 1A2, an isoform also involved in @DRUG$metabolism.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d199.s0.p4", "sentence": "Metoclopramide: When coadministered with @DRUG$, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d458.s3.p3", "sentence": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: @DRUG$ tablets inhibit the metabolism of @DRUG$, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p85", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d115.s3.p0", "sentence": "Drugs that may decrease @DRUG$ plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease @DRUG$ plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d558.s5.p1", "sentence": "If a patient requires @DRUG$ and anti-ulcer therapy, it is suggested that @DRUG$, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p307", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/@DRUG$;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d367.s9.p0", "sentence": "@DRUG$/@DRUG$ (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p86", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, @DRUG$, and astemizole.", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p10", "sentence": "Potential drug interactions between Keppra  and other @DRUG$ (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-MedLine.d5.s0.p5", "sentence": "Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.  ", "label": "0"}
{"id": "DDI-DrugBank.d60.s3.p4", "sentence": "Infusion requirements of NIMBEX in patients administered @DRUG$ prior to infusions of NIMBEX were comparable to or slightly greater than when @DRUG$ was not administered.", "label": "0"}
{"id": "DDI-DrugBank.d54.s8.p3", "sentence": "@DRUG$: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d87.s2.p2", "sentence": "Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral @DRUG$ (4 mg) and intravenous @DRUG$ (0.05 mg x kg(-1)) in a double blind, cross-over study. ", "label": "0"}
{"id": "DDI-DrugBank.d137.s2.p0", "sentence": "@DRUG$: The concomitant use of @DRUG$ and beta-blocking agents has been well tolerated in patients with stable angina.", "label": "0"}
{"id": "DDI-DrugBank.d103.s8.p11", "sentence": "Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.", "label": "0"}
{"id": "DDI-DrugBank.d480.s30.p9", "sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including @DRUG$, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p11", "sentence": "Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d19.s2.p5", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p181", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p168", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d558.s5.p0", "sentence": "If a patient requires @DRUG$ and @DRUG$ therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d386.s9.p1", "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythrnics propatenone and flecainide).", "label": "0"}
{"id": "DDI-MedLine.d83.s13.p5", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with @DRUG$, only bodyweight gain occurred significantly more frequently with @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d566.s2.p16", "sentence": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine @DRUG$ could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking @DRUG$ resin.", "label": "0"}
{"id": "DDI-DrugBank.d107.s10.p27", "sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d536.s3.p0", "sentence": "When such drugs are withdrawn from patients receiving @DRUG$ in combination with @DRUG$ or insulin, patients should be observed closely for any evidence of hypoglycemia.", "label": "0"}
{"id": "DDI-DrugBank.d269.s18.p5", "sentence": "Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.", "label": "0"}
{"id": "DDI-DrugBank.d460.s12.p22", "sentence": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, @DRUG$, @DRUG$, acetylsalicylic acid, and tolbutamide in vitro .", "label": "0"}
{"id": "DDI-DrugBank.d257.s0.p63", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p30", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "label": "0"}
{"id": "DDI-DrugBank.d41.s0.p3", "sentence": "@DRUG$ and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of @DRUG$) concentration .", "label": "0"}
{"id": "DDI-DrugBank.d470.s1.p8", "sentence": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d562.s3.p0", "sentence": "@DRUG$ have also been shown to interfere with the metabolism of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d179.s21.p1", "sentence": "- @DRUG$ (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d284.s8.p0", "sentence": "The concurrent use of intravenously or orally administered @DRUG$ (e.g., @DRUG$, theophylline) by patients receiving BROVANA has not been completely evaluated.", "label": "0"}
{"id": "DDI-DrugBank.d485.s17.p1", "sentence": "@DRUG$: Combination hormonal contraceptives may decrease the clearance of some @DRUG$ (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p528", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d416.s0.p3", "sentence": "Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving @DRUG$, @DRUG$, or thiazolesulfone.", "label": "0"}
{"id": "DDI-DrugBank.d289.s11.p0", "sentence": "Steady-state @DRUG$ plasma concentrations were 3- to 4-fold higher than in the absence of @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s4.p374", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d547.s0.p9", "sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as @DRUG$, nifedipine, digoxin, @DRUG$, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "label": "0"}
{"id": "DDI-DrugBank.d485.s12.p0", "sentence": "@DRUG$ (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "label": "0"}
{"id": "DDI-DrugBank.d420.s5.p7", "sentence": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p40", "sentence": "- a nonsteroidal anti-inflammatory drug (@DRUG$) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (@DRUG$), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d5.s22.p1", "sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of @DRUG$ and agents (e.g., antipsychotics, other @DRUG$, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d396.s2.p0", "sentence": "The use of @DRUG$ or @DRUG$ with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p936", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p1", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d72.s3.p2", "sentence": "Since the pharmacokinetics of @DRUG$ were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p51", "sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d99.s23.p3", "sentence": "Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly @DRUG$, have been reported when @DRUG$ was added to the drug regimen.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p21", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, @DRUG$, @DRUG$, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d3.s1.p7", "sentence": "Warfarin, @DRUG$, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p176", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1138", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d165.s11.p2", "sentence": "Coadministration of Itraconazole with oral @DRUG$ or @DRUG$ has resulted in elevated plasma concentrations of the latter two drugs.", "label": "0"}
{"id": "DDI-DrugBank.d521.s8.p41", "sentence": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), @DRUG$ (Compazine), promethazine (@DRUG$), and others;", "label": "0"}
{"id": "DDI-DrugBank.d48.s15.p76", "sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, @DRUG$, @DRUG$, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "label": "0"}
{"id": "DDI-DrugBank.d544.s3.p9", "sentence": "Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of @DRUG$, USP (MODIFIED) and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p99", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;@DRUG$;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;@DRUG$;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d97.s41.p0", "sentence": "Increasing the @DRUG$ dose to 1000 mg every 8 hours does not compensate for the increased @DRUG$ metabolism due to efavirenz.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p95", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d485.s17.p8", "sentence": "Benzodiazepines: Combination @DRUG$ may decrease the clearance of some @DRUG$ (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d179.s21.p91", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p8", "sentence": "Before taking @DRUG$, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), @DRUG$ (Magan), or bismuth subsalicylate (Pepto-Bismol);", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d411.s4.p513", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p35", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, @DRUG$, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, @DRUG$, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d328.s38.p0", "sentence": "@DRUG$ steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of @DRUG$ (40 mg QD).", "label": "0"}
{"id": "DDI-DrugBank.d533.s9.p5", "sentence": "Furosemide: When aliskiren was co-administered with @DRUG$, the AUC and Cmax of @DRUG$ were reduced by about 30% and 50%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p57", "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p455", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, @DRUG$, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (@DRUG$), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p275", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d431.s1.p5", "sentence": "Studies have shown that @DRUG$ does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, @DRUG$, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d466.s1.p2", "sentence": "However, co  administration of @DRUG$ with either ketoconazole or erythromycin led to increased plasma concentrations of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d143.s27.p15", "sentence": "Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, @DRUG$, and phenytoin, have been used concurrently with amiodarone.", "label": "0"}
{"id": "DDI-DrugBank.d334.s19.p1", "sentence": "@DRUG$ toxicity was usually reversible upon discontinuation of lithium and the @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d297.s2.p7", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d237.s7.p9", "sentence": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "label": "0"}
{"id": "DDI-DrugBank.d299.s6.p18", "sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "label": "0"}
{"id": "DDI-DrugBank.d237.s2.p11", "sentence": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.", "label": "0"}
{"id": "DDI-DrugBank.d72.s1.p14", "sentence": "Fluconazole, and the 5-HT3 antiemetics @DRUG$ (Zofran) and granisetron (Kytril) have all been used with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d144.s1.p2", "sentence": "If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d404.s0.p25", "sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): @DRUG$: @DRUG$ has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p398", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p945", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p73", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, @DRUG$, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/@DRUG$ or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d178.s0.p14", "sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p810", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d215.s0.p9", "sentence": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, @DRUG$, or @DRUG$, as these agents may increase respiratory and circulatory depression.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p24", "sentence": "Chlorotrianisene may interact with @DRUG$, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d468.s4.p1", "sentence": "@DRUG$: Some calcium blockers may increase the concentration of @DRUG$ in the blood.", "label": "0"}
{"id": "DDI-DrugBank.d322.s0.p4", "sentence": "Amantadine, @DRUG$, and MAOIs may increase anticholinergic effect of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d63.s4.p5", "sentence": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of @DRUG$ (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular @DRUG$ (16 micrograms). ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d411.s4.p385", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p861", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d480.s20.p0", "sentence": "After 14 days of co-administration, mean trough concentrations of @DRUG$ and its metabolites, @DRUG$ and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p494", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (@DRUG$, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d500.s2.p1", "sentence": "Absorption of @DRUG$ is impaired by antacids containing @DRUG$, calcium, or magnesium, and iron-containing preparations.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d178.s0.p24", "sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.", "label": "0"}
{"id": "DDI-DrugBank.d288.s12.p8", "sentence": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d123.s8.p20", "sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p546", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (@DRUG$, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), @DRUG$, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d501.s10.p33", "sentence": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and @DRUG$ demonstrated no evidence of incompatibility of these @DRUG$ with EXTRANEAL.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p247", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d488.s7.p1", "sentence": "@DRUG$ Injection should not be mixed with doxorubicin, @DRUG$, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "label": "0"}
{"id": "DDI-DrugBank.d442.s1.p1", "sentence": "Therefore, close monitoring of prothrombin time is recommended and adjustment of the @DRUG$ dose may be necessary when EULEXIN Capsules are administered concomitantly with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d154.s0.p1", "sentence": "The coadministration of @DRUG$ decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.", "label": "0"}
{"id": "DDI-DrugBank.d15.s0.p27", "sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "label": "0"}
{"id": "DDI-DrugBank.d244.s0.p15", "sentence": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p238", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), @DRUG$ (Lodine), indomethacin (Indocin), nabumetone (@DRUG$), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d464.s0.p2", "sentence": "@DRUG$ in combination with other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d521.s2.p132", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), @DRUG$ (Orudis, Orudis KT, Oruvail), @DRUG$ (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p347", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d485.s12.p27", "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.", "label": "0"}
{"id": "DDI-DrugBank.d291.s1.p0", "sentence": "For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with @DRUG$ or Bezalip retard and then titrated according to the blood clotting parameters", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d533.s7.p25", "sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, @DRUG$, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, @DRUG$ or hydrochlorothiazide.", "label": "0"}
{"id": "DDI-DrugBank.d131.s8.p27", "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "label": "0"}
{"id": "DDI-DrugBank.d485.s10.p0", "sentence": "@DRUG$: Combination @DRUG$ may increase or decrease the effects of coumarin derivatives.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p48", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d241.s3.p34", "sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d415.s2.p5", "sentence": "Aspirin: Animal studies wshow that aspirin given with @DRUG$, including @DRUG$, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p524", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p248", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;@DRUG$;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p58", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d521.s6.p11", "sentence": "- a diuretic (water pill) such as hydrochlorothiazide (@DRUG$, Hydrodiuril), chlorothiazide (@DRUG$), and others;", "label": "0"}
{"id": "DDI-DrugBank.d293.s0.p21", "sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "label": "0"}
{"id": "DDI-DrugBank.d318.s2.p4", "sentence": "Corticosteroids and @DRUG$ (ACTH): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d411.s3.p109", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p722", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d26.s0.p4", "sentence": "Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d254.s0.p5", "sentence": "Other CNS depressant drugs (e.g. @DRUG$, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "label": "0"}
{"id": "DDI-MedLine.d57.s2.p15", "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine. ", "label": "0"}
{"id": "DDI-DrugBank.d76.s12.p6", "sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: @DRUG$ metabolized by hepatic oxidation (e.g., alprazolam, @DRUG$, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p451", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;@DRUG$;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d210.s23.p1", "sentence": "Oral @DRUG$ Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ and norethindrone.", "label": "0"}
{"id": "DDI-DrugBank.d198.s10.p5", "sentence": "HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d219.s4.p0", "sentence": "@DRUG$: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.", "label": "0"}
{"id": "DDI-DrugBank.d339.s2.p2", "sentence": "Warfarin and @DRUG$: Increased prothrombin time, with or without clinical bleeding, has been reported when @DRUG$ is administered concomitantly.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p951", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, @DRUG$ (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d525.s5.p0", "sentence": "@DRUG$ doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release nifedipine) with no clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-MedLine.d106.s1.p10", "sentence": "The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d13.s0.p30", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d189.s0.p41", "sentence": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d124.s17.p4", "sentence": "Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "label": "0"}
{"id": "DDI-DrugBank.d509.s0.p5", "sentence": "Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d199.s0.p2", "sentence": "@DRUG$: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p23", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p232", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;@DRUG$;haloperidol;@DRUG$;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d338.s5.p3", "sentence": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite @DRUG$ and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p411", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d424.s6.p0", "sentence": "No interaction trials have been conducted with @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p427", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p43", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.", "label": "0"}
{"id": "DDI-DrugBank.d163.s10.p0", "sentence": "@DRUG$: @DRUG$ has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p83", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d246.s0.p13", "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d277.s9.p2", "sentence": "The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or @DRUG$ concentrations when compared to placebo.", "label": "0"}
{"id": "DDI-DrugBank.d565.s12.p1", "sentence": "A study in six healthy volunteers has shown a significant increase in peak @DRUG$ plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of @DRUG$ 60mg.", "label": "0"}
{"id": "DDI-DrugBank.d503.s3.p2", "sentence": "Avoid the concomitant use of chlorprothixene and @DRUG$ (@DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d305.s5.p2", "sentence": "The combination of therapeutic doses of intravenous dantrolene sodium and @DRUG$ in @DRUG$ a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.", "label": "0"}
{"id": "DDI-DrugBank.d63.s0.p48", "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "label": "0"}
{"id": "DDI-DrugBank.d114.s3.p0", "sentence": "The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.", "label": "0"}
{"id": "DDI-DrugBank.d546.s3.p0", "sentence": "There is limited experience with concomitant @DRUG$ such as @DRUG$, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).", "label": "0"}
{"id": "DDI-DrugBank.d226.s5.p1", "sentence": "In the presence of these @DRUG$, larger doses of adenosine may be required or @DRUG$ may not be effective.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d179.s21.p174", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d425.s1.p41", "sentence": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a @DRUG$) Methotrexate There has been concern about the interaction between vitamin B12 and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p19", "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d3.s7.p1", "sentence": "@DRUG$ significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of @DRUG$ by 13.3-fold. ", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d413.s23.p0", "sentence": "Monitoring of @DRUG$ levels and possible adjustment of @DRUG$ dosage should be considered when these drugs are co-administered.", "label": "0"}
{"id": "DDI-DrugBank.d455.s11.p8", "sentence": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with @DRUG$ without coadministered levodopa/@DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p51", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p872", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d17.s6.p4", "sentence": "Antihypertensive medications, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery", "label": "0"}
{"id": "DDI-DrugBank.d533.s1.p21", "sentence": "Co-administration of lovastatin, atenolol, @DRUG$, @DRUG$, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p8", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d291.s11.p0", "sentence": "- @DRUG$ or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "label": "0"}
{"id": "DDI-DrugBank.d288.s4.p14", "sentence": "Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.", "label": "0"}
{"id": "DDI-DrugBank.d509.s8.p1", "sentence": "Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, @DRUG$, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.", "label": "0"}
{"id": "DDI-DrugBank.d26.s0.p8", "sentence": "Patients receiving other narcotic analgesics, general @DRUG$, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p46", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p128", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d410.s5.p11", "sentence": "Macrolide Antibiotics (e. g. @DRUG$ and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with @DRUG$ of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p320", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d537.s0.p34", "sentence": "Bentiromide may interact with acetaminophen (e.g., @DRUG$), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some @DRUG$), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p254", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p290", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, @DRUG$, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, @DRUG$, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d60.s9.p1", "sentence": "In long surgical procedures during @DRUG$ or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of @DRUG$ may be necessary.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d484.s0.p725", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), @DRUG$ (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d78.s1.p16", "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "label": "0"}
{"id": "DDI-DrugBank.d196.s6.p4", "sentence": "Stavudine and @DRUG$ @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.", "label": "0"}
{"id": "DDI-DrugBank.d81.s13.p0", "sentence": "@DRUG$: The concomitant administration of @DRUG$  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p257", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, @DRUG$, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d426.s3.p13", "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "label": "0"}
{"id": "DDI-DrugBank.d13.s0.p56", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d538.s1.p5", "sentence": "Diphenoxylate HCl and atropine sulfate may interact with @DRUG$ In studies with male rats, @DRUG$ was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "label": "0"}
{"id": "DDI-DrugBank.d94.s8.p19", "sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: @DRUG$, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on @DRUG$, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d284.s6.p6", "sentence": "BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.", "label": "0"}
{"id": "DDI-DrugBank.d364.s10.p1", "sentence": "Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d64.s87.p89", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d397.s10.p3", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating @DRUG$ @DRUG$ and astemizole when taken concomitantly.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p254", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d198.s16.p7", "sentence": "Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, @DRUG$, and ranitidine.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1313", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;@DRUG$;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d328.s21.p1", "sentence": "@DRUG$ serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d76.s12.p8", "sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: @DRUG$ metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by @DRUG$.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d289.s30.p3", "sentence": "Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s3.p0", "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d558.s13.p4", "sentence": "HCTZ 50 mg QD or @DRUG$/@DRUG$ 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).", "label": "0"}
{"id": "DDI-DrugBank.d400.s13.p0", "sentence": "@DRUG$: The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p250", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (@DRUG$), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (@DRUG$), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p267", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (@DRUG$), nabumetone (Relafen), oxaprozin (@DRUG$), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-MedLine.d12.s2.p5", "sentence": "Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s3.p32", "sentence": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p36", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s21.p98", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p12", "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.", "label": "DDI-int"}
{"id": "DDI-MedLine.d8.s6.p4", "sentence": "When combined with ofloxacin, @DRUG$ exhibited strong synergistic activity while only additive effects were observed with the combination of @DRUG$ (or rifabutin) and ofloxacin. ", "label": "0"}
{"id": "DDI-DrugBank.d434.s32.p11", "sentence": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of @DRUG$  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (@DRUG$) plasma concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d15.s0.p20", "sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d131.s9.p0", "sentence": "Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: sertraline and paroxetine.", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p49", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p93", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d138.s0.p8", "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d269.s5.p1", "sentence": "When concomitant treatment with @DRUG$ and clonidine is to be terminated, the @DRUG$ should be discontinued first.", "label": "0"}
{"id": "DDI-DrugBank.d558.s12.p2", "sentence": "@DRUG$ (HCTZ) Alone or in Combination with Triamterene: Concomitant use of @DRUG$ alone or in combination with triamterene is contraindicated.", "label": "0"}
{"id": "DDI-DrugBank.d198.s26.p0", "sentence": "@DRUG$ did not alter the plasma levels of @DRUG$ when taken in combination.", "label": "0"}
{"id": "DDI-DrugBank.d212.s14.p8", "sentence": "Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d198.s27.p0", "sentence": "In these patients whose hypertension was controlled with @DRUG$, @DRUG$ 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d367.s9.p27", "sentence": "Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, @DRUG$, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p85", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, @DRUG$, cabergoline, @DRUG$, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d522.s12.p5", "sentence": "Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg @DRUG$ tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of @DRUG$ was not significantly altered.", "label": "0"}
{"id": "DDI-DrugBank.d94.s2.p0", "sentence": "Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase @DRUG$ is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active @DRUG$, which is further metabolized to the trans-diol by epoxide hydrolase.", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p29", "sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, @DRUG$, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d29.s2.p2", "sentence": "(1968, 1970), the higher serum concentrations of penicillins and @DRUG$ reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body. ", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d328.s47.p0", "sentence": "@DRUG$: @DRUG$ (Valium) is a CYP 3A4 and CYP 2C19 substrate.", "label": "0"}
{"id": "DDI-DrugBank.d471.s1.p0", "sentence": "Administration of @DRUG$ to hypoparathyroid patients who are concurrently being treated with @DRUG$ may cause hypercalcemia.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d434.s30.p21", "sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: @DRUG$ causes an approximate doubling of the clearance of @DRUG$  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d241.s3.p9", "sentence": "In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "label": "0"}
{"id": "DDI-DrugBank.d48.s14.p0", "sentence": "Drugs that may have their plasma concentration altered by @DRUG$ CYP3A4 Substrates: @DRUG$ is a time-dependent inhibitor of CYP3A4.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p73", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p672", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d509.s20.p2", "sentence": "When carbamazepine is added to @DRUG$ therapy, @DRUG$ dose should be doubled.", "label": "0"}
{"id": "DDI-DrugBank.d567.s22.p1", "sentence": "Oral @DRUG$: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with @DRUG$ or with chlorpropamide", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p36", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d251.s0.p13", "sentence": "Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p38", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as @DRUG$ (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), @DRUG$ (Magan), or bismuth subsalicylate (Pepto-Bismol);", "label": "0"}
{"id": "DDI-DrugBank.d521.s4.p11", "sentence": "- a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil);", "label": "0"}
{"id": "DDI-DrugBank.d558.s5.p26", "sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or @DRUG$ (@DRUG$s) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p90", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;@DRUG$;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;@DRUG$;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p56", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, @DRUG$ (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d27.s4.p8", "sentence": "In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d420.s3.p0", "sentence": "If @DRUG$ are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "label": "0"}
{"id": "DDI-DrugBank.d328.s46.p0", "sentence": "These increased exposures of @DRUG$ and @DRUG$ should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.", "label": "0"}
{"id": "DDI-DrugBank.d140.s0.p11", "sentence": "The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p16", "sentence": "Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1465", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d253.s3.p5", "sentence": "Antidepressants (@DRUG$), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.", "label": "0"}
{"id": "DDI-DrugBank.d395.s17.p5", "sentence": "Antacids containing aluminum hydroxide and @DRUG$ reduce the oral absorption of @DRUG$ by 75%.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d484.s0.p842", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, @DRUG$, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d277.s17.p5", "sentence": "Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of @DRUG$ given as a single dose.", "label": "0"}
{"id": "DDI-DrugBank.d527.s2.p100", "sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, @DRUG$ (e.g., in oral contraceptives).", "label": "0"}
{"id": "DDI-DrugBank.d458.s5.p4", "sentence": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of @DRUG$, resulting in elevated plasma levels of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.", "label": "0"}
{"id": "DDI-DrugBank.d558.s35.p42", "sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, @DRUG$, @DRUG$, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "label": "0"}
{"id": "DDI-DrugBank.d135.s11.p1", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d343.s0.p5", "sentence": "Aspirin, warfarin, @DRUG$, @DRUG$", "label": "0"}
{"id": "DDI-DrugBank.d429.s0.p8", "sentence": "Antacids and kaolin: @DRUG$ and kaolin can reduce absorption of @DRUG$;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d321.s6.p5", "sentence": "Theophylline: The pharmacokinetics of theophylline (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.", "label": "0"}
{"id": "DDI-DrugBank.d559.s1.p28", "sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other @DRUG$s, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, @DRUG$, or other CNS depressants, causing increased CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d87.s19.p3", "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither @DRUG$ nor @DRUG$ should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "label": "0"}
{"id": "DDI-DrugBank.d485.s16.p3", "sentence": "Atorvastatin: @DRUG$ increases the AUC for @DRUG$ and ethinyl estradiol.", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d124.s1.p2", "sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous opiate such as @DRUG$. ", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d347.s7.p19", "sentence": "Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "label": "0"}
{"id": "DDI-DrugBank.d289.s31.p9", "sentence": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "label": "0"}
{"id": "DDI-DrugBank.d395.s8.p5", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.", "label": "0"}
{"id": "DDI-DrugBank.d353.s0.p2", "sentence": "@DRUG$:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d569.s2.p0", "sentence": "There is no experience with co-administration of @DRUG$ and plasma expanders such as @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p26", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, @DRUG$, nicardipine, pravastatin, glyburide, warfarin, phenytoin, @DRUG$, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d478.s4.p12", "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p951", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d567.s5.p4", "sentence": "@DRUG$ Ketoconazole Erythromycin Clarithromycin Telithromycin @DRUG$ Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "label": "0"}
{"id": "DDI-DrugBank.d355.s2.p1", "sentence": "Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p846", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p28", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p635", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), @DRUG$ (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, @DRUG$, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d189.s0.p16", "sentence": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d303.s0.p0", "sentence": "@DRUG$: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p59", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d541.s0.p7", "sentence": "May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the @DRUG$ from working properly) and disopyramide, quinidine, @DRUG$, and procainamide (these medicines may increase the risk of heart problems).", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p80", "sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, troleandomycin (TAO), and @DRUG$ .", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p9", "sentence": "- a @DRUG$ (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), @DRUG$ (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d480.s15.p7", "sentence": "Phenytoin, nicotine, and @DRUG$ may decrease @DRUG$ plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d305.s1.p2", "sentence": "However, neither phenobarbital nor @DRUG$ appears to affect @DRUG$ metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d289.s30.p2", "sentence": "@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d75.s2.p17", "sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, @DRUG$, furosemide, iron, ranitidine, hydroxyurea, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p418", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d212.s6.p1", "sentence": "Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "label": "0"}
{"id": "DDI-DrugBank.d244.s0.p16", "sentence": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "label": "0"}
{"id": "DDI-MedLine.d66.s2.p0", "sentence": "The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and @DRUG$-treated rats and the levels shown by rats treated with @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d526.s1.p8", "sentence": "Amphotericin B or potassium-depleting diuretics (@DRUG$ and related drugs, ethacrynic acid and @DRUG$) enhanced hypokalemia.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p239", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p29", "sentence": "- a nonsteroidal anti-inflammatory drug (@DRUG$) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (@DRUG$, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d187.s11.p0", "sentence": "Therophylline: A recent study has shown that concomitan administration of @DRUG$ and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d350.s3.p13", "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, @DRUG$, nelfinavir, or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d410.s5.p14", "sentence": "Macrolide Antibiotics (e. g. erythromycin and @DRUG$): Agents of the ergot alkaloid class, of which @DRUG$  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "label": "0"}
{"id": "DDI-DrugBank.d413.s18.p4", "sentence": "Cytotoxic Agents: Enhanced bone marrow suppression by @DRUG$ and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d329.s4.p1", "sentence": "In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of digoxin or @DRUG$ and that ertapenem is not a substrate for P-glycoprotein-mediated transport.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p417", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d386.s23.p24", "sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or @DRUG$/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., @DRUG$ or diazepam) are additive.", "label": "0"}
{"id": "DDI-DrugBank.d103.s4.p3", "sentence": "@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p43", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.", "label": "0"}
{"id": "DDI-DrugBank.d137.s5.p0", "sentence": "Limited clinical data in angina patients receiving concomitant @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels.", "label": "0"}
{"id": "DDI-DrugBank.d199.s2.p3", "sentence": "Cimetidine: @DRUG$ does not affect the pharmacokinetics of @DRUG$ when coadministered with MONUROL.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p953", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d160.s0.p8", "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p124", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;", "label": "0"}
{"id": "DDI-DrugBank.d175.s22.p4", "sentence": "Loop Diuretics: @DRUG$ administered concurrently with captopril does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p168", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, @DRUG$, Oruvail), diclofenac (Voltaren, Cataflam), @DRUG$ (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-MedLine.d17.s3.p2", "sentence": "In seven experiments reactions to norepinephrine and @DRUG$ were @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d272.s3.p0", "sentence": "Concomitant use of @DRUG$ with other @DRUG$ is not recommended.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d512.s3.p2", "sentence": "@DRUG$: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased @DRUG$ exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "label": "0"}
{"id": "DDI-DrugBank.d47.s2.p3", "sentence": "@DRUG$ (e.g., phenothiazines, butyrophenones, risperidone) and @DRUG$ may reduce the therapeutic effects of levodopa.", "label": "0"}
{"id": "DDI-DrugBank.d351.s0.p7", "sentence": "Probenecid: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d334.s15.p14", "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p82", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, @DRUG$, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, @DRUG$, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p30", "sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d509.s25.p4", "sentence": "In in vivo studies, 10- to 30-mg/day doses of @DRUG$ had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (@DRUG$) substrates.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p14", "sentence": "Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d482.s14.p123", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) @DRUG$ fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa @DRUG$ muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d131.s8.p2", "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p119", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) @DRUG$ fluoxetine (Prozac) intraconazole (@DRUG$) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d485.s12.p5", "sentence": "@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d176.s0.p0", "sentence": "@DRUG$: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.", "label": "0"}
{"id": "DDI-MedLine.d5.s1.p5", "sentence": "Interactions between treatments with coumaphos, @DRUG$ (an @DRUG$), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. ", "label": "0"}
{"id": "DDI-DrugBank.d525.s0.p5", "sentence": "Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d522.s24.p5", "sentence": "Other drugs Drug interactions have been reported with concomitant administration of @DRUG$ and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, @DRUG$, bromocriptine, valproate, astemizole, and lovastatin.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d536.s1.p60", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel-blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d333.s0.p7", "sentence": "Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, @DRUG$, or phenobarbital.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p64", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p308", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, @DRUG$, nicotinamide, protease inhibitors, @DRUG$, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d253.s3.p0", "sentence": "@DRUG$ (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.", "label": "0"}
{"id": "DDI-DrugBank.d224.s1.p16", "sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, @DRUG$, anesthetics) should be considered.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p42", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, @DRUG$, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, @DRUG$, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-MedLine.d115.s2.p47", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p115", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p33", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d237.s18.p2", "sentence": "@DRUG$, bepridil, sparfloxacin, and @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d15.s1.p1", "sentence": "After prolonged administration of @DRUG$ the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on @DRUG$ binding. ", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p52", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), @DRUG$, grepafloxacin, guanethidine, @DRUG$, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d12.s3.p2", "sentence": "Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.", "label": "0"}
{"id": "DDI-DrugBank.d245.s0.p14", "sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p21", "sentence": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d64.s87.p277", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p36", "sentence": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, @DRUG$ (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d98.s2.p9", "sentence": "Phenytoin/Phenobarbital: The coadministration of @DRUG$ or @DRUG$ will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d171.s0.p37", "sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d124.s26.p107", "sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d10.s2.p1", "sentence": "@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.", "label": "0"}
{"id": "DDI-DrugBank.d169.s1.p2", "sentence": "Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of @DRUG-DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d568.s13.p3", "sentence": "@DRUG$ and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.", "label": "0"}
{"id": "DDI-DrugBank.d176.s9.p29", "sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p10", "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d107.s10.p20", "sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p30", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, @DRUG$, cetirizine, @DRUG$, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d77.s5.p0", "sentence": "The plasma concentration of @DRUG$ may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d141.s1.p4", "sentence": "ANTACID (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d45.s5.p8", "sentence": "Concomitant Crohn s disease medications were antibiotics, antivirals, @DRUG$, 6-MP/@DRUG$ and aminosalicylates.", "label": "0"}
{"id": "DDI-DrugBank.d277.s10.p12", "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p406", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p65", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as @DRUG$ (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and @DRUG$ (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p777", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-MedLine.d132.s1.p0", "sentence": "The availability of potent @DRUG$ (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p286", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d249.s13.p2", "sentence": "A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to @DRUG$ or oral @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d350.s14.p8", "sentence": "When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "label": "0"}
{"id": "DDI-DrugBank.d249.s19.p31", "sentence": "Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.", "label": "0"}
{"id": "DDI-DrugBank.d20.s4.p6", "sentence": "ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "label": "0"}
{"id": "DDI-DrugBank.d482.s14.p134", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (@DRUG$) intraconazole (Sporanox) ketoconazole (@DRUG$) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p50", "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d307.s11.p2", "sentence": "Antiepileptic drugs: Potential interactions between @DRUG$ and other @DRUG$ were assessed in clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d460.s11.p59", "sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, @DRUG$, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of @DRUG$ protein binding.", "label": "0"}
{"id": "DDI-MedLine.d78.s2.p5", "sentence": "These agents, including norfloxacin, @DRUG$, ofloxacin, @DRUG$, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. ", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p372", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d328.s4.p2", "sentence": "@DRUG$: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p33", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, @DRUG$, cetirizine, didanosine, efavirenz, fluconazole, @DRUG$, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d20.s9.p1", "sentence": "Serum @DRUG$ levels should be monitored frequently if INSPRA is administered concomitantly with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p39", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d154.s2.p8", "sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p256", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d115.s10.p5", "sentence": "Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p70", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d137.s10.p1", "sentence": "@DRUG$ and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d395.s13.p7", "sentence": "Therefore, administration of quinolones with antacids containing @DRUG$, @DRUG$, or aluminum;", "label": "0"}
{"id": "DDI-DrugBank.d210.s13.p4", "sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d176.s12.p41", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d342.s0.p17", "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d94.s8.p9", "sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of @DRUG$ are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on @DRUG$, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d82.s33.p0", "sentence": "Blunting of the antihypertensive effect of @DRUG$ by @DRUG$ including INDOCIN has been reported.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s21.p246", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d397.s8.p89", "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d107.s10.p33", "sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d367.s3.p1", "sentence": "@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, @DRUG$s, and nonsteroidal anti-inflammatory drugs.", "label": "0"}
{"id": "DDI-DrugBank.d162.s12.p7", "sentence": "Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d220.s9.p12", "sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.", "label": "0"}
{"id": "DDI-DrugBank.d253.s3.p13", "sentence": "Antidepressants (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.", "label": "0"}
{"id": "DDI-DrugBank.d76.s12.p5", "sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: @DRUG$ metabolized by hepatic oxidation (e.g., @DRUG$, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "label": "0"}
{"id": "DDI-DrugBank.d480.s8.p5", "sentence": "Although it has not been established that there is an interaction between Clozapine and @DRUG$ or other @DRUG$, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p952", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p208", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, @DRUG$(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, @DRUG$, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p350", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d415.s6.p0", "sentence": "This may indicate that @DRUG$ could enhance the toxicity of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p404", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, @DRUG$, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p36", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d98.s0.p4", "sentence": "Interactions for @DRUG$ (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): @DRUG$: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p5", "sentence": "Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p6", "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d272.s0.p0", "sentence": "The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of bromocriptine mesylate.", "label": "0"}
{"id": "DDI-DrugBank.d249.s5.p11", "sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d48.s1.p53", "sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, @DRUG$, atazanavir, indinavir, nefazodone, @DRUG$, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p111", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p799", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p108", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d88.s4.p0", "sentence": "Patients taking @DRUG$ concomitantly with @DRUG$ should be monitored regularly for alterations in their coagulation parameters (PT or INR).", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d154.s2.p13", "sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and @DRUG$ is not recommended.", "label": "0"}
{"id": "DDI-DrugBank.d500.s1.p2", "sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving @DRUG$ in conjunction with @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d434.s11.p7", "sentence": "Specific Effects of Felbatol  on Other Antiepileptic Drugs @DRUG$: @DRUG$  causes an increase in steady-state phenytoin plasma concentrations.", "label": "0"}
{"id": "DDI-MedLine.d45.s5.p2", "sentence": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in @DRUG$ and @DRUG$, addicts) were completely inhibited by the drug combination. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d482.s14.p25", "sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (@DRUG$) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens @DRUG$ (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "label": "0"}
{"id": "DDI-DrugBank.d87.s20.p2", "sentence": "There has been too little experience with the coadministration of TAMBOCOR with @DRUG$ or @DRUG$ to recommend concomitant use.", "label": "0"}
{"id": "DDI-DrugBank.d18.s1.p13", "sentence": "Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "label": "0"}
{"id": "DDI-DrugBank.d48.s1.p34", "sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, @DRUG$, clarithromycin, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d457.s0.p9", "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.", "label": "0"}
{"id": "DDI-DrugBank.d75.s2.p6", "sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with @DRUG$ in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d501.s10.p35", "sentence": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these @DRUG$ with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p914", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d131.s0.p8", "sentence": "The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d208.s0.p11", "sentence": "Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "label": "0"}
{"id": "DDI-DrugBank.d132.s27.p4", "sentence": "Naproxen: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d63.s0.p1", "sentence": "Differential actions of intrathecal @DRUG$ on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and @DRUG$ in rats.  ", "label": "0"}
{"id": "DDI-DrugBank.d196.s40.p0", "sentence": "Adverse reactions related to @DRUG$s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of @DRUG$ in this population.", "label": "0"}
{"id": "DDI-DrugBank.d434.s12.p0", "sentence": "In 10 otherwise healthy subjects with epilepsy ingesting @DRUG$, the steadystate trough (Cmin) @DRUG$ plasma concentration was 17 5 micrograms/mL.", "label": "0"}
{"id": "DDI-DrugBank.d350.s3.p14", "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, @DRUG$, or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d154.s7.p2", "sentence": "Patients receiving hydantoins, @DRUG$, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d547.s0.p10", "sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as @DRUG$, nifedipine, digoxin, warfarin, @DRUG$, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "label": "0"}
{"id": "DDI-MedLine.d30.s9.p2", "sentence": "the doses of naloxone required to antagonize the effects of @DRUG$ were more than 100 times higher than those required to antagonize the effects of @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d249.s2.p8", "sentence": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.", "label": "0"}
{"id": "DDI-DrugBank.d43.s4.p14", "sentence": "Antacids: Concomitant administration of antacids containing magnesium or aluminum with @DRUG$ Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the @DRUG$ components.", "label": "0"}
{"id": "DDI-DrugBank.d458.s22.p0", "sentence": "Concomitant administration of @DRUG$ tablets with @DRUG$ may alter the metabolism of one or both of the drugs.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d484.s0.p861", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, @DRUG$, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), @DRUG$, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d263.s22.p12", "sentence": "Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p175", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d415.s15.p1", "sentence": "Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1376", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d485.s43.p2", "sentence": "@DRUG$ / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d251.s0.p0", "sentence": "Antiacid, @DRUG$, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "label": "0"}
{"id": "DDI-DrugBank.d143.s22.p1", "sentence": "Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p147", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), @DRUG$ such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d123.s16.p0", "sentence": "@DRUG$: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.", "label": "0"}
{"id": "DDI-DrugBank.d487.s5.p0", "sentence": "This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when corticosteroid is withdrawn.", "label": "0"}
{"id": "DDI-DrugBank.d299.s5.p0", "sentence": "@DRUG$: The pharmacokinetics of @DRUG$ were not affected by coadministration of propranolol.", "label": "0"}
{"id": "DDI-DrugBank.d425.s1.p2", "sentence": "Medications can interfere with folate utilization, including: @DRUG$ (such as phenytoin, and primidone) @DRUG$ (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.", "label": "0"}
{"id": "DDI-DrugBank.d179.s8.p0", "sentence": "- @DRUG$ (e.g., @DRUG$) or", "label": "0"}
{"id": "DDI-DrugBank.d269.s1.p3", "sentence": "poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "label": "0"}
{"id": "DDI-DrugBank.d88.s2.p2", "sentence": "there was no effect on the 3 major metabolites (5-DFUR, @DRUG$ and @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p245", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;@DRUG$;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;@DRUG$;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p53", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), @DRUG$ (Disalcid, others), choline salicylate (Arthropan), @DRUG$ (Magan), or bismuth subsalicylate (Pepto-Bismol);", "label": "0"}
{"id": "DDI-DrugBank.d46.s19.p4", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p1128", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;@DRUG$;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d308.s0.p8", "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d233.s1.p0", "sentence": "Patients receiving @DRUG$ and @DRUG$ concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d64.s29.p18", "sentence": "Drugs that have been reported to diminish oral @DRUG$ response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;@DRUG$;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d263.s3.p2", "sentence": "Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d198.s10.p4", "sentence": "@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.", "label": "0"}
{"id": "DDI-DrugBank.d434.s37.p2", "sentence": "Effects of @DRUG$  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg @DRUG$ and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1239", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p890", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, @DRUG$, Viracept), morphine (Astramorph, Kadian, MS Contin), @DRUG$, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d289.s32.p26", "sentence": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d89.s7.p2", "sentence": "Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing @DRUG$ as the @DRUG$ was carried out in 22 patients. ", "label": "0"}
{"id": "DDI-MedLine.d99.s11.p1", "sentence": "The clearance by means of @DRUG$ and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of @DRUG$ per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "label": "0"}
{"id": "DDI-DrugBank.d547.s3.p2", "sentence": "An increase in serum @DRUG$ concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.", "label": "0"}
{"id": "DDI-DrugBank.d143.s41.p25", "sentence": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "label": "0"}
{"id": "DDI-DrugBank.d48.s11.p19", "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce @DRUG$ exposure.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d178.s4.p7", "sentence": "These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p778", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d251.s0.p40", "sentence": "Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, @DRUG$, Ritanovir, Saquinavir.", "label": "0"}
{"id": "DDI-DrugBank.d228.s2.p3", "sentence": "Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, @DRUG$), though this has not been studied", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d274.s3.p23", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d434.s28.p9", "sentence": "Phenobarbital: Coadministration of felbamate with @DRUG$ causes an increase in @DRUG$ plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p539", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p209", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d235.s4.p54", "sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d400.s9.p2", "sentence": "@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.", "label": "0"}
{"id": "DDI-DrugBank.d521.s1.p73", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), @DRUG$ (Magan), or @DRUG$ (Pepto-Bismol);", "label": "0"}
{"id": "DDI-MedLine.d58.s3.p9", "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), @DRUG$ (N-type), or @DRUG$ (P-type) in bovine chromaffin cells. ", "label": "0"}
{"id": "DDI-DrugBank.d54.s24.p23", "sentence": "Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral @DRUG$ containing estrogens, @DRUG$-containing preparations and the numerous preparations containing salicylates.", "label": "0"}
{"id": "DDI-DrugBank.d546.s2.p1", "sentence": "Drug Interactions, General: Although there have been no formal interaction studies, intravenous @DRUG$ has been administered safely with drugs such as digitalis and sublingual @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d31.s7.p0", "sentence": "@DRUG$ may decrease the hemodynamic effects of @DRUG$;", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d521.s2.p23", "sentence": "- a @DRUG$ (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, @DRUG$);", "label": "0"}
{"id": "DDI-DrugBank.d179.s32.p0", "sentence": "- @DRUG$ (e.g., @DRUG$) or", "label": "0"}
{"id": "DDI-DrugBank.d54.s8.p1", "sentence": "@DRUG$: Cholestyramine binds both @DRUG$ and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p137", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), @DRUG$, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, @DRUG$, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d66.s2.p0", "sentence": "@DRUG$ - Concomitant use of @DRUG$ and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p16", "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d43.s4.p8", "sentence": "Antacids: Concomitant administration of @DRUG$ containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the @DRUG$ components.", "label": "0"}
{"id": "DDI-DrugBank.d261.s0.p2", "sentence": "Tetracycline, a @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d245.s4.p33", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d223.s16.p4", "sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, @DRUG$ [SSRIs]) may increase the plasma concentration of @DRUG$ when administered concomitantly.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d179.s21.p154", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d176.s9.p25", "sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d267.s3.p3", "sentence": "Isoflurane, @DRUG$, and @DRUG$ decrease the ED50 of NUROMAX by 30% to 45%.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p217", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d537.s0.p6", "sentence": "@DRUG$ may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and @DRUG$), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "label": "DDI-int"}
{"id": "DDI-MedLine.d76.s9.p4", "sentence": "Formulation of fluorescence labelled bacitracin and @DRUG$ in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) @DRUG$7.3 a significantly improved permeation was observed (R= 1.3). ", "label": "0"}
{"id": "DDI-DrugBank.d286.s0.p1", "sentence": "@DRUG$ may increase the action of tricyclics, @DRUG$, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d257.s0.p50", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d306.s0.p20", "sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d446.s0.p2", "sentence": "@DRUG$ may interact with antidepressants, aspirin, @DRUG$, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "label": "DDI-int"}
{"id": "DDI-DrugBank.d97.s52.p1", "sentence": "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving @DRUG$ in combination with ritonavir than those receiving @DRUG$ 800 mg q8h.", "label": "0"}
{"id": "DDI-DrugBank.d246.s0.p19", "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased @DRUG$ effects.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p275", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d536.s1.p16", "sentence": "These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d558.s25.p76", "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p330", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, @DRUG$, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d197.s1.p9", "sentence": "Anesthetics/@DRUG$/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "label": "0"}
{"id": "DDI-DrugBank.d257.s6.p10", "sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "label": "0"}
{"id": "DDI-DrugBank.d274.s3.p72", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d18.s1.p5", "sentence": "Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d85.s1.p1", "sentence": "Because the @DRUG$ CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral @DRUG$, either alone or in combination with the chemosensitizer misonidazole. ", "label": "0"}
{"id": "DDI-DrugBank.d75.s14.p4", "sentence": "The effects of medicinal products with similar properties such as inotropes @DRUG$, enoximone, amrinone, olprinone and cilostazol may be exacerbated by @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d115.s2.p27", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d512.s7.p1", "sentence": "Dose adjustment of @DRUG$ may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, @DRUG$, itraconazole;", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d485.s17.p22", "sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (@DRUG$, chlordiazepoxide, @DRUG$) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "label": "0"}
{"id": "DDI-DrugBank.d60.s12.p58", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-MedLine.d127.s6.p0", "sentence": "Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d132.s25.p4", "sentence": "Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.", "label": "0"}
{"id": "DDI-DrugBank.d141.s9.p3", "sentence": "WARFARIN: Co- administration of @DRUG$ and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.", "label": "0"}
{"id": "DDI-DrugBank.d160.s0.p0", "sentence": "The results of a study of coadministration of @DRUG$ (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p1028", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d296.s0.p14", "sentence": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, @DRUG$, etc).", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p1", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d462.s5.p5", "sentence": "Probenecid: The oral combination of probenecid before intramuscular injection of @DRUG$ produces an increase in @DRUG$ peak serum level of about 30%.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p44", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-MedLine.d12.s2.p9", "sentence": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p424", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d468.s8.p0", "sentence": "@DRUG$: Concomitant administration of @DRUG$ and cyclosporine levels.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p66", "sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, @DRUG$, fluconazole, @DRUG$, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d114.s2.p15", "sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "label": "0"}
{"id": "DDI-DrugBank.d527.s1.p21", "sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, MAO inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.", "label": "0"}
{"id": "DDI-DrugBank.d420.s0.p6", "sentence": "Antacids (@DRUG$- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL @DRUG$ suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "label": "0"}
{"id": "DDI-DrugBank.d350.s14.p0", "sentence": "When @DRUG$ is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d321.s0.p0", "sentence": "@DRUG$: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p171", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;@DRUG$;diet high in @DRUG$;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d382.s31.p21", "sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, @DRUG$, troleandomycin, clarithromycin, ritonavir, @DRUG$) should be approached with caution.", "label": "0"}
{"id": "DDI-DrugBank.d94.s13.p11", "sentence": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: @DRUG$, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with @DRUG$, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p560", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d220.s11.p20", "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d62.s0.p6", "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p527", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d524.s0.p2", "sentence": "@DRUG$, Antihistamines, antidiabetic drugs, @DRUG$, digitalis.", "label": "0"}
{"id": "DDI-DrugBank.d567.s13.p0", "sentence": "@DRUG$s: In a small clinical trial in which @DRUG$ was administered to warfarin treated patients, no effect on prothrombin time was detected.", "label": "0"}
{"id": "DDI-DrugBank.d141.s13.p8", "sentence": "OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d143.s18.p2", "sentence": "@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and CYP3A4.", "label": "0"}
{"id": "DDI-MedLine.d115.s2.p41", "sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d247.s2.p2", "sentence": "Epinephrine should not be administered concomitantly with other @DRUG$ (such as @DRUG$) because of possible additive effects and increased toxicity.", "label": "0"}
{"id": "DDI-MedLine.d29.s2.p1", "sentence": "(1968, 1970), the higher serum concentrations of @DRUG$ and cephaloridine reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body. ", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d512.s7.p5", "sentence": "Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, @DRUG$, @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d54.s19.p1", "sentence": "@DRUG$: When administered to patients on a thyroid preparation, this parenteral @DRUG$ may cause hypertension and tachycardia.", "label": "0"}
{"id": "DDI-DrugBank.d357.s3.p11", "sentence": "Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p14", "sentence": "Drugs that have been reported to diminish oral @DRUG$ response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;@DRUG$;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d484.s0.p640", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (@DRUG$), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d64.s90.p18", "sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, @DRUG$, @DRUG$, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p73", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.", "label": "0"}
{"id": "DDI-DrugBank.d543.s0.p20", "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.", "label": "0"}
{"id": "DDI-DrugBank.d124.s17.p1", "sentence": "@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p37", "sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-MedLine.d106.s1.p13", "sentence": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy. ", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p21", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d401.s0.p8", "sentence": "Drug Interactions: The central @DRUG$ syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p925", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p876", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d384.s0.p9", "sentence": "Interactions for vitamin D analogues (@DRUG$, Vitamin D3, Calcitriol, and @DRUG$): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p885", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p104", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d409.s0.p0", "sentence": "Because the @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their anticoagulant dosage.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d3.s4.p13", "sentence": "Therapeutic concentrations of digoxin, warfarin, @DRUG$, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "label": "0"}
{"id": "DDI-MedLine.d76.s1.p27", "sentence": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, @DRUG$ and @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d283.s5.p3", "sentence": "Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d122.s0.p0", "sentence": "Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d111.s5.p73", "sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital. ", "label": "0"}
{"id": "DDI-DrugBank.d277.s8.p6", "sentence": "Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p16", "sentence": "Caution should be used when administering or taking TARCEVA with @DRUG$ and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p384", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, @DRUG$, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, @DRUG$, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d293.s0.p19", "sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p54", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d263.s13.p113", "sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d392.s2.p7", "sentence": "Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, @DRUG$, and @DRUG$, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.", "label": "0"}
{"id": "DDI-DrugBank.d93.s0.p1", "sentence": "Clinical trials have indicated that @DRUG$ can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, @DRUG$, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p511", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-MedLine.d109.s9.p1", "sentence": "The harmonic mean elimination half-life was 45.7 and 43.4 hours for @DRUG$ + digoxin and placebo + @DRUG$ treatments, respectively. ", "label": "0"}
{"id": "DDI-DrugBank.d107.s13.p8", "sentence": "Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p33", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, @DRUG$, antipsychotics, blood pressure medications (reserpine, methyldopa, @DRUG$), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p586", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;@DRUG$;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d395.s8.p9", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust @DRUG$ doses appropriately.", "label": "0"}
{"id": "DDI-DrugBank.d522.s20.p3", "sentence": "Digoxin: Concomitant administration of @DRUG$ and @DRUG$ has been reported to result in elevated digoxin serum levels.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d289.s6.p14", "sentence": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d568.s35.p4", "sentence": "Metoprolol - Administration of 20 mg/day @DRUG$ for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker @DRUG$ (given in a single dose of 100 mg).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p33", "sentence": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d140.s10.p0", "sentence": "Oral @DRUG$: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.", "label": "0"}
{"id": "DDI-DrugBank.d456.s1.p5", "sentence": "Caution should be used when administering or taking @DRUG$ with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d189.s0.p3", "sentence": "No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.", "label": "0"}
{"id": "DDI-DrugBank.d94.s4.p246", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, @DRUG$, @DRUG$, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-DrugBank.d27.s0.p4", "sentence": "No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p190", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;@DRUG$;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d288.s4.p9", "sentence": "Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.", "label": "0"}
{"id": "DDI-DrugBank.d186.s3.p1", "sentence": "As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d94.s4.p282", "sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, @DRUG$, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, @DRUG$(1), verapamil, zileuton.", "label": "0"}
{"id": "DDI-MedLine.d76.s9.p1", "sentence": "Formulation of fluorescence labelled @DRUG$ and insulin in unconjugated @DRUG$ (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ", "label": "0"}
{"id": "DDI-DrugBank.d499.s19.p1", "sentence": "@DRUG$: Probenecid increases both free and bound @DRUG$ by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d208.s0.p9", "sentence": "Benzthiazide may interact with @DRUG$, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "label": "0"}
{"id": "DDI-DrugBank.d211.s2.p0", "sentence": "@DRUG$: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.", "label": "0"}
{"id": "DDI-DrugBank.d460.s14.p4", "sentence": "Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d476.s2.p2", "sentence": "In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that @DRUG$ be discontinued for several days before the withdrawal of @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d410.s8.p4", "sentence": "fluoxetine, @DRUG$, paroxetine, @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d194.s1.p7", "sentence": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.", "label": "0"}
{"id": "DDI-DrugBank.d98.s0.p10", "sentence": "Interactions for vitamin D analogues (@DRUG$, Vitamin D3, Calcitriol, and Calcidiol): @DRUG$: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d299.s1.p8", "sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d324.s10.p0", "sentence": "@DRUG$: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "label": "0"}
{"id": "DDI-DrugBank.d169.s1.p1", "sentence": "Co-administration of multiple doses of 10 mg of @DRUG$ had no effect on the single dose pharmacokinetics of R- and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d414.s0.p0", "sentence": "@DRUG$ generally should not be given with @DRUG$ because they reduce its renal clearance and add a high risk of lithium toxicity.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d94.s11.p153", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d143.s41.p3", "sentence": "@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "label": "0"}
{"id": "DDI-DrugBank.d211.s5.p0", "sentence": "@DRUG$: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or ampicillin toxicity.", "label": "DDI-mechanism"}
{"id": "DDI-MedLine.d62.s4.p3", "sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an @DRUG$ clozapine. ", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p64", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d25.s0.p0", "sentence": "@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d179.s21.p164", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d76.s28.p0", "sentence": "Therefore, if @DRUG$ is co-administered with @DRUG$, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.", "label": "DDI-advise"}
{"id": "DDI-MedLine.d105.s0.p1", "sentence": "Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p682", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d192.s0.p13", "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "label": "0"}
{"id": "DDI-DrugBank.d345.s13.p35", "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (@DRUG$), tolbutamide, phenytoin or warfarin.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p173", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, @DRUG$, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (@DRUG$), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p106", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d558.s32.p18", "sentence": "Other Drugs: In healthy volunteers, amlodipine, @DRUG$, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and @DRUG$s) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d434.s1.p5", "sentence": "Use in Conjunction with Other Antiepileptic Drugs: The addition of @DRUG$  to antiepileptic drugs (@DRUG$) affects the steady-state plasma concentrations of AEDs.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d236.s7.p3", "sentence": "@DRUG$, tricyclic: Amphetamines may enhance the activity of tricyclic or @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d260.s3.p14", "sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "label": "0"}
{"id": "DDI-DrugBank.d54.s5.p1", "sentence": "@DRUG$ or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in @DRUG$ or oral hypoglycemic requirements.", "label": "0"}
{"id": "DDI-DrugBank.d10.s1.p1", "sentence": "Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d328.s44.p1", "sentence": "Coadministration of @DRUG$ and Ortho-Novum 1/35  increased the exposure of @DRUG$ and ethinyl estradiol by 20% and 34%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d531.s90.p42", "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.", "label": "0"}
{"id": "DDI-DrugBank.d379.s1.p6", "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d480.s21.p0", "sentence": "@DRUG$ produced only minor changes in the levels of @DRUG$ and its metabolites.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s4.p302", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d472.s0.p59", "sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, @DRUG$), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and @DRUG$", "label": "0"}
{"id": "DDI-DrugBank.d528.s2.p0", "sentence": "@DRUG$ - @DRUG$ may protect against the ototoxic effects of gentamicin.", "label": "0"}
{"id": "DDI-DrugBank.d397.s13.p3", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with @DRUG$, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of @DRUG$ by erythromycin.", "label": "0"}
{"id": "DDI-DrugBank.d123.s15.p3", "sentence": "Probenecid: @DRUG$ interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d411.s3.p150", "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, @DRUG$, tamoxifen.", "label": "0"}
{"id": "DDI-DrugBank.d370.s1.p2", "sentence": "Particular caution should be exercised in using preparations containing @DRUG$, resorcinol, or salicylic acid in combination with @DRUG$ Gel.", "label": "0"}
{"id": "DDI-DrugBank.d48.s1.p44", "sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, @DRUG$, ritonavir, atazanavir, @DRUG$, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "label": "0"}
{"id": "DDI-DrugBank.d137.s7.p1", "sentence": "Oral @DRUG$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral hypoglycemic agents.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p811", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, @DRUG$ (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d559.s1.p11", "sentence": "Butalbital, @DRUG$ and caffeine may enhance the effects of: other narcotic analgesics, @DRUG$, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d404.s0.p6", "sentence": "Interactions for @DRUG$ analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of @DRUG$;", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1181", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p3", "sentence": "Interactions may also occur with the following: @DRUG$/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), @DRUG$, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d231.s13.p0", "sentence": "Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of @DRUG$ and @DRUG$ temporarily reduced creatinine clearance in patients with chronic renal insufficiency.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d274.s3.p40", "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1034", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d163.s0.p3", "sentence": "@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects", "label": "0"}
{"id": "DDI-DrugBank.d566.s0.p9", "sentence": "@DRUG$ resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, @DRUG$ and progestins, and digitalis.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d107.s13.p1", "sentence": "@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "label": "0"}
{"id": "DDI-DrugBank.d343.s0.p3", "sentence": "Aspirin, @DRUG$, @DRUG$, NSAIDs", "label": "0"}
{"id": "DDI-DrugBank.d456.s6.p0", "sentence": "Other CYP3A4 inducers include, but are not limited to, @DRUG$, @DRUG$, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.", "label": "0"}
{"id": "DDI-DrugBank.d175.s5.p0", "sentence": "Agents Having Vasodilator Activity: Data on the effect of concomitant use of other @DRUG$ in patients receiving @DRUG$ for heart failure are not available;", "label": "0"}
{"id": "DDI-DrugBank.d382.s36.p9", "sentence": "Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of @DRUG$ increased approximately 5-fold and the mean terminal half-life of @DRUG$ increased approximately 3-fold.", "label": "0"}
{"id": "DDI-MedLine.d103.s3.p3", "sentence": "It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation. ", "label": "0"}
{"id": "DDI-DrugBank.d353.s1.p7", "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.", "label": "0"}
{"id": "DDI-DrugBank.d179.s21.p155", "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "label": "0"}
{"id": "DDI-DrugBank.d413.s6.p2", "sentence": "@DRUG$: It has been reported that allopurinol prolongs the half-life of the anticoagulant, @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d141.s0.p0", "sentence": "@DRUG$, @DRUG$, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.", "label": "0"}
{"id": "DDI-MedLine.d15.s1.p2", "sentence": "After prolonged administration of neuroleptics the displacing effect of @DRUG$, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on @DRUG$ binding. ", "label": "0"}
{"id": "DDI-DrugBank.d212.s11.p40", "sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "label": "0"}
{"id": "DDI-DrugBank.d236.s15.p2", "sentence": "Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d395.s0.p9", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following @DRUG$ administration, decreased @DRUG$ bioavailability by approximately 25%.", "label": "0"}
{"id": "DDI-DrugBank.d510.s0.p2", "sentence": "The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p1329", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d297.s2.p21", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d78.s3.p14", "sentence": "Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of @DRUG$ and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d14.s2.p0", "sentence": "Marked symptomatic orthostatic hypotension has been reported when @DRUG$ and organic @DRUG$ were used in combination.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d99.s7.p11", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).", "label": "0"}
{"id": "DDI-DrugBank.d449.s0.p1", "sentence": "Co-administration with @DRUG$ such as ketoconazole or @DRUG$ is not recommended.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1094", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p948", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "label": "0"}
{"id": "DDI-DrugBank.d468.s5.p0", "sentence": "@DRUG$ usually does not alter the plasma levels of @DRUG$, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.", "label": "0"}
{"id": "DDI-DrugBank.d123.s19.p3", "sentence": "Warfarin: @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p30", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d401.s0.p15", "sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as @DRUG$ are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the @DRUG$ salts, and antihistamines.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d413.s19.p14", "sentence": "However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, @DRUG$ and/or @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d184.s0.p19", "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "label": "0"}
{"id": "DDI-DrugBank.d210.s18.p2", "sentence": "Thus, when VIOXX and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.", "label": "0"}
{"id": "DDI-DrugBank.d191.s1.p8", "sentence": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7", "label": "0"}
{"id": "DDI-DrugBank.d357.s0.p18", "sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "label": "0"}
{"id": "DDI-DrugBank.d474.s1.p11", "sentence": "These agents include medications such as: anticoagulants, platelet inhibitors including @DRUG$, sali-cylates, @DRUG$ (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.", "label": "0"}
{"id": "DDI-MedLine.d118.s2.p8", "sentence": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d176.s12.p49", "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "label": "0"}
{"id": "DDI-DrugBank.d64.s29.p222", "sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;@DRUG$;griseofulvin;@DRUG$;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "label": "0"}
{"id": "DDI-DrugBank.d198.s25.p5", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.", "label": "0"}
{"id": "DDI-DrugBank.d400.s13.p1", "sentence": "@DRUG$: The effects of warfarin and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p232", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;@DRUG$;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d337.s3.p3", "sentence": "Experience with co-administration of HMG-CoA reductase inhibitors and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving Fentanyl.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p541", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;@DRUG$;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d558.s33.p3", "sentence": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.", "label": "0"}
{"id": "DDI-DrugBank.d460.s14.p11", "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "label": "0"}
{"id": "DDI-DrugBank.d170.s5.p0", "sentence": "@DRUG$: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d269.s17.p2", "sentence": "As with other @DRUG$, if COREG is to be administered orally with calcium channel blockers of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "label": "0"}
{"id": "DDI-DrugBank.d97.s84.p5", "sentence": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when @DRUG$ and @DRUG$ are coadministered.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d180.s1.p1", "sentence": "The pressor effects of @DRUG$ such as dopamine or @DRUG$ are enhanced by Bretylium Tosylate.", "label": "0"}
{"id": "DDI-DrugBank.d382.s19.p10", "sentence": "Oral contraceptives: @DRUG$, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of @DRUG$ by 8%;", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p562", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d178.s4.p13", "sentence": "These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d111.s0.p0", "sentence": "@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.", "label": "0"}
{"id": "DDI-DrugBank.d89.s6.p0", "sentence": "Interconversion between @DRUG$ and @DRUG$ has been reported in preterm neonates.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p432", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p690", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d13.s0.p24", "sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "label": "0"}
{"id": "DDI-MedLine.d102.s6.p7", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, @DRUG$- and @DRUG$ + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p563", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d27.s1.p0", "sentence": "In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, @DRUG$ and nifedipine.", "label": "0"}
{"id": "DDI-DrugBank.d210.s10.p1", "sentence": "@DRUG$: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of @DRUG$ by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.", "label": "0"}
{"id": "DDI-DrugBank.d480.s30.p31", "sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide and @DRUG$), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "label": "0"}
{"id": "DDI-DrugBank.d15.s0.p22", "sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "label": "0"}
{"id": "DDI-DrugBank.d434.s31.p10", "sentence": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of @DRUG$  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of @DRUG$  as compared to the same dose of Felbatol  given as monotherapy.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p330", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p695", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d437.s10.p1", "sentence": "Coadministration of @DRUG$ and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum @DRUG$ AUC, Cmax, andCmin, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d110.s5.p0", "sentence": "Therefore, @DRUG$ should not be used in any condition in which a @DRUG$ is being employed.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d521.s1.p44", "sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (@DRUG$), salsalate (Disalcid, others), @DRUG$ (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p1", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d64.s87.p1455", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/@DRUG$;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d318.s8.p13", "sentence": "Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.", "label": "0"}
{"id": "DDI-DrugBank.d501.s5.p12", "sentence": "Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on @DRUG$s ability to control blood glucose when @DRUG$ was administered intraperitoneally with EXTRANEAL.", "label": "0"}
{"id": "DDI-DrugBank.d236.s0.p4", "sentence": "@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.", "label": "0"}
{"id": "DDI-DrugBank.d132.s20.p4", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d441.s6.p3", "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d84.s3.p9", "sentence": "To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (@DRUG$, @DRUG$, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ", "label": "0"}
{"id": "DDI-DrugBank.d98.s0.p13", "sentence": "Interactions for vitamin D analogues (Vitamin D2, @DRUG$, @DRUG$, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "label": "0"}
{"id": "DDI-DrugBank.d212.s6.p10", "sentence": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "label": "0"}
{"id": "DDI-DrugBank.d203.s2.p0", "sentence": "Compounds tested in man include @DRUG$, @DRUG$, phenytoin, diazepam, aminopyrine and antipyrine.", "label": "0"}
{"id": "DDI-DrugBank.d79.s1.p0", "sentence": "Oral @DRUG$ may be less effective while you are taking @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d94.s11.p763", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d3.s4.p6", "sentence": "Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.", "label": "0"}
{"id": "DDI-DrugBank.d277.s13.p8", "sentence": "Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "label": "0"}
{"id": "DDI-DrugBank.d111.s0.p11", "sentence": "Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.", "label": "0"}
{"id": "DDI-DrugBank.d53.s7.p7", "sentence": "When used in therapeutic doses, @DRUG$ had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, @DRUG$, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d48.s15.p21", "sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, @DRUG$, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or @DRUG$ (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "label": "0"}
{"id": "DDI-DrugBank.d485.s14.p5", "sentence": "Ascorbic acid: Doses of ascorbic acid (@DRUG$) 1 g/day have been reported to increase plasma concentration of @DRUG$ by ~47%, possibly by inhibiting conjugation;", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d64.s87.p83", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d347.s4.p5", "sentence": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with @DRUG$ or its derivatives.", "label": "DDI-advise"}
{"id": "DDI-MedLine.d12.s6.p0", "sentence": "However, @DRUG$ stimulated, but did not significantly inhibit, proliferation in the presence of @DRUG$. ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d357.s3.p32", "sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.", "label": "0"}
{"id": "DDI-DrugBank.d536.s1.p51", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d257.s0.p13", "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "label": "0"}
{"id": "DDI-DrugBank.d54.s12.p1", "sentence": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free @DRUG$ may be decreased when estrogens are started thus increasing @DRUG$ requirements.", "label": "0"}
{"id": "DDI-DrugBank.d245.s4.p16", "sentence": "These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d226.s1.p0", "sentence": "@DRUG$ and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with Adenocard.", "label": "0"}
{"id": "DDI-MedLine.d11.s4.p11", "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ", "label": "0"}
{"id": "DDI-MedLine.d58.s3.p2", "sentence": "In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "label": "0"}
{"id": "DDI-DrugBank.d186.s3.p4", "sentence": "As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d514.s2.p20", "sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (@DRUG$), and, to a rising degree, @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d1.s6.p6", "sentence": "No interactions have been observed with beta-receptor blockers, @DRUG$, thiazide and loop diuretics and @DRUG$. ", "label": "0"}
{"id": "DDI-DrugBank.d225.s6.p54", "sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p287", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d395.s13.p5", "sentence": "Therefore, administration of quinolones with @DRUG$ containing calcium, @DRUG$, or aluminum;", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1099", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d476.s1.p0", "sentence": "Patients receiving catecholamine-depleting drugs, such as @DRUG$ or @DRUG$, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.", "label": "0"}
{"id": "DDI-DrugBank.d318.s8.p4", "sentence": "@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "label": "0"}
{"id": "DDI-MedLine.d115.s0.p9", "sentence": "Concomitant cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.", "label": "0"}
{"id": "DDI-DrugBank.d411.s3.p13", "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d499.s3.p9", "sentence": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d114.s10.p11", "sentence": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "label": "0"}
{"id": "DDI-DrugBank.d559.s1.p41", "sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, @DRUG$ such as chlordiazepoxide, sedative-hypnotics, or other @DRUG$, causing increased CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d190.s2.p2", "sentence": "Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (@DRUG$ up to 15,000 units/day) or prophylactic doses of @DRUG$ as indicated in the prescribing information for the specific products.", "label": "0"}
{"id": "DDI-DrugBank.d485.s17.p33", "sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (@DRUG$, @DRUG$, temazepam).", "label": "0"}
{"id": "DDI-DrugBank.d484.s0.p394", "sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, @DRUG$, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d404.s2.p3", "sentence": "@DRUG$/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of @DRUG$, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "label": "0"}
{"id": "DDI-DrugBank.d5.s8.p0", "sentence": "While not systematically studied, certain drugs may induce the metabolism of @DRUG$ (e.g., @DRUG$, phenobarbital, phenytoin).", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d297.s2.p9", "sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.", "label": "0"}
{"id": "DDI-DrugBank.d543.s0.p8", "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "label": "0"}
{"id": "DDI-MedLine.d30.s2.p0", "sentence": "Intermediate doses of @DRUG$ or @DRUG$ produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; ", "label": "0"}
{"id": "DDI-DrugBank.d434.s28.p14", "sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting @DRUG$, the steady-state trough (Cmin) @DRUG$ concentration was 14.2 micrograms/mL.", "label": "0"}
{"id": "DDI-DrugBank.d328.s43.p7", "sentence": "Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).", "label": "0"}
{"id": "DDI-DrugBank.d568.s25.p7", "sentence": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and @DRUG$ (200 mg) decreased the Cmax and AUC of @DRUG$ by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p680", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p291", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d289.s6.p13", "sentence": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1019", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d249.s3.p6", "sentence": "Digoxin, @DRUG$, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.", "label": "0"}
{"id": "DDI-DrugBank.d521.s2.p217", "sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (@DRUG$), and naproxen (Anaprox, Naprosyn, Aleve);", "label": "0"}
{"id": "DDI-DrugBank.d333.s7.p52", "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "label": "0"}
{"id": "DDI-DrugBank.d568.s7.p0", "sentence": "@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d176.s3.p2", "sentence": "@DRUG$ Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p387", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d250.s2.p12", "sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "label": "0"}
{"id": "DDI-DrugBank.d260.s0.p105", "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "label": "0"}
{"id": "DDI-DrugBank.d272.s2.p2", "sentence": "Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, @DRUG$, pimozide.", "label": "DDI-effect"}
{"id": "DDI-MedLine.d111.s14.p8", "sentence": "Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug. ", "label": "0"}
{"id": "DDI-DrugBank.d143.s41.p15", "sentence": "Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "label": "0"}
{"id": "DDI-DrugBank.d277.s10.p3", "sentence": "Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.", "label": "0"}
{"id": "DDI-DrugBank.d420.s5.p15", "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p51", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "0"}
{"id": "DDI-DrugBank.d3.s13.p1", "sentence": "@DRUG$: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1231", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d26.s0.p19", "sentence": "Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.", "label": "0"}
{"id": "DDI-DrugBank.d303.s3.p2", "sentence": "Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking @DRUG$ and @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d9.s0.p11", "sentence": "Azlocillin should not be administered concomitantly with amikacin, @DRUG$, gentamicin, netilmicin, or @DRUG$.", "label": "0"}
{"id": "DDI-MedLine.d30.s6.p1", "sentence": "In monkeys, @DRUG$ was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with (+)-NANM. ", "label": "0"}
{"id": "DDI-MedLine.d102.s6.p0", "sentence": "Endothelium-intact aortic rings from high-@DRUG$ rats were supersensitive to @DRUG$ when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d279.s11.p0", "sentence": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by @DRUG$, the physician may wish to withhold @DRUG$ during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.", "label": "0"}
{"id": "DDI-DrugBank.d94.s13.p0", "sentence": "Agents with Increased Levels in the Presence of @DRUG$: @DRUG$ increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p935", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d547.s0.p22", "sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, @DRUG$, @DRUG$, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "label": "0"}
{"id": "DDI-DrugBank.d565.s33.p0", "sentence": "Studies showed that @DRUG$ increased the AUC of @DRUG$ and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d350.s12.p1", "sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d94.s11.p176", "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "label": "0"}
{"id": "DDI-DrugBank.d14.s0.p0", "sentence": "The vasodilating effects of @DRUG$ may be additive with those of other @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d313.s13.p0", "sentence": "When used in external subcutaneous infusion pumps for @DRUG$, @DRUG$ should not be mixed with any other insulins or diluent.", "label": "0"}
{"id": "DDI-DrugBank.d41.s15.p2", "sentence": "Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both @DRUG$ and @DRUG$.", "label": "DDI-advise"}
{"id": "DDI-DrugBank.d97.s83.p0", "sentence": "@DRUG$ concentration   @DRUG$ concentration", "label": "0"}
{"id": "DDI-DrugBank.d411.s4.p80", "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "label": "0"}
{"id": "DDI-DrugBank.d395.s23.p7", "sentence": "Warfarin: Quinolones, including @DRUG$, decrease the clearance of @DRUG$, the less active isomer of racemic warfarin.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d434.s30.p33", "sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of @DRUG$ causes an approximate 45% decrease in the steady-state trough concentrations of @DRUG$  as compared to the same dose of Felbatol  given as monotherapy.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d316.s14.p6", "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.", "label": "DDI-mechanism"}
{"id": "DDI-DrugBank.d289.s27.p4", "sentence": "Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d5.s17.p91", "sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "label": "0"}
{"id": "DDI-DrugBank.d397.s5.p2", "sentence": "Concurrent use of erythromycin and @DRUG$ or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "label": "0"}
{"id": "DDI-DrugBank.d558.s5.p15", "sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that @DRUG$, @DRUG$, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "label": "0"}
{"id": "DDI-DrugBank.d533.s1.p57", "sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, @DRUG$, valsartan, @DRUG$ and amlodipine did not result in clinically significant increases in aliskiren exposure.", "label": "0"}
{"id": "DDI-DrugBank.d350.s12.p8", "sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "label": "0"}
{"id": "DDI-DrugBank.d387.s0.p2", "sentence": "Potential drug interactions for doxylamine include, increased sedation if @DRUG$ is combined with other @DRUG$.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d60.s2.p0", "sentence": "Prior administration of @DRUG$ had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of @DRUG$.", "label": "0"}
{"id": "DDI-DrugBank.d209.s3.p50", "sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "label": "0"}
{"id": "DDI-DrugBank.d141.s0.p3", "sentence": "@DRUG$, Fibric Acid Derivatives, Niacin (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.", "label": "0"}
{"id": "DDI-DrugBank.d20.s4.p8", "sentence": "ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).", "label": "0"}
{"id": "DDI-DrugBank.d267.s5.p3", "sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "label": "DDI-effect"}
{"id": "DDI-DrugBank.d170.s5.p43", "sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "label": "0"}
{"id": "DDI-DrugBank.d86.s1.p76", "sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, @DRUG$, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., @DRUG$), any other drugs that may make you drowsy.", "label": "0"}
{"id": "DDI-DrugBank.d64.s87.p1188", "sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "label": "0"}
{"id": "DDI-DrugBank.d413.s4.p7", "sentence": "In patients receiving mercaptopurine (@DRUG$) or azathioprine (@DRUG$), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "label": "0"}
